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ABSTRACT 
 
 
The Effect of Dietary n-3 Polyunsaturated Fatty Acids on T Cell Subset Activation-
Induced Cell Death.  (August 2004) 
Kirsten Collette Switzer, B.S., University of Nebraska, Lincoln 
Co-Chairs of Advisory Committee:  Dr. Robert S. Chapkin  
                                                              Dr. David N. McMurray 
 
 
 Dietary n-3 polyunsaturated fatty acids (PUFA) have been shown to potently 
attenuate T cell-mediated inflammation, in part, by suppressing T cell activation and 
proliferation.  Apoptosis is an important mechanism for preventing chronic inflammation 
by maintaining T cell homeostasis through the contraction of populations of activated T 
cells.  We hypothesized that dietary n-3 PUFA would promote T cell apoptosis, thus, 
providing an additional mechanism to explain the anti-inflammatory effects.  We 
specifically examined activation-induced cell death (AICD) since it is the form of 
apoptosis associated with peripheral T cell deletion involved in immunological tolerance 
and T cell homeostasis.  Female C57BL/6 mice were fed diets containing either n-6 
PUFA (control) or n-3 PUFA for 14 d.  Splenic T cells were stimulated with 
aCD3/aCD28, aCD3/PMA, or PMA/Ionomycin for 48 h followed by reactivation with 
the same stimuli for 5 h.  Apoptosis was measured using Annexin V/propidium iodide 
and flow cytometry.  Cytokine analyses revealed that n-3 PUFA enhanced AICD only in 
T cells expressing a Th1-like cytokine profile (high IFNg, low IL-4) compared to mice 
fed the n-6 PUFA control diet.  Dietary n-3 PUFA significantly altered the fatty acid 
composition of phosphatidylcholine and phosphatidylethanolamine in T cell membranes.  
iv 
To examine the apparently selective effect of dietary n-3 PUFA on AICD in Th1 cells, 
CD4+ T cells were polarized in vitro to a Th1 phenotype by culture with aIL-4, IL-2, 
and IL-12 for 2 d, followed by culture with IL-2 and IL-12 for 3 d in the presence of 
diet-matched homologous mouse serum (MS) to prevent loss of cell membrane fatty 
acids.  Following polarization and reactivation, we observed that n-3 PUFA enhanced 
Th1 polarization and AICD only in cells cultured in the presence of MS, but not in fetal 
bovine serum.  The n-3 PUFA enhancement of Th1 polarization and AICD was 
associated with the maintenance of diet-induced changes in EPA (20:5n-3) and DHA 
(22:6n-3) in plasma T cell membrane lipid rafts.  Overall, these results suggest that 
dietary n-3 PUFA enhance both the polarization and deletion of pro-inflammatory Th1 
cells, possibly as a result of alterations in lipid raft fatty acid composition. 
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CHAPTER I 
 
 
 
INTRODUCTION 
 
Autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease, 
Type I diabetes) are associated with severe morbidity and mortality, affecting more than 
3% of the U.S. population (1).  The chronic nature of many of these diseases results in a 
significant impact in terms of medical intervention and costs, and quality of life (1).  
Autoimmune diseases can be classified as either organ-specific or systemic (2).  The 
defining feature is the damage to tissues and organs that arises due to an adaptive 
immune response to self antigens.  The maintenance of self tolerance prevents the body 
from mounting an immune response against itself.  Immunological tolerance is a state of 
unresponsiveness to a particular antigen that is induced by prior exposure to that antigen 
(3).  There are a number of ways in which self-reactive lymphocytes are prevented from 
responding to self antigens: (a) ignorance-which occurs when the antigen is present in 
sub-stimulatory concentrations or is sequestered anatomically from the self-reactive 
lymphocytes; (b) anergy-which occurs when self-reactive cells see antigen in the 
absence of costimulation resulting in an inability to produce interleukin-2 (IL-2) and 
proliferate; (c) programmed cell death (apoptosis)-which occurs as a result of repeated 
antigenic stimulation; or (d) immune deviation-the activation of an antagonistic or  
________________________________ 
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suppressive arm of the immune system (3,4).  With this in mind, most of the etiological 
mechanisms leading to autoimmunity result from a failure of one of the above processes.  
Genetic factors may contribute to self-antigen reactivity, e.g., defects of apoptotic genes 
and genes affecting cytokine expression may lead to T cell population imbalances (5). 
 The induction of autoimmune disease is usually triggered by an exogenous 
factor.  Infectious agents may initiate autoreactivity through molecular mimicry, 
polyclonal activation, or release of previously sequestered antigens (2).  Drugs can 
induce autoreactivity by acting as haptens and rendering auto-antigens immunogenic and 
inducing anti-nuclear antibodies (2).  Finally, cytokine dysregulation may also lead to 
activation of autoreactive cells.   
 Most autoimmune diseases are associated with chronic inflammation.  
Inflammation is a response that is caused by tissue damage or injury, characterized by 
redness, heat, pain, and swelling (“rubor, calor, dolor, and tumor”) (6).  The 
inflammatory response involves three major stages: (i) capillary dilation to increase 
blood flow; (ii) increase in vascular permeability and release of chemokines and other 
chemotactic molecules; and (iii) leukocyte migration across the endothelium and 
accumulation at the site of injury (6).  The inflammatory process is usually tightly 
regulated, involving both mediators that initiate and maintain inflammation and 
mediators that shut the process down (7).  In states of chronic inflammation, an 
imbalance between the two types of mediators leaves inflammation unchecked, resulting 
in damage (7).  CD4+ T cells are involved in the induction of inflammation, orchestrating 
the cell-mediated response by stimulating monocytes and macrophages to secrete 
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inflammatory cytokines such as IL-1, IL-6, and TNFa (7).  Activated CD4+ T cells also 
stimulate B cells to produce immunoglobulins.  As will be discussed in more detail later, 
differentiated CD4+ T cells are functionally heterogeneous as defined by their different 
cytokine profiles.  T helper 1 (Th1) cells, important in cell-mediated immunity, secrete 
interferon g (IFNg) and IL-2, while Th2 cells, associated with humoral responses, secrete 
IL-4, IL-5, and IL-10 (8).  While a Th1 response is appropriate for the eradication of 
some microbial pathogens, if this response is elicited inappropriately against self 
antigens, inflammation, tissue destruction, and pathology may result (4,9).  Th2 cells can 
downregulate the development and potentiation of Th1 driven cell-mediated immune 
responses (8).  That cell-mediated and humoral immune responses are often mutually 
exclusive (10), suggests that a switch from a Th1- to a Th2-type response could explain 
the immune deviation from cell-mediated immunity to tolerance (4,9).  However, the 
proposal that Th1 cells are pathogenic and Th2 cells are regulatory in the context of 
autoimmune disease may be too simplistic (4).  Recent evidence suggests that a 
regulatory population distinct from Th2 cells exists in normal mice, but is absent in 
immunodeficient mice (11).  A number of T cell subpopulations with regulatory or 
suppressor activities have been described.  Among them are CD4+CD25+ T cells, 
Tr1/Th3, NK T cells, gd T cells, and CD8+CD28- T cells (12).  These cells are thought to 
mediate their immune responses through direct cell-cell contact and/or secretion of 
TGFb and IL-10 (13).  
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CURRENT THERAPEUTIC STRATEGIES 
 Current pharmacological means of reducing inflammation include non-steroidal 
anti-inflammatory drugs (NSAIDs), inhibitors of pro-inflammatory cyclooxygenases; 
cytotoxic drugs; corticosteroids; antibodies against cytokines (e.g., the anti-TNFa agents 
etanercept and infliximab) and cytokine receptor antagonists (2).  There are drawbacks 
to the use of some of these substances.  For example, infliximab must be used in 
combination with methotrexate to be effective (14).  For other molecules, there is 
frequently a short half-life in the plasma which necessitates frequent daily treatment and 
high doses (15).  Most importantly, the long-term safety of these new agents, particularly 
with respect to the risk of infections, cancer, and other autoimmune diseases limits their 
use in all patients. 
 In the late 1970s, epidemiological studies revealed that Greenland Inuits had 
substantially reduced incidence of inflammatory diseases compared to Western 
populations (16).  Similar observations were made in the Japanese, which led to the 
correlation between a lower incidence of inflammatory disease and a high consumption 
of cold-water fatty fish (17).  The overwhelming evidence from these and other 
epidemiological studies led to a number of clinical trials using fish oil (FO), which is 
enriched with the two n-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA).  The majority of clinical studies have focused 
on the use of FO supplementation in rheumatoid arthritis.  Inflammatory bowel disease, 
systemic lupus erythematosus (SLE), and psoriasis have also been examined.  Placebo-
controlled, double blind studies of n-3 PUFA to treat inflammatory diseases have used 
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between 1 and 7 g/d of EPA plus DHA over a 12-52 week duration (18).  As a point of 
reference, the traditional Inuit diet provides 6-12 g/d of EPA and DHA while the average 
American diet provides approximately 0.1 g/d (19,20).  All studies in rheumatoid 
arthritis reported improvements in various clinical measurements including reduced 
tender or swollen joints, increased grip strength, and reduced joint pain (21-23).  
Furthermore, Skoldstam et al. (24) reported that NSAID usage was significantly 
decreased following 6 months of supplementation with 3.0 g/d of EPA and DHA.  Aslan 
et al. (25) demonstrated beneficial effects of FO in patients with ulcerative colitis and 
Alimallah et al. (26) demonstrated clinical improvements of patients with procto-colitis.  
Additionally, a one-year double-blind placebo controlled study of remission 
maintenance in patients with Crohn's disease reported significantly greater remission 
rates in the group receiving 2.7 g/d of FO versus the placebo group (27).  Furthermore, 
studies have shown decreased total serum PUFA, as well as deficiencies of both n-3 and 
n-6 PUFA in patients with chronic intestinal disorders (28).  Symptoms of spontaneous 
lupus erythematosus (SLE) are also alleviated by FO supplementation (29).  n-3 PUFA 
treatment hasn’t always been successful.  A study by Soyland et al. (30) provided 6 g/d 
of EPA and DHA to patients with psoriasis and saw no clinical improvements. 
 Studies have also employed animal models of inflammation in order to elucidate 
the mechanism(s) of the anti-inflammatory properties of n-3 PUFA.  In (NZB X 
NZW)F1 mice, which spontaneously develop a disease similar to human SLE, a diet 
composed of 25% FO (wt/wt) increased survival from renal complications (31).  Using 
the same animal model, Fernandes et al. (32) found similar results, i.e., increased 
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survival and decreased proteinuria, using a 10% FO by weight diet.  Vilaseca et al. (33) 
pretreated rats with n-6 and n-3 PUFA prior to trinitrobenzenesulfonic acid-induced 
colitis.  The n-3 PUFA supplemented group had significantly less colonic damage than 
did the n-6 PUFA supplemented group.  The effects of n-3 PUFA supplementation are 
more dramatic in animal models than in human clinical trials.  This may be due to the 
fact that n-3 PUFA treatment in animals begins prior to disease onset, whereas human 
trials begin supplementation after disease onset. 
 
EFFECT OF n-3 PUFA ON CELL FUNCTION 
 PUFA are divided into two major classes: n-3 and n-6.  Fatty acid nomenclature 
indicates the number of carbon atoms in the hydrocarbon chain, the number of double 
bonds, and the position of the first double bond from the methyl end in the chain.  For 
example, 22:6n-3 (DHA) has 22 carbons, 6 double bonds, and the first double bond is on 
the third carbon from the methyl end.  Of the n-3 PUFA class, EPA (20:5n-3) and DHA 
are found in cold-water fatty fish while alinolenic acid (ALA, 18:3n-3) is found in green 
leafy vegetables, and walnut and flaxseed oils.  n-6 PUFA are primarily found in animal 
fats and plant-based oils, with linoleic acid (LA, 18:2n-6) being the most abundant.  As 
described above, there is strong evidence for a protective effect of n-3 PUFA on 
autoimmune and inflammatory diseases.  In contrast, n-6 PUFA can be deleterious with 
respect to the incidence and severity of such diseases (34-36).  This is significant 
because the typical Western diet contains 10-20 times more n-6 than n-3 PUFA (37). 
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 n-3 PUFA may exert their anti-inflammatory effects through a variety of 
mechanisms.  Most importantly, n-3 PUFA affect the fatty acid composition of 
membrane phospholipids.  This, in turn, could affect eicosanoid synthesis, membrane 
structure and function, and signal transduction.  In addition, n-3 PUFA may directly 
regulate gene expression.  Eicosanoids are signaling molecules that include 
prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and hydroxy and 
hydroperoxy derivatives (HETE, HPETE).  Non-esterified arachidonic acid (AA, 20:4n-
6) released from membrane phospholipids by phospholipases acts as a substrate for 
cyclooxygenases (COX-1, a constitutive enzyme or COX-2, an inducible enzyme) and 
lipoxygenases (LOX).  Cyclooxygenase products of AA give rise to PGs and TXs, which 
are mostly pro-inflammatory due to vascular permeability and vasodilation 
enhancement.  Lipoxygenase products give rise to LT, HETE and HPETE, which are 
involved in vascular permeability and vasoconstriction (38).  Compared to AA, EPA and 
DHA are poor substrates for COX and LOX, thus the cell's ability to produce 
eicosanoids and resulting inflammatory responses is strongly influenced by the fatty acid 
composition of the membrane phospholipids.  Increasing dietary n-3 PUFA will decrease 
AA substrate availability for eicosanoid synthesis as shown by Endres et al. (39) who 
saw decreased PGE2 production following n-3 PUFA feeding.   
 The plasma membrane is an asymmetrical lipid bilayer composed of 
phospholipids, cholesterol, sphingolipids, and integral proteins.  In 1972, Singer and 
Nicolson proposed the fluid-mosaic model which described the fluid nature of the 
membrane bilayer (40).  The fluidity of the membrane affects the organization and 
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dynamics of both lipids and proteins within the membrane and, thus, its biological 
function.  Fluidity of the membrane depends, in part, on its composition.  The length and 
saturation of the fatty acyl chain of phospholipids influences the ability of the 
phospholipid molecules to pack against one another.  A shorter chain length reduces the 
tendency of the acyl chains to interact with one another, and cis-double bonds create 
kinks in the chains that prevent them from packing together.  The presence of cholesterol 
and sphingolipids promotes rigidity.  Saturation is more prevalent in sphingolipid acyl 
chains and the sterol structure of cholesterol causes the fatty acyl chains to become 
closely packed.  It is also known that cholesterol preferentially interacts with 
sphingolipids (41) and, together with glycosylphosphatidylinositol (GPI)-anchored 
proteins, they form liquid-ordered microdomains that float in the liquid-disordered bulk 
membranes (42).  These "rafts" are resistant to solubilization by non-ionic detergents, 
facilitating isolation for study (43).   
 Lipid rafts have been implicated in an ever-increasing number of biologically 
important phenomena such as signaling.  Lipid raft domains play an important role in 
cell signaling, particularly through the organization of surface receptors and adaptor 
molecules into complexes at specific sites in the plasma membrane (44).  Binding of 
proteins by an extracellular ligand can induce rapid lateral translocation to rafts and 
clustering, both events which are important for signal transduction.  In T cells, lipid rafts 
are important in the formation and stabilization of macromolecular complexes 
containing the T cell receptor (TCR), CD4 and CD45, acting as platforms that facilitate 
intramolecular associations and propagation of signal transduction cascades (44).  
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Changes in raft lipid and/or protein composition can alter cell function and phenotype.  
Fan et al. (45) have recently shown that dietary n-3 PUFA remodel the phospholipid 
composition of murine T cell rafts.  In addition, it has been reported that Jurkat T cells 
cultured in vitro with PUFA undergo modification of lipid raft composition and 
suppression of signal transduction (46,47).   
 Many cellular proteins are modified by fatty acid acylation with myristate (14:0) 
and palmitate (16:0) (48).  The Src kinase family of protein tyrosine kinases plays an 
important role in T cell activation and their myristoylation and palmitoylation are 
required for localization to the plasma membrane and rafts (49).  Proteins acylated with 
saturated fatty acids have a higher affinity for rafts and the two Src kinases Lck and Fyn 
are concentrated on the cytoplasmic side of rafts.  The profile of Fyn acylation parallels 
the composition of fatty acids available to the cell.  PUFA treatment of T cells results in 
PUFA acylation of Fyn, most-likely due to the promiscuous nature of the palmitoyl 
acyltransferase enzyme that will covalently attach a broad spectrum of fatty acids to 
proteins.  Inhibition of Fyn palmitoylation by AA and EPA blocked Fyn localization to 
rafts (49).  Therefore, changes in membrane phospholipid composition as well as protein 
acylation can affect signaling from the plasma membrane and, thus, the effect of PUFA 
on these phenomena is likely to have a broad impact on signaling pathways. 
 In addition to its effects on membrane composition, PUFA can directly affect 
gene expression.  A number of inflammatory genes have been identified as targets for n-
3 PUFA including COX-2, 5-LOX, adhesion molecules ICAM-1, VCAM-1 and E-
selectin, and proinflammatory cytokines IL-1a, IL-1b, TNFa, and IL-6 (50-53).  In 
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contrast, constitutively expressed COX-1 and anti-inflammatory genes were unaffected 
(50).  Nuclear factor kB (NFkB) is a transcription factor that is involved in the induction 
of a number of inflammatory genes.  NFkB exists in a latent form comprising a 
transcriptionally active dimer bound to an inhibitor protein, IkB.  Following stimulation, 
IkB is phosphorylated, which targets it for ubiquitination and subsequent degradation.  
The released NFkB can then translocate to the nucleus and activate genes by binding to 
kB response elements in their promoters (54).  Decreased nuclear NFkB has been 
demonstrated following n-3 PUFA feeding (55) and this may be due to decreased 
phosphorylation of IkB (56).  Another group of transcription factors regulated by n-3 
PUFA are the nuclear receptors (57).  Nuclear receptors function as ligand-activated 
transcription factors that regulate the expression of target genes.  PUFA have been 
shown to serve as ligands for peroxisome proliferators-activated receptors (57) and 
retinoid X receptors (58,59).   
 In summary, n-3 PUFA may act through a variety of mechanisms to suppress 
inflammation, including indirect effects via alterations in membrane composition, or 
direct effects via regulation of gene expression. 
 
T CELL ACTIVATION AND DIFFERENTIATION 
 T cell activation is essential for an efficient immune response.  A primary 
stimulus is generated upon interactions between a foreign antigen presented in the 
context of self major histocompatibility complex (MHC) class I or II and the TCR/CD3 
complex.  This signal is on its own insufficient to induce a T cell response.  A second, or 
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costimulatory, signal delivered by an antigen presenting cell (APC) is necessary.  The 
principal costimulatory molecules are B7.1 and B7.2 expressed on the APC that bind to 
CD28 and CTLA-4 on the T cell.  This second signal appears to be fundamental since, in 
its absence, TCR stimulation may lead to anergy (60).  CTLA-4 binds B7 molecules 
with about 20 times more avidity than CD28 and delivers an inhibitory signal which 
effectively shuts down the proliferative phase of the response (61).  The net effect of 
stimulatory signals delivered to the TCR/CD3 complex and the CD28 co-receptor is the 
synthesis and secretion of IL-2.  NF-AT, NFkB, and AP-1 are all necessary transcription 
factors for the expression of IL-2 and IL-2 receptor a chain (IL-2Ra) (60).  IL-2 is the 
most powerful autocrine and paracrine T cell growth factor and activator and its 
production determines whether a T cell will proliferate and become an armed effector 
cell. 
 T cells can be divided into CD4+ and CD8+ subsets based on the mutually 
exclusive presentation of these molecules on their surfaces and their different effector 
functions.  CD4+ and CD8+ T cells can further differentiate in a highly polarized manner 
into Th1/Tc1 or Th2/Tc2 effector cells (8,62).  Th1 cells are characterized by the 
production of IL-2, IFNg, and TNFb and are required to mount a cell-mediated 
immunological response against intracellular pathogens.  Th2 cells are characterized by 
the production of IL-4, IL-5, and IL-10 and are important in humoral immunity and 
defense against extracellular pathogens (8).  In addition to their protective roles in host 
defense, both Th subsets have been implicated in pathological responses.  Th1 cells are 
proinflammatory and can mediate autoimmune and inflammatory diseases, while Th2 
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cells have been implicated in the pathogenesis of asthma and allergy (63).  The two 
helper subsets cross-regulate each other to maintain a balanced heterogeneous response 
using cytokines; Th1 cells inhibit Th2 responses with IFNg, and Th2 cells inhibit Th1 
responses with IL-10 (64).   
 Many factors influence the cell's decision to become a Th1 or Th2 effector.  It 
has been proposed that antigen dose, strength of signal through the TCR, costimulators, 
and genetic modifiers all influence the dominance of a Th cell response, but cytokines 
released from accessory cells have emerged as critical inducers of Th subset 
development (64).  The major accessory cells appear to be dendritic cells (DC) which 
display unique properties aimed at inducing an immune response against antigens from 
invading organisms (65).  Specific DC subsets located in distinct splenic micro-
environments appear to bias Th subset development by secreting critical cytokines.  
CD8a+ DCs produce IL-12 in response to microbes, whereas CD8a- DCs induce IL-4 
production.  Signaling through the IL-12 receptor (IL-12R) on the T cell surface 
activates Stat-4 (signal transducer and activator of transcription 4) which induces T-bet 
(T-box expressed in T cells) and promotes Th1 lineage commitment.  In contrast, 
signaling through the IL-4 receptor activates Stat-6 which induces GATA-3 leading to 
Th2 differentiation (64).  T-bet is a Th1-specific factor that is involved in chromatin 
remodeling of the IFNg gene promoter and induces IL-12Rb2-subunit expression.  
Transcriptionally inactive genes have regions of condensed chromatin, unmodified 
histones, and are densely methylated.  Histone acylation and DNA de-methylation favor 
chromatin decondensation, providing an open conformation for transcription factor 
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access (66).  GATA-3 seems to be crucial for inducing some, but perhaps not all, key 
attributes of Th2 cells.  GATA-3 has been shown to directly regulate IL-5 expression, 
and indirectly affect IL-4 transcription.  GATA-3 remodels the chromatin of the IL-4 
promoter in a manner similar to that by which T-bet remodels the IFNg promoter.  
GATA-3 also upregulates c-Maf, an acute transcription factor for IL-4 (63). 
 In addition to the functional differences of Th1 and Th2 cells, there are also 
differences in their patterns of membrane compartmentalization into lipid rafts (44).  
Leitenberg et al. (67) have recently shown that Th1 cells recruit both the TCR/CD3 
complex and CD45 to rafts following stimulation, while Th2 cell stimulation does not 
result in stable association of TCR complex components with raft domains.  Possibly as 
a result, Th2 cells have been shown to exhibit defects in proximal signaling events such 
as ZAP-70 phosphorylation, Fyn phosphorylation, and calcium mobilization (68).  Thus, 
it is evident that Th1 and Th2 cells have unique ways of organizing molecules at the 
plasma membrane, which is likely to impact the cell’s ability to signal and ultimately 
function. 
 
n-3 PUFA REGULATION OF T CELL FUNCTION 
 There have been numerous investigations measuring a variety of outcomes on n-
3 PUFA and T cell function in humans, mice, rats, and cell culture systems.  Several 
studies have examined lymphoproliferation.  Three different clinical trials of dietary 
supplements ranging from 2.4-18 g/d of EPA and DHA reported significant reductions in 
mitogen-induced proliferation and IL-2 production in human peripheral blood 
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mononuclear cells (PBMC) (69-71).  Another human study found similar reductions in 
proliferation and IL-2 secretion when 180 g/d of fish was used rather than oil (72).  
Additionally, Grimble et al. (73) found that 6 g/d of FO was able to decrease TNFa 
production.   
Similar studies have been conducted in rodents.  Jolly et al. (74,75) fed mice 
10g/kg EPA or DHA for 10 days and reported a significant decrease in ConA-stimluated 
splenocyte proliferation in both diet groups.  This was accompanied by a decrease in IL-
2, IL-2Ra expression, and reductions in DAG and ceramide, lipid second messengers.  
Feeding rats a diet containing 20% (wt/wt) FO for 10 weeks, a much higher level of fat 
and longer feeding duration, also suppressed splenocyte proliferation (76).  Additional 
cytokine analyses have reported decreased IFNg (77,78) and IL-12 (77) in mitogen-
stimulated or Listeria monocytogenes-infected splenocytes from n-3 PUFA-fed mice.  
Interestingly, Fritsche et al. (79) found that 18% dietary FO by weight enhanced in vivo 
IFNg in serum and the spleen from Listeria-infected mice.  They suggested that the FO-
induced increase in circulating IFNg could be a consequence of alterations in the 
expression and/or function of the IFNg receptor (IFNgR).  In a follow-up study, Feng et 
al. (80) showed a decrease in IFNgR-1 expression in FO-fed mouse splenocytes and 
peritoneal macrophages infected with Listeria.  More recently, Arrington et al. (81) 
noted decreased splenocyte IL-2 secretion from mice fed diets containing 1% DHA by 
weight only when cultures were stimulated with antibodies against CD3 and CD28 
(aCD3/aCD28).  Thus, in that experimental system, dietary n-3 PUFA appear to alter 
TCR-dependant or costimulatory (CD28) signal transduction.  Using the same set of 
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stimuli, Sasaki et al. (82) showed a decrease in CD4 and CD8 and an increase in CD28 
surface expression in DHA-fed mouse splenocytes.  In a further attempt to elucidate a 
mechanism of action, Arrington et al. (83) isolated CD4+ and CD8+ T cell populations 
from mice following a 14 day diet of 2% (wt/wt) FO.  They found that an effect on 
proliferation was dependant on the stimulus used in culture.  FO suppressed CD8+ T cell 
proliferation in cells stimulated with aCD3/aCD28.  In contrast, FO increased CD4+ T 
cell proliferation when cells were stimulated with aCD3 plus phorbal-12-myristate-13-
acetate (PMA), an agonist that stimulates PKC (protein kinase C).  Interestingly, this 
stimulation combination directs cells towards a Th2-like phenotype (83,84).  Another 
study saw a decrease in reduction in PLCg tyrosine phosphorylation in mitogen-
stimulated rat splenocytes fed 20% (wt/wt) FO (85).  Fan et al. (submitted) have recently 
shown that CD3+ T cells from 4% FO (wt/wt)-fed mice had decreased PKCq 
colocalization with lipid rafts after aCD3/aCD28 stimulation.  PKCq is an important 
molecule in the regulation of T cell proliferation and apoptosis and requires translocation 
to lipid rafts to be active (86).  These data indicate that changes in membrane 
composition induced by dietary n-3 PUFA have functional consequences with respect to 
the membrane distribution of T cell signaling proteins. 
In cell culture experiments, mouse splenocytes and human PBMC cultured in 
DHA or EPA had reduced levels of proliferation, IL-2, and IL-2Ra expression following 
mitogen stimulation (78,87,88).  In more mechanistic studies, Denys et al. (89) noted a 
decrease in PMA-stimulated PKC activation and ERK1/ERK2 signaling in Jurkat T cells 
that were cultured in the presence of up to 60 mM EPA and DHA.  Diaz et al. (90) 
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showed that mitogen-stimulated human PBMC had increased phospholipase D (PLD) 
activity, a regulator of T cell proliferation and apoptosis, following culture in 5-15 mM 
DHA.  They also found greater DHA incorporation in the phospholipids of rafts than 
non-rafts.  Therefore, they concluded that DHA stimulates PLD by an indirect 
mechanism involving lipid modification of rafts. 
 In an attempt to explain the suppressive effect of n-3 PUFA on T cell 
proliferation, studies have examined the effect of dietary n-3 PUFA on T cell apoptosis.  
Avula et al. (91) showed that feeding young (4 months) and old (9 months) mice 5% 
(wt/wt) FO resulted in increased splenocyte apoptosis in both age groups.  Fernandes et 
al. (92) reported an increase in mouse splenocyte apoptosis following a 10% (wt/wt) FO 
diet, and this was associated with an increase in the surface expression of Fas, a death 
receptor and mediator of apoptosis.  In a similar study, FasL, the molecule that binds to 
and activates Fas, was upregulated and Bcl-2, an anti-apoptotic molecule, was decreased 
in mouse splenocytes after a 4% (wt/wt) FO diet (93).  Additionally, Jurkat T cells 
cultured in 0-90 mM DHA for up to 48 hours produced more caspase 3, a cysteine 
protease involved in the apoptotic process (94). 
 
APOPTOSIS 
 Apoptosis refers to a morphologically defined mode of programmed cell death, 
which shapes the lymphocyte repertoire though selection of maturing T cells in the 
thymus and maintains homeostasis in the mature lymphocyte pool after antigenic 
expansion.  The dysregulation of apoptosis plays a major role in the pathogenesis of 
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disease.  The fundamental morphological features of apoptosis are chromatin 
condensation and cell shrinkage, accompanied by membrane blebbing, culminating in 
the break up into membrane-bound apoptotic bodies (95).  During this process, 
phosphatidylserine flips to the outer leaflet of the cell membrane and is recognized and 
phagocytosed by macrophages or adjacent cells.  Thus, apoptosis does not trigger an 
inflammatory response (95,96).  Due to the distinctive characteristics, apoptosis can 
easily be detected using a variety of assays.  For example, DNA fragmentation can be 
detected by TUNEL (terminal-deoxynucleotidyl-transferase-mediated dUTP-
digoxygenin nick end labeling) or subdiploid assays, and phosphatidylserine 
externalization can be detected by Annexin V binding assays (95). 
 There are at least two major pathways of T cell apoptosis.  One pathway, known 
as passive cell death, results from the absence of growth factors and other survival 
stimuli (97).  Passive cell death is important in the elimination of cells that fail to 
undergo positive selection in the thymus (98).  The second pathway, known as 
activation-induced cell death (AICD), is induced by chronic antigen stimulation (97) and 
plays an essential role in peripheral deletion involved in tolerance and homeostasis 
(96,99).  Additionally, AICD is important in negative selection in the thymus.  Negative 
selection occurs when the TCR of a thymocyte binds a peptide-MHC ligand with high 
affinity, leading to apoptotic death of the cell (98).  The biochemical mechanisms of 
passive cell death and AICD are distinct.  However, both are mediated by the action of 
caspases, cysteine proteases with specificity for aspartate residues.  Caspases exist as 
inactive zymogens (proenzymes) in the cytoplasm until activated by proteolytic 
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cleavage.  They are organized in cascades that amplify the initial death signal (100).  
Passive cell death results from activity of the intrinsic or the mitochondrial pathway.  
AICD occurs following events which follow the extrinsic or death receptor pathway. 
 When cells are deprived of survival stimuli, there is an increase in mitochondrial 
permeability and breakdown of mitochondrial membrane potential.  As a consequence, 
cytochrome c is released into the cytoplasm and binds to Apaf-1.  Pro-caspase 9 
associates with this complex, leading to its proteolytic activation.  Active caspase 9 
subsequently activates downstream caspases including caspase 3, leading to cell death 
(97,101).  Mitochondrial membrane permeability is highly regulated by members of the 
Bcl-2 family.  Anti-apoptotic members of the Bcl-2 family, including Bcl-2 and Bcl-xL, 
prevent membrane permeability and release of cytochrome c.  Pro-apoptotic members, 
including Bax, Bak, Bid, and Bad, enhance membrane permeability and resulting 
cytochrome c release (95). 
 In the immune system, AICD acts as feedback mechanism for terminating an 
ongoing immune response and serves to maintain peripheral tolerance.  T cells 
responding to an antigenic stimulus first expand in number and then decrease as a result 
of AICD.  Repeated antigen stimulation leads to the expression of death receptors that 
link extracellular signals to apoptosis.  Death receptors belong to the tumor necrosis 
factor receptor (TNFR) superfamily and include Fas, TNFR1, and TRAIL-R (102).  
They are characterized by multiple cysteine-rich repeats in their extracellular domain 
and a protein-protein interaction death domain (DD) in their cytoplasmic tail (103).  Fas 
(CD95, APO-1) is the best-studied receptor and is the principal mediator of CD4+ T cell 
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AICD (97).  Fas-mediated apoptosis is initiated by its interaction with FasL (CD95L), 
which is a TNF-related type II transmembrane molecule (103).  Unlike Fas, which is 
expressed in wide variety of tissues including thymus, spleen, lymph node, kidney, liver, 
and heart (104), FasL is expressed primarily in activated T cells and NK cells (103,105).  
Interestingly, while IL-2 plays a critical role in cell growth, it also sensitizes the same 
cells to apoptosis.  When high levels of IL-2 are present, this cytokine promotes FasL 
expression (106).  Fas trimerization, necessary for apoptosis transduction, is triggered by 
FasL binding and immediately recruits a complex of associated proteins known as the 
death-inducing signaling complex (DISC).  The adaptor molecule, Fas-associated death 
domain protein (FADD), binds to Fas via its DD.  In addition, FADD also has a death-
effector domain (DED) with which it recruits the DED-containing pro-caspase 8 into the 
DISC (103).  Pro-caspase 8 is then cleaved and active caspase 8 dissociates from the 
DISC to cleave pro-caspase 3, initiating the caspase cascade that results in cell death.  
The importance of Fas/FasL in AICD is illustrated by the development of 
lymphoproliferative disorders in lpr/lpr and gld/gld mice due to mutations in the genes 
encoding Fas and FasL, respectively (97). 
 Recent studies have shown that Fas and components of the DISC translocate into 
lipid rafts following TCR restimulation and/or Fas ligation (107-109).  Furthermore, they 
reported that rafts are required for efficient propagation of apoptotic signals.  Grassme et 
al. (110) have implicated ceramide generation in Fas clustering in membrane 
microdomains.  They showed that ligation of Fas results in the activation of acidic 
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sphingomyelinase (ASM) which hydrolyzes sphingomyelin into ceramide.  Ceramide is 
able to coalesce and form membrane microdomains.  
 Two pathways of Fas-mediated apoptosis have been described, dependent on the 
quantity of caspase 8 activated (101).  In type I cells (e.g., lymphocytes), a high amount 
of caspase 8 is released from the DISC leading to direct caspase 3 activation.  However, 
in type II cells (e.g., hepatocytes), despite similar expression levels of Fas and signaling 
molecules, the DISC is poorly formed and the amount of caspase 8 activated is 
insufficient to process caspase 3, but sufficient to cleave the Bcl-2 family member Bid 
(101,111).  Bid cleavage results in a pro-apoptotic fragment called tBid that mediates 
mitochondrial cytochrome c release and resulting apoptosis.  
 T cells are not equally sensitive to AICD (112).  In addition to their differential 
cytokine production and functions, Th1 and Th2 cells have different susceptibilities to 
AICD, with Th1 cells reported to be AICD sensitive and Th2 cells reported to be AICD 
resistant (112,113).  The selective death of Th1 cells has been attributed to a preferential 
requirement for phorbol ester-sensitive PKC isoforms (114), and the upregulation of Fas 
(114) and FasL (114,115).  In contrast, the resistance of Th2 cells to AICD has been 
linked to expression of c-FLIP, an enzymatically inert homologue of caspase 8 (116), 
and PI3-K activity (117). 
 
RATIONALE AND EXPERIMENTAL MODEL 
 Major observations in our lab have demonstrated that dietary n-3 PUFA suppress 
splenic and T cell proliferation (74,75,81,83,118), and diminish delayed-type 
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hypersensitivity (118).  Additionally, our lab has found that dietary n-3 PUFA suppress 
Th1 proliferative capacity in mice due to a reduction in IL-2 production and/or function, 
and enhance counter-regulatory IL-4-driven Th2 cells (83).  These observations may 
implicate a role for apoptosis in these processes.  An increase in AICD may explain a 
loss of proliferative capacity of T cells from n-3 PUFA-fed mice and explain the 
immunosuppressive effects described above.  There are relatively little data on the 
effects of n-3 PUFA on lymphocyte apoptosis.  The few studies that have addressed this 
issue have examined mixed cell populations, i.e., whole splenocytes (92,93).  Avula et 
al. (93) did examine CD4+ and CD8+ T cell subset apoptosis, however this study did not 
culture purified CD4+ or CD8+ T cells, but rather used flow cytometry to quantify the 
subset populations after stimulation of the mixture.  We believe that AICD is a critical 
apoptotic pathway to examine since it is the form of apoptosis associated with the 
deletion of cells involved in chronic inflammation and autoimmune disease.  Consistent 
with this thinking, we will focus on the CD4+ Th1 subset, as it is the cell mediator of 
chronic inflammation.  
 Previous studies from our lab have demonstrated that low dose, short-term n-3 
PUFA dietary supplementation can modulate specific functions and responses of murine 
splenic lymphocytes (118).  That study found that a 10 day feeding period using 1% 
(wt/wt) of highly purified EPA or DHA was effective at modulating lymphocyte 
membrane composition and proliferation.  Thus, we have continued to use a similar 
feeding paradigm. 
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 Our lab has used the C57BL/6 mouse strain as the model to study n-3 PUFA and 
immune function.  The C57BL/6 mouse is the most widely used mouse strain and is 
extensively used in immunology.  In addition, it is Th1 biased, making it a suitable 
choice to study inflammatory processes and other Th1-mediated pathologies (119). 
 We have chosen to use three main sets of agonists to activate T cells.  Previous 
experiments have determined the optimal concentrations for effectiveness (81).  These 
agonists include a pair of monoclonal antibodies that engage the TCR/CD3 complex and 
the important costimulatory molecule CD28 (aCD3/aCD28); a pair of stimuli that 
bypasses the membrane to stimulate intracellular PKC and calcineurin 
(PMA/Ionomycin); and two agonists which act on membrane and intracellular 
components (aCD3/PMA).  Interestingly, the nature of the stimulus can result in T cell 
bias towards specific cytokine secretion profiles (83,84).  Noble et al. (84) showed that 
when unprimed T cells received a strong calcium signal and a weak PKC signal they 
preferentially shifted towards Th1 effector cells.  In contrast, strong PKC combined with 
a weaker calcium signal resulted in a Th2 shift.  Comparably, Arrington et al. (83) 
showed that our PMA/Ionomycin pair directed T cells towards a Th1 phenotype and the 
aCD3/PMA pair directed T cells towards a Th2 phenotype. 
 The overall objective of these experiments is to determine the extent to which 
dietary n-3 PUFA modulate AICD in the Th1 subset of CD4+ murine T cells.  The 
results of these experiments, combined with our previous studies, will contribute to the 
elucidation of the mechanisms by which dietary n-3 PUFA suppress chronic 
inflammation mediated by T cells.
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CHAPTER II 
 
 
 
n-3 POLYUNSATURATED FATTY ACIDS PROMOTE ACTIVATION-
INDUCED CELL DEATH IN MURINE T LYMPHOCYTES* 
 
 Previous studies showing dietary n-3 polyunsaturated fatty acids (PUFA) 
attenuate T cell immune-mediated inflammatory diseases led us to hypothesize that n-3 
PUFA promote activation-induced cell death (AICD) in T cells.  Since T cell subsets 
display a differential resistance to AICD, we compared the effects of n-3 PUFA feeding 
on T cells stimulated in vitro to express different cytokine profiles.  Mice were fed either 
diets lacking n-3 PUFA (control) or n-3 PUFA-containing diets for 14 days.  Splenic T 
cells were stimulated with aCD3/aCD28, PMA/Ionomycin, or aCD3/PMA for 48 h, 
followed by reactivation with the same stimuli for 5 h.  Apoptosis was measured using 
AnnexinV/propidium iodide.  n-3 PUFA were selectively incorporated into membrane 
phospholipid pools.  Cytokine analyses revealed that n-3 PUFA enhanced AICD only in 
T cells expressing a Th1-like cytokine profile following stimulation with 
PMA/Ionomycin compared to mice fed the n-6 PUFA control diet (p=0.0008).  In 
contrast, no increase in apoptosis was seen in T cells stimulated with aCD3/PMA, which 
exhibited a Th2 cytokine profile.  These data demonstrate that the ability of n-3 PUFA to 
promote AICD is dependent upon the activation stimulus.  In conclusion, we have  
________________________________ 
*Part of this chapter is reprinted with permission from "n-3 Polyunsaturated fatty acids 
promote activation-induced cell death in murine T lymphocytes" by Switzer, K.C. et al., 
2003.  Journal of Nutrition, 133, 496-503.  Copyright 2003 by American Society for 
Nutritional Sciences. 
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identified a novel mechanism by which n-3 PUFA modulate T cell mediated immunity 
by selective deletion of Th1-like cells while maintaining or enhancing the Th2 mediated 
humoral immune response. 
 
INTRODUCTION 
Apoptosis is a highly regulated process resulting in cell death without an ensuing 
inflammatory response, thus playing an important role in maintaining lymphocyte 
homeostasis and T cell repertoire, and ensuring peripheral tolerance (96).  T cells can 
succumb to apoptosis by two pathways; passive cell death (absence of growth factors) 
and chronic antigen stimulation (activation-induced cell death, AICD).  AICD is 
specifically responsible for the signal-induced elimination of previously activated 
lymphocytes.  The induction of AICD, in part, is mediated by the co-expression of Fas 
and its ligand, FasL, on the T cell plasma membrane (96,120,121).  The Fas death 
receptor is a member of the nerve growth factor receptor/TNF receptor family and 
transmits signals resulting in apoptosis (122).  Stimulation upregulates the expression of 
FasL and other death factors in AICD-sensitive T cells, which, in turn, induce Fas on the 
same or neighboring cells.  Death receptors are activated by oligomerization by rapidly 
assembling a number of adaptor proteins resulting in an irreversible activation of 
proteases and nucleases which culminate in apoptosis (123).  Mutations in Fas or FasL 
result in lymphoproliferation and manifestations of autoimmunity in both mice and 
humans (124,125), illustrating the critical role of AICD in the maintenance of self-
tolerance.  
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T cells can be divided into CD4+ and CD8+ subsets based on the mutually 
exclusive presentation of these molecules on their surfaces and their different effector 
functions.  Mature CD4+ effector cells can be further polarized into Th1 and Th2 subsets 
according to the cytokines they produce (8).  Th1 cells produce IL-2, IFNg, and TNFb 
and are important in cell-mediated immunity against intracellular pathogens (8,66).  Th1 
cells are proinflammatory and have been implicated in the pathogenesis of human 
inflammatory and autoimmune diseases such as rheumatoid arthritis, type-1 diabetes, 
and inflammatory bowel diseases (9,126).  Th2 cells produce IL-4, IL-5, and IL-10 and 
are important in humoral immunity and defense against extracellular pathogens (66).  
Th1 and Th2 effectors have differential susceptibilities to AICD, with Th1 cells being 
AICD sensitive and Th2 cells being AICD resistant (115).  The selective death of Th1 
cells has been attributed to a preferential requirement for phorbol ester-sensitive protein 
kinase C (PKC) isoforms (114) and the upregulation of FasL expression (115).  In 
addition, the resistance of Th2 cells to AICD has been linked to expression of FAP-1, an 
inhibitor of apoptosis (112), and the selective upregulation of phosphatidylinositol-3’-
kinase (PI-3-K) activity (117). 
Among dietary factors, n-3 polyunsaturated fatty acids (PUFA) found in fish oil 
(FO) have been shown to potently attenuate T cell-mediated inflammatory diseases in 
humans and experimental model systems (34,127).  In contrast, dietary lipids rich in n-6 
PUFA, found in vegetable oils and animal fats, can be deleterious in some inflammatory 
diseases (34-36,70,128).  This is significant because the Western diet contains 10 to 20 
times more n-6 than n-3 PUFA (37).  Previous studies have demonstrated that n-3 PUFA 
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decrease T cell proliferation (74,83), cytokine secretion (70,77,129), intracellular 
enzyme activity (130), and gene transcription (75,77,131).  Additionally, we have found 
that n-3 PUFA suppress T cell proliferative capacity due to a reduction in IL-2 
production and/or function, and to enhancement of counter-regulatory IL-4-driven Th2 
cells (83).  Several investigators have examined the effects of n-3 PUFA on apoptosis in 
mixed cell populations, e.g. whole splenocytes (132).  In those studies, n-3 PUFA 
increased T cell apoptosis in cultures of whole splenocytes.  Since we have recently 
found that the diet-induced changes in T cell proliferation are due principally to intrinsic 
alterations in the T cell response to mitogenic stimuli (133), the effects of n-3 PUFA on 
apoptosis in purified T cells remained to be examined.  Our results indicate that dietary 
n-3 PUFA preferentially promote AICD in a T cell subset exhibiting a Th1 cytokine 
profile.  This exciting observation provides yet another unique mechanism by which n-3 
PUFA exert a significant and selective effect on T cell proinflammatory function in the 
whole animal. 
 
MATERIALS AND METHODS 
Diet and animals 
All experimental procedures using laboratory animals were approved by the 
University Laboratory Animal Care Committee of Texas A&M University.  Female, 
pathogen-free (12–14g) C57BL/6 mice were purchased from Frederick National Cancer 
Research Facility, Frederick, MD.  Animals were housed in autoclaved polycarbonate 
microisolator cages and were maintained at room temperature (~25°C) on a 12 h 
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light:dark cycle.  Mice were initially fed standard mouse chow (Teklad 9F Sterilizable 
Rodent diet, Madison, WI) during a 1 week acclimation period and had free access to 
autoclaved water and diet. The study was completed in two phases.  For the first 
experiment, mice were assigned to one of three semi-purified diets containing:  2% 
safflower oil ethyl ester (SAF, n-6 PUFA control), 2% olive oil ethyl esters (OO, 
monounsaturated fatty acid devoid of both n-3 and n-6 PUFA) or 2% Menhaden fish oil 
(FO2, n-3 PUFA) for 14 d.  For the second experiment, mice were assigned to one of the 
following diets: SAF, 4% Menhaden fish oil (FO4) or 9% Menhaden fish oil (FO9) for 
14 d.  In a third study, mice were assigned to a 5% corn oil (CO) or 1% DHA diet.  The 
purified diets met National Research Council nutrition requirements and varied only in 
lipid composition (81,134).  The diet composition, expressed in g/kg of complete diet, 
was as follows for experiment I: 200 g casein, 420 g sucrose, 219.8 g starch, 60 g 
cellulose, 35 g AIN-76 mineral mix, 10 g vitamin mix AIN-76, 3 g dl-methionine, 2 g 
choline chloride, and 0.2 g tertiary butyl hydroquinone.  The lipid content of the three 
diet groups was: SAF, 30g/kg CO combined with 20 g/kg safflower oil ethyl esters; OO, 
30g/kg CO combined with 20 g/kg olive oil ethyl esters; FO2, 30g/kg CO combined with 
20 g/kg menhaden fish oil.  For experiment II, the basic diet composition differed only in 
the reduced amount of sucrose for FO9 (370 g/kg) to compensate for the increase in fat 
content.  The lipid content of the three diet groups was: SAF, 30g/kg CO combined with 
20 g/kg safflower oil ethyl esters; FO4, 10 g/kg CO combined with 40 g/kg menhaden 
fish oil; FO9, 10 g/kg CO combined with 90 g/kg menhaden fish oil.  For the third study, 
the lipid content of the two diets was: CO, 50g/kg CO; DHA, 10g/kg DHA ethyl esters 
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combined with 40g/kg CO.  The fatty acid composition, expressed in g/kg of complete 
diet, is detailed in Table 1.  The linoleic acid (18:2 n-6) content from CO was 2-7% of 
total energy and, thus, met the minimum 1–2% essential fatty acid requirement for 
rodents (134).  The vitamin A, D, and E levels were approximately equal and exceeded 
the minimum requirement.  Safflower oil (70.5% as 18:2 n-6) was obtained in ethyl ester 
form from the National Institute of Health Test Materials Program (Charleston, SC).  
Control dietary lipids lacking n-3 PUFA, olive oil and corn oil (57.3% as 18:2 n-6), were 
obtained from Degussa Bioactives (Champaign, IL), Menhaden fish oil (13.1% as 20:5 
n-3, 9.7% as 22:6 n-3) was provided by the National Institutes of Health Test Materials 
Program.  Diets were analyzed by gas chromatography (Table 1), aliquoted, and stored 
at -80°C.  Diets were provided ad libitum and were changed daily to prevent 
peroxidation.  The analysis confirmed the enrichment of 18:2 (n-6) in the SAF diet 
(53.3% of total lipid), 20:5 (n-3) and 22:6 (n-3) in the FO2 diet (6.1% and 4.3% of total 
lipid, respectively), 20:5 (n-3) and 22:6 (n-3) in the FO4 diet (11.7% and 8.1% of total 
lipid, respectively), and 20:5 (n-3) and 22:6 (n-3) in the FO9 diet (13.4% and 9.4% of 
total lipid, respectively).  There was no significant difference in food intake between 
dietary groups, and weight gain was similar in all groups (data not shown). 
  
Isolation and preparation of splenic lymphocytes 
Mice were euthanized by CO2 asphyxiation.  Spleens were placed in 3 ml of 
RPMI-complete medium [RPMI 1640 with 25 mM HEPES (Irvine Scientific, Santa Ana, 
CA) supplemented with 10% FBS (Irvine Scientific), 1 x 105 U/L penicillin and 100 
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mg/L streptomycin (Irvine Scientific), 2 mM L-glutamine, and 10 µM 2-
mercaptoethanol] (74).  Spleens were dispersed with glass homogenizers and passed 
through a 149 micron wire mesh filter (Pall Gelman, Fisher Scientific) to create single-
cell suspensions.  Cells were subsequently washed with RPMI-complete medium prior to 
T cell enrichment. 
 
 
 
 
T cell purification 
Total lymphocytes were initially enriched by a density gradient centrifugation 
method using Lympholyte-M (Cedarlane, Toronto, Canada) (81) in accordance with the 
manufacturer’s protocol. Subsequently, 60–90 x 106 mononuclear cells were loaded onto 
 
Table 1.  Fatty Acid Composition of Experimental Diets    
        
Fatty Acid CO SAF OO FO2 FO4 FO9 DHA 
          
14:0 tr 0.3 0.4 3.7 7.4 8.2 tr 
16:0 12.2 12.4 14.8 13.2 16.1 16.9 10.0 
16:1 (n-7) 0.1 tr 0.9 4.8 9.6 11.0 0.2 
18:0 2.0 2.8 5.1 2.6 3.0 3.1 2.1 
18:1 (n-7 + n-9) 30.0 28.4 37.4 20.8 13.8 11.8 25.9 
18:2 (n-6) 54.3 53.3 34.1 35.5 13.5 8.0 46.6 
18:3 (n-3) 1.1 1.0 2.0 1.2 1.4 1.2 1.0 
20:5 (n-3) tr tr tr 6.1 11.7 13.4 tr 
22:5 (n-3) tr tr tr 1.1 1.7 1.9 tr 
22:6 (n-3) tr tr tr 4.3 8.1 9.4 14.0 
Total SFA 14.2 16.0 21.2 20.1 26.9 28.7 12.1 
Total MUFA 30.1 28.8 39.0 26.4 24.0 23.5 52.0 
Total (n-6) PUFA 54.3 53.3 34.1 35.5 14.3 9.4 46.6 
Total (n-3) PUFA 1.1 1.0 3.0 12.8 22.9 25.9 15.0 
Only the major fatty acids are listed.  CO, corn oil-containing diet;  SFA, saturated fatty acid;  MUFA, monounsaturated fatty 
acid;  PUFA, polyunsaturated fatty acid;  SAF, linoleic acid-containing diet;  OO, oleic acid-containing diet;  FO2, fish oil (2%, 
w/w)-containing diet;  FO4, fish oil (4%, w/w)-containing diet; FO9, fish oil (9%, w/w)-containing diet;  DHA, docosahexanoic 
acid-containing diet;  tr, trace amount (<0.1 g/100 g).   Values are expressed as g/100g of total fatty acids in each diet. 
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a negative-selection mouse T cell purification column (R&D Systems, Minneapolis, 
MN) and incubated for 10 min at room temperature.  Nonadherent cells were eluted for 
assay.  The purity of the T cell population as analyzed by flow cytometry was 
determined to be 90.3 ± 1.4%, n=3 (81). 
 
T cell apoptosis assay 
T cells, 5 x 105 cells/well from each mouse, were cultured in the presence of each 
of five sets of stimuli: (a) 1 µg/ml plate-bound purified hamster anti-mouse CD3e 
(aCD3) monoclonal antibody (PharMingen, San Diego, CA) with 5 µg/ml soluble 
purified hamster anti-mouse CD28 (aCD28) monoclonal antibody (PharMingen); (b) 0.5 
ng/ml phorbol-12-myristate-13-acetate (PMA) (Sigma, St Louis, MO) with 1 µg/ml 
aCD3; (c) 1 ng/ml PMA with 500 nM Ionomycin (Calbiochem-Novabiochem, San 
Diego, CA); (d) 50 ng/ml recombinant human soluble FasL fused to a FLAG-tag (FasL) 
(Alexis Biochemicals, San Diego, CA) with 1 mg/ml Enhancer (aFLAG) (Alexis 
Biochemicals); or (e) 330 ng/ml dexamethasone (Sigma).  Choice of concentrations were 
determined in previous experiments (81).  Cells were incubated at 37°C, 5% CO2 for 24 
h.  Apoptosis was assessed via flow cytometry (see below). 
 
Induction of AICD 
AICD was induced as previously described by Dao et al. (122) with slight 
modifications.  T cells, 5 x 106 cells/well, were cultured in duplicate in the presence of 
either stimuli (a), (b), or (c) as described above for 48 h at 37°C, 5% CO2 (Figure 1).  
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Cells were harvested, washed and recultured at 3 x 106 cells/well in RPMI-complete 
medium overnight at 37°C, 5% CO2.  Cultures were reharvested and dead cells were 
removed using Lympholyte-M in accordance with the manufacturer's protocol (81).  
Subsequently, 1 x 106 cells/well were recultured either in the presence of the initial 
stimuli (“reactivated”) or in RPMI-complete medium (“unreactivated”) for 5 h at 37°C, 
5% CO2.  Following reactivation, apoptosis was assessed via flow cytometry (see 
below). 
 
Staining and flow cytometric analysis for apoptotic cells 
 Harvested T cells (1 x 106 cells) were washed with cold 1X PBS and stained with 
fluorescein isothiocyanate (FITC)-conjugated Annexin V (PharMingen) and propidium 
iodide (PharMingen) for 15 min according to PharMingen’s Annexin V Kit I.  Stained 
cells were subsequently analyzed for apoptosis via flow cytometry (FACSCalibur; 
Becton-Dickinson, Bedford, MA).  Controls consisted of single staining for Annexin V-
FITC only and PI only.  T cell population purity was assessed by staining 5 x 105 cells 
with 5 µg/ml of a FITC-conjugated anti-mouse CD3e monoclonal antibody 
(PharMingen) following 5 µg/ml anti-mouse CD16/CD32 monoclonal antibody (Fc 
Block; PharMingen) treatment. 
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Figure 1.  Experimental design for AICD induction.  Purified splenic T cells from mice fed the test 
diets were activated as follows: aCD3/aCD28, PMA/aCD3, or PMA/Ionomycin for 48 h.  Following an 
overnight rest period in RPMI-complete medium, T cells were either reactivated with the initial stimuli or 
cultured in RPMI-complete medium for 5 h.  Apoptosis was analyzed with Annexin V/PI as described in 
the Materials and Methods. 
 
 
 
 
Cytokine ELISAs 
 For cytokine analyses, cells were cultured for 48 h as described in Figure 1.  Cell 
culture supernatants from duplicate wells of T cells for each stimulus were harvested, 
pooled, and stored at -80°C.  After thawing, supernatants were assayed in duplicate for 
IL-2, IL-4, IL-10, and IFNg using Mouse Immunoassay (ELISA) Kits (R&D Systems).  
Results are expressed as pg/3 x 106 cells as previously described (74). 
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T cell membrane phospholipid analysis 
T cell lipids were extracted by the method of Folch et al. (135).  The individual 
phospholipid classes were separated by thin layer chromatography (TLC) on silica gel 
60 plates using chloroform/ methanol/ acetic acid/ water (50: 37.5: 3.5: 2, v/v) (136).  
Bands were detected under ultraviolet light after spraying with 0.1% 8-anilino-
naphthalene-sulfonic acid.  Fractions were scraped from the plates, transesterified, and 
fatty acid methyl esters were extracted using hexane and 0.1 M potassium chloride.  The 
fatty acid composition of sphingomyelin, phosphatidylcholine (PC), phosphatidylserine 
(PS), phosphatidylinositol (PI), phosphatidylethanolamine (PE), and cardiolipin were 
analyzed by gas chromatography as previously described (136). 
 
Assessment of systemic oxidative stress 
Livers were removed from mice at the time of necropsy, flash frozen in liquid 
nitrogen and RNA was isolated using Ambion's Totally RNA Kit (Austin, TX) 
according to the manufacturer's protocol.  The isolated RNA was subsequently treated 
with DNase Inactivation Reagent (Ambion) to remove contaminating DNA.  Reverse 
transcription was performed with 2 mg RNA in a 50 ml reaction using Superscript II 
(Gibco BRL, Rockville, MD).  Reactions in the absence of reverse transcriptase enzyme 
served as negative controls.  Real time PCR was performed using an ABI 7700 unit 
(Applied Biosystems, Foster City, CA).  Primer pairs for mouse CD36, peroxisome 
proliferator-activated receptor g (PPARg), and scavenger receptor type A (SRA) were 
designed with Primer Express software, version 1.5.  The sequences of the primers were 
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as follows: CD36, forward, 5'-CAA GCT CCT TGG CAT GGT AGA-3', and reverse, 5'-
TGG ATT TGC AAG CAC AAT ATG AA-3'; PPARg, forward, 5'-GAT GAA TAA 
AGA TGG AGT CCT CAT CTC-3', and reverse, 5'-CCG CAG GCT TTT GAG GAA-
3'; and SRA, forward, 5'-CAG GAA TAA GAG GTA TTC CAG GTG TTA-3', and 
reverse, 5'-TCC TGG TGC TCC TGG GTT T-3'.  Primer sequences were checked for 
sequence homology against known genes using BLAST 
(http://www.ncbi.nlm.nih.gov/blast/).  Each PCR reaction consisted of 25 ml 2X SYBR 
Green master mix (Applied Biosystems), 300 nM final concentration forward and 
reverse primers, and 2 ml reverse transcription reaction in a 50 ml final reaction volume.  
To assess assay reproducibility, select RT reactions were performed in triplicate 
followed by PCR.  Values for cycle threshold (CT), the point at which exponential 
amplification of the PCR products is detected, were obtained from the Applied 
Biosystems software. 
 
Fluorescence microscopy 
Morphological assessment of apoptosis was performed by 4’,6-diamidine-2’-
phenylindole dihydrochloride (DAPI) staining on a TE 300 Nikon Eclipse microscope 
equipped with a Princeton Instruments MicroMax 5 MHz cooled digital CCD camera.  
Images were processed using Metamorph software, version 4.6r3 (Universal Imaging 
Corp., Downing, PA). 
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Statistical analysis 
A mixed model was used to assess whether the dietary effects differed among the 
various stimuli.  This mixed model is essentially a 2-way ANOVA with factors diet and 
stimulus, but accounts for the correlation among multiple measurements coming from 
the T cells taken from a single mouse.  The procedure MIXED in SAS software was 
used for the analysis (SAS, Cary NC).  When diet effects were significantly different 
among stimuli, comparisons between the diet groups were conducted using Fisher's 
protected Least Significant Difference (LSD) test.  In that case, two diets were deemed 
statistically different if their p-value was less than a=0.05.  Values presented in the text 
are means ± SEM.  
 
RESULTS 
n-3 PUFA differentially affect T cell apoptosis depending on stimulus 
Since previous studies have indicated a suppressive effect of n-3 PUFA on T cell 
proliferation (74), we determined the effect of n-3 PUFA on T cell apoptosis.  In order to 
validate our system, we stimulated T cells from chow-fed mice with an apoptotic 
positive control.  Figure 2 shows the 4 h (A) and 24 h (B) early and late apoptotic T cell 
response following stimulation with rhsFasL fused to a FLAG-tag plus an aFLAG 
antibody that crosslinks the FasL-FLAG (FasL + aFLAG) or FasL + aFLAG plus Z-
VAD-fmk (a pan-caspase inhibitor).  As expected, FasL + aFLAG increased late 
apoptosis by 34% and 40% compared to RPMI levels for 4 h and 24 h, respectively (Fig. 
2).
36 
 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Validation of apoptosis model.  Purified splenic T cells from chow-fed mice were cultured for 
4 h (A) and 24 h (B) in the presence of RPMI-complete medium, 1% DMSO, an aFLAG antibody, FasL + 
aFLAG, FasL + aFLAG + 50 mM Z-VAD-fmk, FasL + aFLAG + 20 mM Z-VAD-fmk, or 20 mM Z-
VAD-fmk followed by Annexin V/PI staining and FACS analysis.  Data shows cells classified as either 
early apoptotic or late apoptotic and represent the mean ± SEM, n=3 per group.  Different letters denote 
significant differences between stimuli (p<0.05). 
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Figure 3.  n-3 PUFA differentially affect T cell apoptosis depending on stimulus.  A, Representative 2 
parameter flow cytometric dot plots of early and late stage apoptosis.  Cells were distinguished as being 
early apoptotic or late apoptotic by Annexin V positive, PI negative (left panel) or Annexin V positive/PI 
positive (right panel) staining, respectively.  B, T cells (5 x 105/well) from animals fed the test diets were 
cultured in the presence of aCD3/aCD28, PMA/aCD3, PMA/Ionomycin, or RPMI-complete medium for 
24 h, followed by Annexin V/PI staining and FACS analysis. 
 
 
Early Apoptosis
AV+/ PI-
Late Apoptosis
AV+/ PI+
CD3/CD28 CD3/PMA PMA/Iono RPMI
0
2
4
6
8
10
12
14
%
 A
n
n
ex
in
V
+/
P
I -
SAF
OO
FO2
Stimulus
24h
a
a
a
b
a
aa
abb
b b
b
A 
B 
38 
 
 
 
Figure 3.  Continued. 
C, T cells (5 x 105/well) from animals fed the test diets were cultured in the presence of FasL + aFLAG or 
dexamethasone for 24 h, followed by Annexin V/PI staining and FACS analysis.  Data shows cells 
classified as early apoptotic (B & C) or late apoptotic (D) and represent the mean ± SEM, n=6 per group.  
Different letters denote significant differences within each stimulus group (p<0.05).  SAF, safflower oil; 
OO, olive oil; FO2, fish oil (2%, w/w). 
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Because signaling downstream from Fas is mediated by caspases, Z-VAD-fmk is 
expected to inhibit apoptosis.  Figure 2A shows that when Z-VAD-fmk was added to 
FasL + aFLAG apoptosis was decreased by as much as 45%, reducing apoptosis to 
RPMI levels.  Culture in 1% DMSO (the vehicle for Z-VAD-fmk and at the level of the 
highest concentration of Z-VAD-fmk) did not affect T cell apoptosis. 
 Purified splenic T cells from n-3 PUFA-fed mice were stimulated with various 
agonists which act at the plasma membrane receptor level (aCD3/aCD28), intracellular 
level (PMA/Ionomycin), or at both the receptor and intracellular levels (aCD3/PMA).  
Figure 3A shows a representative 2 parameter flow cytometric histogram of early and 
late stage apoptosis following a 24 h stimulation period.  Cells were classified as early 
stage apoptotic (Annexin V positive, PI negative) or late stage apoptotic (Annexin V 
positive, PI positive).  Figure 3B shows the early apoptotic response of 24 h single 
activated T cells taken from mice fed SAF, OO, or FO2 (containing n-3 PUFA).  Since 
the diet effects were different depending on stimulus group (p = 0.001), differences 
among the diets were investigated separately for the individual stimuli.  FO2 increased 
the percentage of apoptosis relative to SAF (p = 0.04) and OO (p = 0.005) only in 
PMA/Ionomycin stimulated cells.  In contrast, FO2 decreased apoptosis in the 
aCD3/aCD28 [FO2 vs SAF and OO (p = 0.01)], aCD3/PMA [FO2 vs SAF (p = 0.02)],  
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and RPMI-complete medium (negative control) [FO2 vs SAF (p = 0.007)] stimulated 
groups.  These data indicate that the effect of n-3 PUFA is dependent on the nature of 
the stimulus.  Figure 3C shows the early apoptotic response of T cells from SAF, OO, or 
FO2-fed mice activated for 24 h with known apoptotic inducers.  T cells were incubated 
with dexamethasone or FasL + aFLAG for 24 h in order to induce apoptosis either 
pharmacologically or physiologically, respectively.  Of interest, FO2 produced a modest 
increase in apoptosis (p = 0.068) in FasL + aFLAG stimulated cells, suggesting that n-3 
PUFA may modulate Fas signaling pathways.  The late apoptotic T cell response is 
shown in Figure 3D.  Both sets of stimuli promoted substantial levels of apoptosis when 
late apoptosis was examined (dexamethasone, 93.1 ± 0.6% and FasL + aFLAG, 87.9 ± 
0.6%) indicating that the reagents were effective (Fig. 3D). 
 Figure 4 illustrates the use of DAPI staining to assess morphological evidence of 
apoptosis.  In some experiments, T cells were stimulated for 24 h followed by DAPI 
staining and examined for the presence of apoptotic bodies.  In general, the number of 
apoptotic bodies present in the cultures was proportional to the levels of apoptosis as 
determined by Annexin V/PI staining. 
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Figure 4.  Morphological assessment of apoptosis.  Purified T cells (2 x 106/ml) from chow-fed mice 
were cultured in the presence of RPMI-complete medium, FasL/aFLAG, or dexamethasone for 24 h 
followed by DAPI staining and subsequent examination of apoptotic bodies.  Magnification, 600x.   
 
 
DexamethasoneRPMI FasL + aFLAG
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Differential effect of cell stimulus on T cell cytokine profiles 
Because the nature of the stimulus can result in T cell bias toward specific 
cytokine secretion profiles (83,84), we analyzed cell culture supernatant cytokines.  
Figure 5 shows the ability of selected stimuli to induce naive T cells to produce different 
cytokine profiles.  The data show that T cells in all diet groups stimulated with 
PMA/Ionomycin for 48 h secreted significantly (p = 0.0001) more IL-2 than 
aCD3/aCD28 or aCD3/PMA stimulated T cells.  Stimulation with PMA/Ionomycin 
resulted in cytokine ratios as follows: IFNg:IL-4=2560; IFNg:IL-2=4.5; and IL-4:IL-
2=0.002.  Since Th1 cells secrete high levels of IL-2 and IFNg, PMA/Ionomycin appears 
to have generated a Th1-like phenotype (66).  In comparison, aCD3/PMA stimulated T 
cells secreted significantly (p = 0.0001) more IL-10 and IL-4 compared to aCD3/aCD28 
or PMA/Ionomycin (Fig. 5), and produced cytokine ratios of: IFNg:IL-4=167.1; 
IFNg:IL-2=383.6; and IL-4:IL-2=2.3.  IL-4 and IL-10 are secreted by Th2 polarized cells 
and are also cross-regulatory cytokines which inhibit Th1 polarization (66).  Therefore, 
these data indicate that aCD3/PMA induced T cells to express a Th2-like cytokine 
profile.  Stimulation with aCD3/aCD28 produced the following cytokine ratios: 
IFNg:IL-4=278.6; IFNg:IL-2=72.1; and IL-4:IL-2=0.26. 
Figure 6 shows the effect of diet on cytokine secretion.  The data show that for 
the two Th2 cytokines, IL-4 and IL-10, dietary FO enhanced secretion only in the 
aCD3/PMA stimulated T cells (Th2-like).  In contrast, whereas there was no diet effect 
on IFNg secretion, dietary FO enhanced IL-2 secretion only in PMA/Ionomycin 
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stimulated T cells (Th1-like).  These data suggest that FO promotes T cells to 
differentiate into either Th1 or Th2 cells when induced to do so. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Cytokine profiles of T cells from diet-fed mice incubated with selected stimuli.  Following 
48 h of stimulation with aCD3/aCD28, PMA/aCD3, or PMA/Ionomycin, supernatants were collected and 
IL-2, IL-4, IL-10 and IFNg were quantified as described in Materials and Methods.  Data represent the 
mean ± SEM, n=18 per group.  Different letters denote significant differences between stimulus groups (p 
< 0.05).
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Figure 6.  n-3 PUFA enhancement of cytokine secretion is dependent upon the stimulus.  Purified 
splenic T cells from mice fed diets containing SAF, FO2 (2%, w/v), FO4 (4%, w/v), or FO9 (9%, w/v) 
were stimulated for 48 h with aCD3/aCD28, aCD3/PMA, or PMA/Ionomycin.  Supernatants were 
collected and IL-2, IL-4, IL-10, and IFNg were quantified as described in Materials and Methods.  Data 
represent the mean ± SEM, n=6 per diet (for IL-2 and IL-10) or n=3 (for IL-4 and IFNg).  Different letters 
denote significant differences between diet groups (p<0.05). 
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Dietary lipids alter T cell membrane phospholipid composition  
Dietary lipids can be incorporated into cellular membranes and thereby regulate 
cell function (137).  For this reason, we determined the effect of dietary lipid on the fatty 
acid composition of phospholipid classes in T cell membranes.  Tables 2-5 show the PC, 
PE, PS, and PI fatty acid compositions of purified T cell membranes from SAF, OO, and 
FO2-fed mice.  Gas chromatographic analysis revealed fatty acid differences in the PC 
and PE pools only.  In the PC class (Table 2), FO-fed mice had significantly less 18:1n-
7 and 20:4n-6 and significantly more 18:2n-6.  18:1n-7 was significantly enriched in the 
PC class from OO-fed mice.  Docosahexanoic acid (22:6n-3), one of the major fatty 
acids found in fish oil, and eicosapentanoic acid (22:5n-3) were significantly enriched (p 
< 0.05) in the PE class from FO2-fed mice (Table 3).  No significant dietary influence 
was observed on the fatty acid composition of PS (Table 4) and PI (Table 5) pools.  
These data indicate a remodeling of T cell membrane composition by dietary n-3 PUFA. 
 
n-3 PUFA significantly enhance AICD 
 Since dietary FO may enhance Fas-mediated apoptosis (see above), we 
determined the effect of n-3 PUFA on T cell AICD, a process largely regulated by the 
expression of Fas and FasL (96,120,121).  T cells were initially activated and 
subsequently restimulated or incubated in RPMI-complete medium as described in 
Figure 1.  The experimental design was effective at inducing AICD.  In aCD3/aCD28-
stimulated cells, there was a highly statistically significant 2.5-fold increase in total 
apoptosis (early and late stage apoptosis values of all diet groups) following reactivation 
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Table 2.  Fatty Acid Composition of T Cell Phosphatidylcholine (%mol)
Fatty Acid SAF OO FO2
14:0 3.68 ± 0.16 3.12 ± 0.77 3.08 ± 0.83
14:1 4.08 ± 0.60 2.33 ± 0.67 1.88 ± 1.88
16:0 34.82 ± 1.38 34.95 ± 1.27 40.65 ± 3.44
16:1n-7 2.39 ± 0.21 2.50 ± 0.40 2.38 ± 0.90
18:0 11.33 ± 0.52 10.24 ± 0.64 13.26 ± 3.92
18:1n-9 11.11 ± 0.79 12.03 ± 0.13 9.42 ± 0.53
18:1n-7 1.45 ± 1.45 b 5.55 ± 0.29 a trb
18:2n-6 5.37 ± 0.21 b 4.13 ± 0.44 b 7.66 ± 1.29 a
18:3n-6 0.82 ± 0.69 0.96 ± 0.96 1.11 ± 0.15
18:3n-3 0.16 ± 0.16 0.23 ± 0.23 4.71 ± 4.71
20:1n-9 tr tr tr
20:2n-6 tr tr 0.42 ± 0.42
20:3n-6 2.01 ± 0.23 1.83 ± 0.26 1.74  ± 1.21
20:4n-6 20.88 ± 1.24 a 19.58 ± 0.24 a 9.35 ± 5.72 b
20:5n-3 tr 0.07 ± 0.07 0.44 ± 0.44
22:0 tr tr tr
22:1n-9 tr tr tr
22:4n-6 1.53 ± 0 .80 1.09 ± 0.55 tr
22:5n-3 tr tr 1.70 ± 1.09
22:6n-3 0.37 ± 0.37 1.36 ± 0.16 2.21 ± 1.37
Only the major fatty acids are listed.  Mol % values are expressed as means  ± SEM, n=6 per 
group.  Different letters denote significant differences between diet groups (p<0.05).  
tr, trace (<0.01%); SAF, safflower oil; OO, olive oil; FO, fish oil.
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Table 3.  Fatty Acid Composition of T Cell Phosphatidylethanolamine (%mol)
Fatty Acid SAF OO FO2
14:0 tr tr tr
14:1 tr tr tr
16:0 4.38 ± 3.41 2.87 ± 2.87 2.71 ± 2.71
16:1n-7 1.54 ± 0.78 0.76 ± 0.76 0.56 ± 0.56
18:0 24.53 ± 1.54 21.95 ± 1.01 25.42 ± 1.80
18:1n-9 7.45 ± 0.72 6.90 ± 0.45 5.94 ± 0.40
18:1n-7 1.27 ± 0.65 2.56 ± 0.30 1.56 ± 0.18
18:2n-6 3.45 ± 0.95 2.12 ± 0.25 2.87 ± 0.11
18:3n-6 0.49 ± 0.49 tr tr
18:3n-3 0.30 ± 0.30 tr tr
20:1n-9 tr tr tr
20:2n-6 0.57 ± 0.57 tr tr
20:3n-6 0.25 ± 0.25 0.96 ± 0.60 1.78 ± 0.22
20:4n-6 23.25 ± 1.53 24.02 ± 2.50 20.57 ± 1.82
20:5n-3 tr tr tr
22:0 tr tr tr
22:1n-9 tr 1.95 ± 1.95 4.36 ± 1.25
22:4n-6 1.34 ± 1.34 3.38 ± 0.33 tr
22:5n-3 tr tr 4.70 ± 0.27 a
22:6n-3 2.05 ± 1.13 c 5.40 ± 0.75 b 11.65 ± 0.19 a
Refer to Table 2  for legend details.
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Table 4.  Fatty Acid Composition of T cell Phosphatidylserine (%mol)
Fatty Acid SAF OO FO2
14:0 3.23 ± 0.13 ab 0.01 ± 0.01 a 8.86 ± 3.81 b
14:1 23.35 ± 5.05 b tra 4.06 ± 3.10 a
16:0 tr tr 17.46 ± 10.65
16:1n-7 2.65 ± 2.65 tr 4.43 ± 3.14
18:0 39.37 ± 1.04 49.67 ± 6.20 24.40 ± 7.60
18:1n-9 9.91 ± 3.40 14.34 ± 2.97 13.50 ± 0.84
18:1n-7 1.63 ± 1.63 0.59 ± 0.59 1.65 ± 1.65
18:2n-6 8.19 ± 4.64 6.31 ± 2.37 9.37 ± 1.60
18:3n-6 1.58 ± 1.58 tr 0.03 ± 0.03
18:3n-3 tr tr 0.15 ± 0.15
20:1n-9 tr tr 0.37 ± 0.37
20:2n-6 tr tr tr
20:3n-6 tr 2.77 ± 1.82 0.77 ± 0.77
20:4n-6 10.61 ± 5.56 11.88 ± 0.19 9.89 ± 1.46
20:5n-3 tr tr 3.26 ± 3.02
22:0 tr tr tr
22:1n-9 tr tr tr
22:4n-6 tr 4.28 ± 2.78 0.11 ± 0.11
22:5n-3 tr tr 0.57 ± 0.57
22:6n-3 tr 4.28 ± 2.29 0.86 ± 0.86
Refer to Table 2  for legend details.
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Table 5.  Fatty Acid Composition of T cell Phosphatidylinositol (%mol)
Fatty Acid SAF OO FO2
14:0 tr tr tr
14:1 tr tr tr
16:0 tr tr tr
16:1n-7 tr tr tr
18:0 19.50 ± 2.73 26.63 ± 4.69 16.20 ± 0.23
18:1n-9 15.35 ± 4.50 13.00 ± 2.94 14.59 ± 1.18
18:1n-7 3.57 ± 3.57 3.90 ± 3.90 tr
18:2n-6 6.04 ± 4.72 5.83 ± 1.66 3.76 ± 3.76
18:3n-6 6.35 ± 6.35 tr 4.42 ± 4.42
18:3n-3 1.38 ± 1.38 tr tr
20:1n-9 10.00 ± 10.00 7.56 ± 7.56 7.48 ± 1.44
20:2n-6 tr tr tr
20:3n-6 tr tr tr
20:4n-6 36.91 ± 10.00 38.03 ± 16.42 33.57 ± 3.72
20:5n-3 0.90 ± 0.90 tr tr
22:0 tr tr tr
22:1n-9 tr tr tr
22:4n-6 tr tr tr
22:5n-3 tr tr tr
22:6n-3 tr tr tr
Refer to Table 2  for legend details.
50 
[reactivated, 37.4 ± 0.9% vs. unreactivated, 20.9 ± 0.4%, p=0.0001, n=48].  In 
PMA/Ionomycin-stimulated cells, there was a nearly 2-fold increase in total apoptosis, 
which was highly statistically significant [reactivated, 12.5 ± 0.8% vs. unreactivated, 7.5 
± 0.2%, p=0.0001, n=48]. 
Figure 7 shows further validation of our AICD model.  T cells were stimulated 
with PMA/Ionomycin for the initial 48 h and restimulated with PMA/Ionomycin plus 
soluble Fas-Fc, PMA/Ionomycin plus the pan-caspase inhibitor Z-VAD-fmk, or  
 
 
 
 
Figure 7.  Validation of AICD model.  Purified splenic T cells from chow-fed mice were initially 
activated with PMA/Ionomycin and then restimulated, as described in Figure 1, with PMA/Ionomycin, 
PMA/Ionomycin + soluble Fas-Fc, PMA/Ionomycin + IgG (isotype control for Fas-Fc), PMA/Ionomycin 
+ Z-VAD-fmk, or RPMI-complete medium.  Data are expressed as the percent difference from the mean 
PMA/Ionomycin value for either early or late apoptosis and represent the mean ± SEM, n=4-7 per group.  
Different letters denote significant differences between diet groups (p<0.05). 
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incubated with RPMI-complete medium.  Cells left unreactivated underwent nearly 50% 
less early apoptosis than PMA/Ionomycin restimulated T cells.  Fas-Fc decreased early 
apoptosis by 18%.  Unexpectedly, Z-VAD-fmk only decreased apoptosis 4.7%.  This 
could be explained by the fact that this reagent was most-likely not added early enough 
to cultures to inhibit substantial caspase activation and thus suppress apoptosis. 
 Figure 8A shows the effect of stimulus among all diet groups on AICD.  Each 
stimulus was significantly different from the other (p < 0.05) in early stage apoptosis 
following reactivation, with aCD3/PMA stimulating the greatest degree of apoptosis 
(42.9 ± 0.5%), and PMA/Ionomycin stimulating the least (8.2 ± 0.3%).  Figures 8B-E 
illustrate the effect of each diet on early (B-D) and late (E) apoptosis within particular 
stimulus groups, aCD3/aCD28, aCD3/PMA, and PMA/Ionomycin-stimulated, 
respectively.  In PMA/Ionomycin-stimulated (Th1-like) T cells, dietary FO, independent 
of dose, was accompanied by a significantly (p=0.0008) greater percentage of early stage 
apoptosis than was observed in T cells from control mice fed SAF (Fig. 8D).  In 
comparison, no dietary effect on early apoptosis was seen when T cells were 
restimulated with either aCD3/aCD28 or aCD3/PMA (Fig. 8B & 8C).  
 Previously, we have shown that DHA is the active component in FO for reducing 
T cell proliferation (81).  Therefore, we determined the effect of DHA on T cell AICD.  
Figure 9 shows the effect of DHA and CO on T cell AICD.  There were no dietary 
differences among all stimulus pairs in early (Fig. 9) and total apoptosis (data not 
shown).  These results suggest that DHA is not the active molecule in FO with respect to 
AICD.  It remains to be determined what effect EPA has on T cell AICD. 
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Figure 8.  n-3 PUFA significantly enhance AICD in PMA/Ionomycin-stimulated T cells.  A-D, 
Splenic T cells from SAF, FO4 (4%, w/w), and FO9 (9%, w/w)-fed mice were initially activated and 
restimulated as described in Figure 1.  A, The effect of stimulus among all diet groups on AICD.  Data 
represent the mean ± SEM, n=48 per stimulus. Different letters denote significant differences between 
stimulus groups (p<0.05).  B-D show the effect of diet on aCD3/aCD28-stimulated, aCD3/PMA-
stimulated, and PMA/Ionomycin-stimulated T cell early apoptosis, respectively. 
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E 
Figure 8.  Continued. 
E, The late apoptotic response of aCD3/aCD28-stimulated, aCD3/PMA-stimulated, and 
PMA/Ionomycin-stimulated T cells.  Data represent the mean ± SEM, n=12 per diet group. Different 
letters denote significant differences between diet groups (p=0.0008). 
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Figure 9.  DHA does not affect T cell AICD.  Splenic T cells from CO (5%, w/v) and DHA ethyl ester 
(1%, w/v)-fed mice were initially activated and restimulated to induce AICD as described in Figure 1.  
Data represent the mean ± SEM, n=6 per diet group. 
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n-3 PUFA do not induce systemic oxidative stress 
In order to determine whether the ingestion of different lipid sources altered 
oxidative stress, three known markers of systemic oxidative stress were evaluated: 
PPARg, SRA, and CD36 (138).  Table 6 shows the mRNA expression levels from the 
liver for PPARg, SRA, and CD36.  There were no statistically significant differences 
between mice fed either the SAF, OO, or FO2 diets with respect to the levels of liver 
mRNA for PPARg, SRA, or CD36 (Table 6).  These results indicate that short-term 
feeding of n-3 PUFA does not elevate biomarkers of systemic lipid peroxidation in our 
model. 
 
 
 
 
 
Table 6:   mRNA Expression of PPARg, CD36, and SRA  
     
  SAF OO FO2  
       
PPARg  26.40 ± 0.35 26.63 ± 0.33 27.14 ± 0.32  
     
CD36 24.18 ± 0.50 24.09 ± 0.34 24.78 ± 0.35  
     
SRA 25.75 ± 0.47 25.51 ± 0.28 26.34 ± 0.34  
Liver RNA was isolated and expression of PPARg, CD36, and SRA mRNA was quantified  
by real time RT-PCR. Values represent cycle threshold (CT) as described in  Materials and 
Methods and are expressed as means ± SEM, n = 6 per group.  SRA, scavenger receptor  
type A; Diet groups: SAF, safflower oil; OO, olive oil; FO2, fish oil (2%). 
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DISCUSSION 
 Among dietary factors, there is considerable evidence for a protective effect of n-
3 PUFA in autoimmune/inflammatory diseases (34,35,70,127).  Additionally, the 
significant effects of diets rich in n-3 PUFA on a variety of T cell functions have been 
firmly established in both humans and animal models (34,35,70,127).  The primary 
dietary effector molecules are thought to be eicosapentaenoic acid (20:5n-3, EPA) and 
docosahexaenoic acid (22:6n-3, DHA) (74,81).  However, the precise effects of dietary 
n-3 PUFA on CD4+ cells, and the mechanisms by which dietary PUFA influence the 
maintenance of appropriate T cell subset balance to promote a healthy immune system, 
have not been elucidated.  Previous experiments have demonstrated a blunting effect of 
n-3 PUFA on T cell proliferation (74,83).  Since the suppressive effects of dietary n-3 
PUFA on the accumulation of inflammatory T cells could result from either reduced 
proliferation or enhanced apoptosis of activated T cells, or both, we investigated the 
effect of dietary n-3 PUFA on T cell apoptosis.  Our data clearly show that dietary n-3 
PUFA enhanced T cell apoptosis following in vitro incubation with selective stimuli 
(Fig. 3B).  With regard to the biological relevance of this effect, it is now clear that 
small changes in apoptosis can profoundly alter downstream events such as cancer and 
autoimmune disease risk (139).  For example, when multipotential-stage 
(undifferentiated) cells fail to undergo AICD, exponential growth in cell numbers may 
occur, perturbing the balance between responsiveness and nonresponsiveness (tolerance) 
(126,140).  n-3 PUFA effects on these mechanisms are consistent with a wealth of 
literature supporting the contention that diet in general, and dietary fat in particular, is an 
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important determinant of the quantity and quality of the host’s immune responses 
(34,35,127,132). 
 Apoptotic death of T cells is an important mechanism for regulating immune 
responses.  There are two distinct pathways of apoptosis (a) passive cell death, mediated 
in part by the loss of Bcl-2 proteins, and (b) AICD, primarily regulated by extrinsic 
signals from death receptors, such as Fas (96,120-123).  Passive cell death results from 
the absence of growth factors and is important for loss of immature T cells.  AICD 
occurs as a result of repeated stimulation through the TCR, upregulating plasma 
membrane expression of Fas and its ligand (FasL), thereby acting as a feedback 
mechanism for terminating an ongoing immune response.  It has been shown that T cell 
subsets differ in their propensity to undergo AICD (112,114,117).  Interestingly, in our 
experimental system, the selected stimuli influenced the profile of cytokines produced 
by the cells in culture (Fig. 5).  T cells stimulated with aCD3/PMA secreted 
significantly more IL-4 and IL-10, Th2 cytokines, while PMA/Ionomycin-stimulated T 
cells secreted much more IFNg and much less IL-4, indicative of a Th1-like phenotype.  
Because these cells had not been subjected to the selective effects of long-term culture, 
they likely represent physiologically polarized T cell effector precursors which arise in 
primary immune responses (112).  These data suggest a means by which T cell 
functional subclasses could be individually analyzed following dietary treatment.  
 When naive T cells were stimulated with PMA/Ionomycin there was an increase 
in AICD in cells from mice fed both of the n-3 PUFA-containing diets (FO4 and FO9) 
(Fig. 8D).  Therefore it is conceivable that the ability of n-3 PUFA to enhance AICD 
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following PMA/Ionomycin stimulation could be due to the induction of a biased pattern 
of cytokine production in the T cells.  These data are consistent with our previous 
observations showing an increase in IL-4 dependent Th2 proliferation following n-3 
PUFA feeding (83), and indicate that dietary n-3 PUFA act differently on distinct T cell 
subsets.  These important findings provide evidence for both direct and indirect 
mechanisms whereby selected T cell subset functions would be suppressed by dietary n-
3 PUFA. 
 The elucidation of the mechanisms which regulate apoptosis is important because 
the failure of T cells to undergo appropriate AICD is associated with a variety of 
immunopathological diseases, including inflammatory bowel diseases (IBD) (140).  
With regard to diet, a critical question remaining to be addressed is the identity of the 
relevant cellular targets in Th1-like cells which mediate the apoptogenic effects of n-3 
PUFA.  AICD depends, in part, on a FasL-dependent pathway (96,120,121) and FasL is 
expressed at higher levels on the surface of activated Th1 cells than Th2 cells (114,115).  
The fact that n-3 PUFA enhanced Th1-like AICD in our experiments, combined with a 
report indicating a 30% increase in FasL expression in splenocytes from n-3 PUFA-fed 
mice (93), support the notion that certain dietary lipids upregulate FasL expression in 
Th1 cells, rendering them more susceptible to AICD.  Additional studies are underway 
in order to test this hypothesis. 
 Several intracellular second messengers (e.g., ceramide) have been implicated in 
the generation of the Fas/FasL death signal and may mediate the n-3 PUFA enhanced 
AICD in Th1 cells.  Ceramide is a lipid second messenger cleaved from membrane 
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sphingomyelin by sphingomyelinases.  Interaction of FasL with membrane-bound Fas 
results in a transient and weak activation of a limited number of Fas trimers insufficient 
to trigger apoptosis but sufficient for acidic sphingomyelinase (ASM) translocation 
(110).  Translocated ASM subsequently hydrolyzes sphingomyelin into ceramide which 
spontaneously self-aggregates into membrane microdomains, thereby inducing Fas 
receptor clustering and apoptosis (110).  Interestingly, we have previously demonstrated 
(74) that dietary n-3 PUFA are capable of modulating ceramide levels in murine splenic 
T cells.  In addition, our data indicate that n-3 PUFA modify the fatty acid composition 
of membrane PC and PE (Tables 2 & 3) in purified T cells.  Since membrane fatty acid 
content can influence sphingomyelin hydrolysis (141), these data suggest that ceramide 
formation, and hence AICD, could be modulated via the incorporation of n-3 PUFA into 
specific membrane phospholipid pools.  
 Within the T cell plasma membrane, there are specific detergent-resistant 
domains in which key signal transduction proteins are localized (142).  These “lipid 
rafts” are composed mostly of cholesterol and sphingolipids and do not integrate well 
into the fluid phospholipid bilayers, thereby forming microdomains.  Upon T cell 
activation, rafts compartmentalize the activated TCR and associated signal-transducing 
molecules, thus providing an environment conducive to signal transduction (67).  With 
respect to apoptosis, Fas and FasL translocate to lipid rafts after stimulation (110).  Our 
data demonstrating that dietary PUFA remodel the membrane composition of T cells 
(Tables 2 & 3) provide evidence for a direct diet effect on membrane properties.  This is 
supported by recent in vitro studies using a Jurkat T cell line, where n-3 PUFA 
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enrichment selectively modified lipid rafts and suppressed signal transduction (47).  
Interestingly, conditions that modify raft structure can disrupt T cell signaling events 
(142).  Recent studies indicate that the macromolecular complex organization in lipid 
rafts is distinct in T cell subsets (44,67), suggesting that these subsets could respond 
differently to dietary PUFA-induced perturbation.  Experiments are currently underway 
to determine the effects of dietary n-3 PUFA on the lipid composition of T cell rafts in 
our model. 
 Long chain n-3 PUFA are highly susceptible to lipid peroxidation (143).  This is 
significant because the formation of reactive oxygen species and/or glutathione depletion 
can regulate signals involved in AICD which contribute to T cell deletion (144).  
Interestingly, we saw no change in systemic oxidative stress following ingestion of 
different lipid sources (Table 6).  This indicates that short-term feeding of n-3 PUFA did 
not promote the generation of proapoptotic reactive oxygen species in our model.   
 Taken together, these data support our hypothesis that dietary n-3 PUFA 
preferentially suppress functions of a T cell subset induced to secrete a biased cytokine 
pattern resembling Th1 cells in mice, in part, by increasing AICD in these cells.  
Furthermore, a comparison of FO4 versus FO9 demonstrated that the effect seen on 
AICD can occur efficiently at low n-3 PUFA intakes.  These novel findings contribute 
significantly to the elucidation of the mechanisms by which dietary n-3 PUFA 
selectively modulate T cell subset function.  Studies such as these could result in the 
establishment of dietary guidelines designed to promote a balanced immune system, so 
that protective host responses (e.g., to infectious agents) can be maintained, while 
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potentially detrimental host responses (e.g. chronic inflammation and hypersensitivity) 
can be controlled appropriately.  Further studies are needed to determine the precise 
cellular and molecular mechanisms by which dietary n-3 PUFA differentially modulate 
AICD in Th subsets. 
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CHAPTER III 
 
 
 
DIETARY n-3 POLYUNSATURATED FATTY ACIDS PROMOTE 
ACTIVATION-INDUCED CELL DEATH IN Th1-POLARIZED MURINE 
CD4+ T CELLS* 
 
 
Dietary n-3 polyunsaturated fatty acids (PUFA) have been shown to attenuate T 
cell-mediated inflammation.  To investigate whether dietary n-3 PUFA promote 
activation-induced cell death (AICD) in CD4+ T cells induced in vitro to a polarized Th1 
phenotype, C57BL/6 mice were fed diets containing either 5% corn oil (n-6 PUFA 
control) or 4% fish oil + 1% corn oil (n-3 PUFA) for 2 wk.  Splenic CD4+ T cells were 
cultured with aIL-4, IL-12, and IL-2 for 2 d and then rIL-12 and rIL-2 for 3 d in the 
presence of diet-matched homologous mouse serum (MS) to prevent loss of cell 
membrane fatty acids, or fetal bovine serum.  Following polarization, Th1 cells were 
reactivated and analyzed for IFNg and IL-4 by intracellular cytokine staining, and for 
apoptosis by Annexin V/PI.  Dietary fish oil (FO) enhanced Th1 polarization by 49% 
(p=0.0001) and AICD by 24% (p=0.0001) only in cells cultured in the presence of MS. 
FO enhancement of Th1 polarization and AICD following culture was associated with  
________________________________ 
*Part of this chapter is reprinted with permission from "n-3 Polyunsaturated fatty acids 
promote activation-induced cell death in Th1-polarized murine CD4+ T cells" by 
Switzer, K.C. et al., 2004.  Journal of Lipid Research, in press.  Copyright 2004 by The 
American Society for Biochemistry and Molecular Biology. 
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the maintenance of EPA (20:5n-3) and DHA (22:6n-3) in plasma membrane lipid rafts.  
In conclusion, n-3 PUFA enhance the polarization and deletion of proinflammatory Th1 
cells, possibly as a result of alterations in membrane microdomain fatty acid 
composition. 
 
INTRODUCTION 
The differentiation of naive CD4+ T cells into helper (Th) 1 or Th2 effector cells 
is a critical process during immune responses (8).  Th1 cells are characterized by the 
production of interleukin-2 (IL-2), interferon g (IFNg) and tumor necrosis factor b 
(TNFb) and are required to mount a cell-mediated immunological response against 
intracellular pathogens (8).  Th1 cells are proinflammatory and have been implicated in 
the pathogenesis of human inflammatory and autoimmune diseases such as rheumatoid 
arthritis, Type I diabetes, and inflammatory bowel disease (9).  In contrast, Th2 cells are 
characterized by the production of IL-4, IL-5, and IL-10 and are important in humoral 
immunity and defense against extracellular pathogens, but can promote allergy (8).  
Additionally, Th1 and Th2 effectors apparently have different susceptibilities to 
activation-induced cell death (AICD), with Th1 cells reported to be AICD sensitive and 
Th2 cells reported to be AICD resistant (112).  The selective death of Th1 cells has been 
attributed to a preferential requirement for phorbol ester-sensitive protein kinase C 
(PKC) isoforms (114) and the upregulation of FasL expression (115).  In contrast, the 
resistance of Th2 cells to AICD has been linked to expression of c-FLIP and FAP-1, 
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inhibitors of apoptosis (112), and the selective upregulation of phosphatidylinositol-3’-
kinase (PI-3-K) activity (117). 
 AICD is a form of apoptosis resulting from chronic antigen stimulation and is 
responsible for the peripheral deletion of previously activated lymphocytes.  Apoptosis 
is a highly regulated process resulting in cell death without an ensuing inflammatory 
response, thus playing an important role in maintaining lymphocyte homeostasis and a 
balanced T cell repertoire (96).  The inability of T cells to undergo AICD is associated 
with a variety of immunopathological diseases.  The induction of AICD in CD4+ T cells 
is mediated by interactions between Fas and FasL.  The Fas death receptor is a member 
of the TNF/nerve growth factor-receptor superfamily (120).  The binding of Fas by its 
ligand (FasL) results in receptor trimerization, recruitment of the Fas-associated death 
domain (FADD) to the death domain of Fas, and binding of caspase 8 to the death-
effector domain of FADD (108).  This process results in the formation of the death-
inducing signaling complex (DISC).  Activation of caspase 8 leads to the induction of a 
cascade of caspases culminating in apoptosis. 
 Recent studies on non-transformed human T cells have shown that Fas and 
components of the DISC are recruited to lipid rafts following Fas ligation and that raft 
structures are required for efficient propagation of apoptotic signals (108).  Rafts are 
highly organized plasma membrane microdomains rich in cholesterol and sphingolipids 
and their polar lipids are predominantly composed of saturated fatty acyl chains (145).  
These lipids form liquid-ordered membrane regions that are insoluble in non-ionic 
detergents facilitating raft isolation as detergent-resistant membrane domains (145).  
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Lipid raft domains play an important role in the localization and distribution of key 
receptors and associated signal-transducing molecules (44), and are crucial in regulating 
the susceptibility of T cells to AICD (107).  Interestingly, Th1 and Th2 cells have 
distinct resident protein/lipid membrane microdomain compositions (67).  This is likely 
to impact T cell signaling and thereby modulate effector function, which may help 
explain the differential susceptibility to AICD in the two T helper subsets. 
 We have recently shown that dietary n-3 polyunsaturated fatty acids (PUFA) 
remodel the phospholipid composition of membrane rafts in murine T cells (45).  In 
addition, Stulnig et al. (47) have shown that Jurkat T cells cultured in vitro with PUFA 
are capable of modifying lipid rafts and suppressing signal transduction.  The anti-
inflammatory properties of diets rich in n-3 PUFA on T cell function have been firmly 
established in human and animal models (34,35,127).  The primary effector molecules 
are thought to be eicosapentaenoic acid [20:5n-3, EPA] and docosahexaenoic acid 
[22:6n-3, DHA].  In general, consumption of diets rich in n-3 PUFA is associated with a 
reduced pro-inflammatory T cell response due, in part, to a decreased proliferative 
capacity attributed to a reduction in IL-2 production and/or function and an increase in T 
cell apoptosis (83,132,146).  Previously, we have shown that n-3 PUFA promote AICD 
in T cells induced to secrete a biased cytokine pattern resembling Th1 cells (146).  
However, the effect of n-3 PUFA on polarized Th1 cell function has not been 
determined.  In addition, previous research has shown that cell culture conditions, with 
respect to the lipid content in the serum added to tissue culture medium, have a 
significant influence on cell fatty acid composition (147,148).  Using homologous MS in 
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the cultures, we examined the effect of dietary n-3 PUFA on Th1 AICD and membrane 
microdomain fatty acid composition.  Our results indicate that dietary n-3 PUFA 
enhance both the polarization and deletion of pro-inflammatory Th1 cells, possibly as a 
result of alterations in membrane microdomain fatty acid composition. 
 
MATERIALS AND METHODS 
Diet and animals    
All experimental procedures using laboratory animals were approved by the 
University Laboratory Animal Care Committee of Texas A&M University.  Female, 
pathogen-free weanling (12–14g) C57BL/6 mice (Frederick National Cancer Research 
Facility, Frederick, MD) were housed in autoclaved polycarbonate microisolator cages 
and were maintained at room temperature (~25°C) on a 12 h light:dark cycle.  Mice were 
fed standard nonpurified diet (Teklad 9F Sterilizable Rodent diet) during a 1 wk 
acclimation period and had free access to autoclaved water and diet.  Thereafter, animals 
were randomly assigned to one of two semi-purified diets (24-30 mice/diet group): corn 
oil (CO, n-6 PUFA) or an n-3 PUFA-enriched menhaden fish:corn oil (FO) mixture (4:1, 
w/w) at 50 g/kg diet for 14 d (146).  The purified diets met NRC requirements and 
varied only in lipid composition (81,134).  The diet composition, expressed in g/kg of 
complete diet, was: 200 g casein, 420 g sucrose, 219.8 g cornstarch, 60 g cellulose, 35 g 
AIN-76 mineral mix, 10 g AIN-76 vitamin mix, 3 g DL-methionine, 2 g choline 
chloride, 0.2 g tertiary butyl hydroquinone, and 5 g oil (146).  Diets were aliquoted and 
stored at -80°C.  Diets were provided ad libitum and were changed daily to prevent 
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peroxidation.  The fatty acid composition as assessed by gas chromatography, expressed 
in g/kg of complete diet, is detailed in Table 7.  The linoleic acid (18:2 n-6) content was 
5.5% and 1.4% of total energy in the CO and FO diets, respectively, and thus, met the 
minimum 1–2% essential fatty acid requirement for rodents (134).  Vitamin A, D, and E 
levels were approximately equal and exceeded the minimum requirement (146).  Corn 
oil was obtained from Degussa Bioactives (Champaign, IL), and menhaden fish oil was 
provided by the National Institutes of Health Test Materials Program.  There was no 
significant difference in food intake between dietary groups, and weight gain was similar 
in all groups (data not shown). 
 
 
 
Table 7.  Fatty Acid Composition of Experimental Diets
Fatty Acid CO FO4
        g/100g fatty acids
14:0 tr 7.4
16:0 12.4 16.4
16:1 (n-7) tr 9.2
18:0 2.2 3.0
18:1 (n-7 + n-9) 32.8 11.0
18:2 (n-6) 50.2 12.5
18:3 (n-3) 1.1 1.2
20:5 (n-3) tr 12.2
22:5 (n-3) tr 2.1
22:6 (n-3) tr 9.2
Only the major fatty acids are listed.  CO, 5 g/100 g corn oil; 
FO, 4 g/100 g fish oil + 1 g/100 g corn oil; tr, trace amount
(<0.1 g/ 100 g).  Values are expressed as g/100g of total fatty
acids in each diet.
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Splenocyte isolation and CD4+ T cell enrichment 
Mice were euthanized by CO2 asphyxiation.  Spleens were placed in 3 ml RPMI 
complete medium [(RPMI 1640 with 25 mmol/l HEPES (Irvine Scientific, Santa Ana, 
CA) supplemented with 5% heat-inactivated fetal bovine serum (Irvine Scientific), 1 x 
105 U/L penicillin and 100mg/L streptomycin (Irvine Scientific), 2 mmol/l L-glutamine, 
and 10 mmol/l 2-mercaptoethanol].  Spleens were dispersed with glass homogenizers and 
passed through a 149 mm wire mesh filter to create single-cell suspensions.  Total 
lymphocytes were initially enriched by density gradient centrifugation using 
Lympholyte-M (Cedarlane, Toronto, Canada) as previously described (146).  
Subsequently, approximately 120 x 106 mononuclear cells were loaded onto negative-
selection CD4+ T cell purification columns (R&D Systems, Minneapolis, MN).  
Nonadherent cells were eluted for assay.  The purity of the T cell population as analyzed 
by flow cytometry was determined to be 90.3 ± 1.4%, n=3 (83). 
 
Th1 polarization  
Th1 cells were induced in vitro using standardized polarization methodology 
(149).  In general, CD4+ T cells, 5 x 106 cells/well, were cultured in the presence of 1 
ng/ml phorbol-12-myristate-13-acetate (PMA) (Sigma, St Louis, MO) with 500 nM 
Ionomycin (Calbiochem-Novabiochem, San Diego, CA) combined with 10 mg/ml aIL-4 
monoclonal antibody (National Cancer Institute), 20 ng/ml recombinant IL-2 (R&D 
Systems), and 5 ng/ml recombinant IL-12 (BD PharMingen, San Diego, CA) (Th1 
Cocktail) in either 5% FBS-complete medium (FBS) or 2.5% homologous mouse serum 
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+ 2.5% FBS-complete medium (MS) for 2 d at 37°C, 5% CO2.  Cells were harvested and 
recultured in 20 ng/ml rIL-2 and 5 ng/ml rIL-12 for an additional 3 d at 37°C, 5% CO2 in 
the presence of FBS or MS.  The serum was changed each time cytokines and antibodies 
were provided, i.e., on days 2 and 3.  Polarized Th1 cells were subsequently analyzed for 
intracellular cytokine expression and AICD. 
 
Intracellular cytokine staining 
Following Th1 polarization, cultures were harvested, dead cells were removed by 
density gradient centrifugation using Lympholyte-M, and 1 x 106 cells/well were 
reactivated with PMA/Ionomycin with 3 mM monensin for 5 h at 37°C, 5% CO2.  Cells 
were then washed, fixed and permeabilized using a Cytofix/Cytoperm Kit (BD 
PharMingen) before staining with aIL-4-PE (BD PharMingen) and aIFNg-FITC (BD 
PharMingen).  Cytokine staining was assessed via flow cytometry (FACSCalibur; 
Becton Dickinson, Bedford, MA) as previously described (146). 
 
Induction of AICD 
Following Th1 polarization, cultures were harvested, dead cells were removed by 
density gradient centrifugation using Lympholyte-M, and 1 x 106 cells/well were 
reactivated with PMA/Ionomycin for 5 h at 37°C, 5% CO2 (122,146).  Cells were then 
washed with cold 1 X PBS and stained with 5 ml FITC-conjugated Annexin V and 2 ml 
Propidium Iodide for 15 min followed by flow cytometry analysis.  Controls consisted of 
single staining for Annexin V-FITC only and PI only. 
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Density gradient centrifugation and isolation of lipid rafts 
Raft microdomains were isolated from CD4+ T cells as previously described by 
Tamir et al. (150) and Fan et al. (45) with slight modification immediately following 
isolation (Day 0), after 5 days in culture with FBS, or after 5 days in culture with 
homologous MS.  Cells were resuspended in lysis buffer [100 mmol/L NaCl, 2 mmol/L 
EDTA, 0.14 mmol/L 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), 0.2 mmol/L 
Na3VO4, 50 mmol/L aprotinin, 88 mmol/L leupeptin, 160 mmol/L bestain, 60 mmol/L 
pepstain A, and 56 mmol/L E-64, pH 6.9] supplemented with 1% Brij-58.  Cell lysates 
were passed through a 27G needle twice, followed by a 30 min incubation on ice.  An 
850 g/L sucrose solution in lysis buffer was added to the homogenate and mixed by 
pipetting to generate a 450 g/L sucrose lysate.  Cell lysates were transferred to the 
bottom of a 2 ml polyallomer ultracentrifuge tube, which was subsequently overlaid with 
350 and 50 g/L sucrose, respectively.  After centrifugation at 200,000 x g (Beckman 
Coulter Optima Max-E Ultracentrifuge, TLS 55 rotor) for 16 h at 4°C, aliquots from the 
top (low density detergent insoluble glycerolipid enriched raft fraction, liquid ordered 
membrane rafts) and from the bottom (cytosol-high density membrane detergent soluble 
fraction, liquid disordered soluble fractions) of each tube were collected for lipid 
analysis.  We have previously shown that the protein distribution patterns are consistent 
with the features of lipid rafts, i.e., enrichment of ganglioside GM-1 and exclusion of 
CD3, etc. (45).  
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Analysis of mouse sera and membrane fraction phospholipid fatty acid composition 
Total lipids from mouse sera and in liquid ordered membrane rafts and liquid 
disordered soluble fractions were extracted by the method of Folch et al. (135).  Total 
phospholipids from the membrane fractions were separated by thin layer 
chromatography (TLC) on silica gel 60 G plates using chloroform/ methanol/ acetic 
acid/ water (90, 8, 1, 0.8, v/v) as the developing solvent.  Bands were detected under 
ultraviolet light after spraying with 0.1% 8-anilino-naphthalene-sulfonic acid.  Total 
phospholipids were scraped from the plates, spiked with heptadecanoic acid (17:0) and 
transesterified in the presence of 6% methanolic HCl (45).  Fatty acid methyl esters from 
serum lipids and phospholipids of membrane fractions were extracted using hexane and 
0.1 M potassium chloride and analyzed by capillary gas chromatography as previously 
described (45). 
 
Cholesterol analysis 
Following lipid extraction, cholesterol was analyzed using the Amplex Red 
Cholesterol Assay Kit (Molecular Probes, Eugene, OR).  Total lipids in liquid ordered 
membrane rafts and liquid disordered soluble fractions were dried down under nitrogen 
and redissolved in Reaction Buffer.  Samples were assayed in duplicate using a 300 mM 
solution of Amplex Red reagent mix containing 2 U/ml horseradish peroxidase, 2 U/ml 
cholesterol oxidase, and 2 U/ml cholesterol as per kit instructions. 
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Statistical analysis 
 Membrane lipid data were analyzed using a robust ANOVA method (151).  A 
cell mean model was fitted using S-PLUS software (Insightful, Seattle, WA).  Huber’s 
weights were implemented to downweight potentially outlying observations.  This 
approach enables all data points to be considered without the drawback of having one or 
few outlying data points dominate and bias the outcomes.  For the group containing no 
outlying observations, the cell means are identical to those obtained by the regular 
ANOVA.  The corresponding T/F tests were then used to test the existence of 
differences between treatment groups.  Remaining data was analyzed using one-way 
ANOVA.  Differences of p<0.05 were considered significant. 
 
RESULTS 
Dietary lipids differentially affect Th1 polarization 
Th1 cells were induced in vitro using standardized polarization methodology 
(149).  To verify that CD4+ T cells were polarized towards a Th1 phenotype, cells were 
analyzed by flow cytometry for coexpression of IFNg and IL-4 using intracellular 
cytokine staining. Representative 2 parameter flow cytometric histograms of IFNg-FITC 
and IL-4-PE labeled cells are shown in Figure 10A.  The numbers in each quadrant 
represent the percentage of cells positive for IFNg and/or IL-4.  Figure 10B shows the 
effect of diet and culture conditions on cells positively expressing IFNg but not? IL-4.  ?A 
majority of the cells were IFNg+IL-4- and less than 1% of the cells were IL-4+IFNg- 
producing T cells, indicating successful Th1 polarization.  With respect to the effect of 
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dietary treatment on Th1 polarization status, CD4+ T cells from mice fed CO had 
significantly fewer IFNg+ cells than FO-fed mice (36.9% in MS-CO vs. 55.1% in MS-
FO, p = 0.0001), but the change was only observed in cells cultured in the presence of 
homologous MS (Fig. 10). 
The fatty acid composition of MS and FBS, as shown in Table 8, revealed that 
FBS was relatively devoid of n-3 PUFA (20:5n-3, 22:5n-3, 22:6n-3).  With respect to the 
effect of dietary source on MS, serum from FO vs CO-fed mice had an elevated n-3/n-6 
PUFA molar ratio, markedly lower levels of saturated and monounsaturated fatty acids, 
and n-6 PUFA (18:2n-6, 20:4n-6), and was highly enriched in 20:5n-3.   
 
n-3 PUFA promote Th1 AICD 
In order to assess the effect of diet on AICD following Th1 polarization, cells 
were reactivated and analyzed for apoptosis using AnnexinV-FITC/PI labeling.  Annexin 
V binding is an excellent marker for apoptotic cells because the early distribution of 
plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the 
initiating stimulus (107,152,153).  To rule out the possibility of primary necrosis, Fas-
Fc, an inhibitor of the Fas death receptor, and Z-VAD-fmk (50 µmol/L), a pan-caspase 
inhibitor, were added to select cultures (146).  Unreactivated CD4+ T cells from both 
diet groups had equivalent levels of apoptosis (13.53 ± 0.77 in FO vs 13.32 ± 0.72 % in 
CO treatments, n=36 per diet) after 3 days in culture.  Upon restimulation (reactivation), 
apoptosis was increased two-fold (data not shown), consistent with our previously 
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published results (146).  These data indicate that T cells were not compromised in any 
way prior to restimulation.  
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Figure 10.  Diet-induced alteration of Th1 cell polarization is observed only in the presence of 
homologous mouse serum.  Splenic CD4+ T cells were isolated from mice fed CO or FO-containing diets 
for 2 weeks followed by polarization towards Th1 in the presence of MS or FBS.  After 5 days in culture, 
cells were reactivated with PMA/Ionomycin in the presence of monensin and assessed for the 
coexpression of IFNg and IL-4 by intracellular cytokine staining as described in the Materials and 
Methods. (A) Representative 2 parameter flow cytometric histograms of MS vs FBS-cultured cells.  
Numbers in each quadrant represent the percentage of cells positive for IFNg and/or IL-4. 
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Figure 10.  Continued. 
(B) Bars with different letters denote significant differences (p<0.05).  Data represent the mean ± SEM, 
n=6 replicates per diet group, 4 mice pooled per analysis. 
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Representative 2 parameter flow cytometric histograms of Annexin V-FITC 
and PI labeled cells are shown in Figure 11A.  The numbers in each quadrant represent 
the percentage of cells positive for Annexin V-FITC and/or PI.  The relative number of 
apoptotic cells (indicated by Annexin V positive, PI negative and Annexin V positive, PI 
positive) from CD4+ T cells from CO and FO-fed mice polarized in FBS or homologous 
MS is detailed in Figure 11B.  CD4+ T cells from FO-fed mice exhibited a statistically 
significant enhancement in AICD (55.9% in MS-CO vs. 69.3% in MS-FO, p = 0.0001).  
Similar to the polarization results illustrated above (Fig. 10), this effect only occurred in 
Table 8.  Fatty acid composition of sera used for cell culture
Fatty Acid FBS MS-CO MS-FO
16:0 1.71 ± 0.02 14.20 ± 0.55 5.03 ± 0.22
18:0 0.80 ± 0.02 7.93 ± 0.20 1.84 ± 0.07
18:1n-9/n-7 1.63 ± 0.05 15.54 ± 0.22 3.82 ± 0.15
18:2n-6 0.40 ± 0.01 17.72 ± 0.37 2.10 ± 0.09
20:4n-6 0.53 ± 0.01 12.32 ± 0.63 1.12 ± 0.07
20:5n-3 tr tr 2.99 ± 0.07
22:5n-3 0.15 ± 0.0 tr 0.22 ± 0.02
22:6n-3 0.17 ± 0.01 2.24 ± 0.24 2.22 ± 0.13
n-3/n-6 0.34 ± 0.00 0.07 ± 0.01 0.76 ± 0.04
Mouse serum from CO and FO-fed mice were extracted and analyzed to assess fatty 
acid composition.  FBS is shown for comparison.  Values are expressed as 
mg fatty acid/ml serum and represent means ± SEM, n=3.  FBS, fetal bovine serum; 
MS-CO, serum from corn oil fed mice; MS-FO, serum from fish oil fed mice; tr, trace 
amount (<0.1 mg/ml).
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MS-cultured cells, as this phenotype was lost when cells were cultured in FBS. In other 
words, dietary changes in CD4+ T cell function were maintained in cells cultured in 
homologous MS, but were lost when cells were cultured in FBS during the 5 day 
polarization period. 
To determine the relationship between cell polarization status and the amount of 
AICD induced, a correlation analysis of IFNg+ cells versus apoptotic cells was 
performed.  Figure 12 shows the correlation of MS-CO and MS-FO CD4+ T cells.  Both 
the Spearman and the Pearson correlation tests indicated that there was a significant 
positive correlation (p=0.0119 and p < 0.0005, respectively) between IFNg+ cells and the 
number of apoptotic cells when the data from the MS-CO and MS-FO cultures were 
analyzed together.  There was also a statistically significant positive correlation, 
p=0.0139 (Spearman test) and p=0.0073 (Pearson test), in FBS-cultured cells (data not 
shown).  
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Figure 11.  Dietary n-3 PUFA promote CD4+ T cell AICD only in the presence of homologous mouse 
serum.  Splenic CD4+ T cells were isolated from mice fed CO or FO-containing diets for 2 weeks 
followed by polarization towards Th1 in the presence of MS or FBS.  After 5 days in culture, cells were 
reactivated with PMA/Ionomycin and assessed for apoptosis by Annexin V-FITC and propidium iodide 
staining as described in the Materials and Methods.  (A) Representative 2 parameter flow cytometric 
histograms of MS vs FBS-cultured cells.  Numbers in each quadrant represent the percentage of cells 
positive for Annexin V-FITC and/or PI. 
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Figure 11.  Continued. 
(B) Bars with different letters denote significant differences (p<0.05).  Data represent the mean ± SEM, 
n=6 replicates per diet group, 4 mice pooled per analysis. 
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Figure 12.  AICD and Th1 differentiation are highly correlated in mouse serum-cultured CD4+ T 
cells.  The relationship between AICD and intracellular IFNg levels was examined by both Spearman and 
Pearson tests of IFNg + cells versus apoptotic cells.  Filled circles represent MS-cultured cells isolated 
from FO-fed animals and open circles represent MS-cultured cells isolated from CO-fed animals.  Data 
represent the mean ± SEM, n=6 replicates per diet group, 4 mice pooled per analysis (p<0.05). 
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Effect of culture conditions on Th1 cell membrane microdomains 
In order to clarify how dietary n-3 PUFA membrane enrichment is influenced by 
the 5 day culture period necessary for Th1 polarization, we examined lipid raft (liquid 
ordered) and soluble (liquid disordered) membrane fractions from CD4+ T cells 
immediately following isolation (Day 0), and after 5 days in culture with either FBS or 
homologous MS.  Table 9 shows the effect of diet and culture conditions on the fatty 
acid composition of raft and soluble membrane domains.  Consistent with previous 
reports (47,154), the raft membrane fraction had a 36% greater cholesterol to 
phospholipid molar ratio (chol/PL) compared to the soluble fractions (p = 0.07) (shown 
in Figure 13).  In addition, the total phospholipid unsaturation index was lower in rafts 
than in soluble membrane fractions (Table 9).  Collectively, these data indicate that 
proper fractionization was accomplished. 
Gas chromatographic analysis of the fatty acid composition of cell phospholipids 
showed that the amount of DHA (22:6n-3) in both raft and soluble fractions was 
decreased in FBS cultures of CD4+ T cells from FO-fed mice 5 days after culture (Table 
9).  In contrast, the inclusion of MS prevented the culture-induced rearrangement of T 
cell membrane lipids.  This phenomenon was observed with respect to other PUFA and 
fatty acid classes in both diets and both membrane fractions (Table 9).  Examination of 
membrane microdomain distributions of EPA (20:5n-3) and DHA (22:6n-3) from CO 
and FO-fed mouse CD4+ T cells (shown in Figure 14) revealed that the significant 
enhancement of these two n-3 PUFA in the CD4+ T cells of FO-fed, compared to CO-
fed, mice was lost in the rafts from CD4+ T cells in the FBS cultures.
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Table 9. Fatty acid composition in raft and soluble membrane fractions of CO and FO-fed mouse CD4+ T cells
CO
RAFT SOLUBLE
Fatty acid Day 0 Day 5 (FBS) Day 5 (MS) Day 0 Day 5 (FBS) Day 5 (MS)
SFA 70.57 ± 0.76 69.33 ± 2.04 68.97 ± 1.30 55.13 ± 0.81 53.69 ± 1.46 54.88 ± 6.25
MUFA 10.72 ± 0.43a* 20.30 ± 1.79b 12.57 ± 0.38a 10.27 ± 1.60a 31.09 ± 2.19b 14.82 ± 1.43a
PUFA 18.70 ± 1.01b 10.38 ± 1.26a 18.46 1.58b 34.59 ± 1.87b 15.22 ± 1.87a 30.30 ± 5.15b
n-6 PUFA 15.65 ± 2.43b 8.58 ± 1.45a 15.29 ± 1.71b 28.07 ± 1.27b 12.78 ± 1.66a 25.67 ± 5.45b
n-3 PUFA 3.05 ± 2.50 1.79 ± 0.30 3.17 ± 0.71 6.52 ± 1.38b 2.44 ± 0.35a 4.64 ± 0.36ab
n-3/n-6 0.26 ± 0.23 0.23 ± 0.06 0.21 ± 0.06 0.23 ± 0.05 0.19 ± 0.03 0.21 ± 0.06
UI** 54.79 ± 3.44ab 36.81 ± 3.62a 65.35 ± 4.36b 124.24 ± 8.25b 53.47 ± 5.80a 99.58 ± 17.26b
18:2n-6 3.76 ± 1.96 2.61 ± 0.42 4.82 ± 0.69 6.44 ± 0.33b 3.52 ± 0.49a 12.74 ± 0.77c
20:3n-6 3.32 ± 1.50b 0.59 ± 0.35a 2.05 ± 0.61ab 8.36 ± 0.94b 2.48 ± 1.2a 1.11 ± 0.56a
20:4n-6 4.69 ± 0.68 3.72 ± 0.45 6.49 ± 0.58 11.43 ± 1.88b 5.14 ± 0.26a 8.33 ± 3.39ab
20:5n-3 tr tr 0.29 ± 0.16 0.45 ± 0.45 tr tr
22:6n-3 0.61 ± 0.31 1.01 ± 0.17 1.95 ± 0.12 2.42 ± 0.50
ab 1.29 ± 0.14a 3.80 ± 0.24b
FO
RAFT SOLUBLE
Fatty acid Day 0 Day 5 (FBS) Day 5 (MS) Day 0 Day 5 (FBS) Day 5 (MS)
SFA 71.22 ± 3.07 76.52 ± 5.01 71.02 ± 1.58 65.16 ± 1.57 53.15 ± 0.83 54.39 ± 2.79
MUFA 12.64 ± 2.51 13.50 ± 4.07 13.62 ± 1.66 10.87 ± 0.79a 30.23 ± 0.29c 19.16 ± 3.61b
PUFA 16.14 ± 1.25 9.98 ± 1.22 15.36 ± 0.35 23.97 ± 1.37ab 16.63 ± 0.67a 26.45 ± 6.37b
n-6 PUFA 13.93 ± 1.39b 7.80 ± 1.20a 9.03 ± 0.15ab 16.28 ± 0.64 12.52 ± 0.56 14.26 ± 2.93
n-3 PUFA 2.21 ± 0.29a 2.18 ± 0.04a 6.34 ± 0.49b 7.69 ± 1.92a 4.10 ± 0.68a 12.19 ± 3.44b
n-3/n-6 0.17 ± 0.03a 0.30 ± 0.05a 0.70 ± 0.07b 0.48 ± 0.13a 0.33 ± 0.06a 0.82 ± 0.09b
UI 54.24 ± 3.67 36.96 ± 3.99 60.75 ± 2.21 97.36 ± 10.03b 63.42 ± 3.92a 109.55 ± 27.50b
18:2n-6 3.39 ± 0.28 2.00 ± 0.46 4.15 ± 0.55 4.78 ± 1.48ab 2.78 ± 0.42a 6.01 ± 1.02b
20:3n-6 2.43 + 0.85 1.42 ± 0.22 0.81 ± 0.81 0.82 ± 0.42 1.66 ± 0.09 1.04 ± 0.52
20:4n-6 5.20 ± 2.02 3.48 ± 0.68 2.54 ± 0.20 10.30 ± 0.86b 6.43 ± 0.74ab 5.56 ± 1.27a
20:5n-3 0.83 ± 0.66 tr 0.26 ± 0.14 1.14 ± 0.62 0.26 ± 0.13 0.96 ± 0.50
22:6n-3 2.47 ± 1.27
ab
1.17 ± 0.06
a
3.61 ± 0.38
b
4.54 ± 0.34
b
1.92 ± 0.04
a
6.26 ± 1.31
c
Splenic CD4+ T cells were isolated from mice fed CO or FO-containing diets for 2 weeks followed by membrane preparation (Day 0)
or cultured in the presence of either 5% FBS-complete medium (Day 5 (FBS)) or 5% homologous mouse serum-complete medium (Day 5 (MS))
for 5 days.  Rafts and soluble membrane fractions were isolated and fatty acid composition was analyzed.
Values are expressed as mol/100 mol fatty acids (mol%) and represent means ± SEM, n=3, 10 mice pooled per analysis.
* Letters indicate significant differences between culture conditions of the same diet and membrane fraction (p<0.05).
**  Unsaturation Index (UI) represents the summed mol/100 mol multiplied by the number of double bonds.
Abbreviations:  SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; tr, trace amounts (<0.1 mol%).
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Figure 13.  Characterization of membrane microdomain fractions.  Splenic CD4+ T cells were isolated 
from mice fed CO or FO-containing diets for 2 weeks followed by membrane isolation (Day 0) or after 
culture in the presence of either 5% FBS-complete medium (FBS) or homologous mouse serum (MS) for 5 
days.  Raft and soluble membrane fractions were isolated and total phospholipid and cholesterol levels 
were expressed as a mole percentage ratio.  Data represent the mean ± SEM, n = 18 replicates per 
membrane fraction.
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Figure 14.  Membrane microdomain distribution of EPA and DHA in CO and FO-fed mouse CD4+ 
T cells.  Splenic CD4+ T cell membrane fractions were isolated from mice fed CO or FO-containing diets 
for 2 weeks either immediately (Day 0) or after culture in the presence of either 5% FBS-complete 
medium (FBS) or homologous mouse serum (MS) for 5 days.  Raft and soluble membrane fractions were 
isolated and 20:5n-3 (EPA) and 22:6n-3 (DHA) were analyzed.  Data represent the mean ± SEM, n = 3 
replicates per diet group, 10 mice pooled per analysis.  Letters indicate significant differences between 
diets for the same membrane fraction and fatty acid (p<0.05). 
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Since cholesterol is critical for raft integrity (145), we examined the cholesterol 
level by assessing the molar chol/PL ratio in the various cell membrane fractions.  
Figure 15 shows the effect of diet and culture conditions on the molar ratio of 
cholesterol to total phospholipid.  In both diets groups, chol/PL significantly dropped 
from day 0 to day 5-FBS (p < 0.02) in CD4+ T cell membrane rafts.  However, in 
cultures of CD4+ T cells from FO-fed, but not CO-fed mice, the addition of MS 
prevented culture-induced loss of cholesterol.  In comparison, in soluble membrane 
fractions, a significant reduction (p < 0.05) in the chol/PL ratio occurred overtime 
regardless of culture conditions (Fig. 15). 
 
DISCUSSION 
Among dietary factors, there is overwhelming evidence for a protective effect of 
n-3 PUFA on autoimmune/inflammatory diseases (34,35,127).  In contrast, dietary lipids 
rich in n-6 PUFA can be deleterious with respect to the incidence and severity of 
inflammatory diseases.  This is significant because the typical Western diet contains 10-
20 times more n-6 than n-3 PUFA (37).  Additionally, the immunosuppressive effects of 
diets rich in n-3 PUFA on a variety of T cell functions has been firmly established in 
both human and animal models (17,34,35,70,127,155).  With respect to the physiological 
relevance of the diets used in our study, the FO diet contained approximately 1.4 and 1.0 
energy % as EPA and DHA, respectively.  As a point of reference, the Japanese typically 
consume n-3 PUFA at 1-2% of energy in their diet (156), while most European countries  
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Figure 15.  CD4+ T cells from n-3 PUFA-fed mice cultured in the presence of homologous MS 
maintain the cholesterol content of lipid rafts.  Splenic CD4+ T cells were isolated from mice fed CO or 
FO-containing diets for 2 weeks followed by membrane isolation (Day 0) or after culture in the presence 
of either 5% FBS-complete medium (FBS) or homologous mouse serum (MS) for 5 days.  Raft and 
soluble membrane fractions were isolated and total phospholipid and cholesterol levels were expressed as 
a mole percentage ratio.  Data represent the mean ± SEM, n = 3 replicates per diet group, 10 mice pooled 
per analysis.  Letters indicate significant differences between culture conditions within the same 
membrane fraction and diet (p<0.05).   
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and the U.S. consume 0.1-0.2% of energy as n-3 PUFA (157).  Therefore, the n-3 PUFA 
content of the experimental diets used in this study was well within the range consumed 
by humans.   
 We have observed previously that the dietary effect of n-3 PUFA on T cell 
proliferation and apoptosis depended upon the propensity of the in vitro stimulus to bias 
T cells towards a predominantly IL-2/IFNg producing population (a putative Th1-like 
subset) or an IL-4/IL-10 producing population (a putative Th2-like subset) (83,146).  
Specifically, n-3 PUFA increased proliferation only in CD4+ T cells stimulated with 
aCD3/PMA, a Th2-biasing stimulus (83).  With respect to apoptosis, we have 
previously shown that n-3 PUFA enhanced AICD in T cells induced to secrete a biased 
cytokine pattern, resembling Th1 cells, following stimulation with PMA/Ionomycin 
(146).  Therefore, we hypothesized that n-3 PUFA would promote AICD in polarized 
Th1 cells.  CD4+ T cells were driven to differentiate in vitro towards a Th1 cytokine pole 
using standard polarization methodology (149).  Due to the extended time in culture to 
achieve polarization (5 days), a set of cells from each diet group were cultured in diet-
matched homologous MS, rather than fetal bovine serum, to prevent culture-induced loss 
of n-3 PUFA from membrane phospholipids.  Fatty acid quantitation of medium 
containing MS or FBS revealed that there were significant differences in fatty acid 
composition between MS-CO, MS-FO, and FBS complete medium (Table 8).  Previous 
research has shown that cell culture conditions have a significant influence on 
lymphocyte bulk membrane fatty acid composition (147,148).  Yaqoob et al. (147) 
reported that culturing lymphocytes in medium containing autologous serum, which had 
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a fatty acid composition closely resembling that of the diet, allowed maintenance of diet-
induced changes in fatty acid composition.  In addition, culturing in autologous or 
homologous serum was shown to have a significant effect on lymphocyte function.  
Yaqoob et al. (76) and Pompos et al. (148) reported that n-3 PUFA decreased T cell 
proliferation when cells were cultured in autologous/homologous serum, but had little 
effect when the same cells were cultured in standard medium.  These results provided 
the rationale to include homologous MS in our cultures. 
 To verify that CD4+ T cells were polarized towards a Th1 phenotype, cells were 
analyzed for the coexpression of IFNg and IL-4.  Consistent with previous reports (149), 
a majority of the cells were IFNg+ IL-4-, indicating a predominant Th1 phenotype (Fig. 
10).  A noteworthy outcome from these analyses was that dietary CO suppressed Th1 
polarization relative to FO, however, this effect only occurred in cells cultured in the 
presence of homologous MS (Fig. 10).  These results are not consistent with the findings 
from other researchers who have shown that n-3 PUFA decrease IFNg (77,78).  
Specifically, Fritsche et al. (77) reported decreased serum IFNg and splenic IFNg mRNA 
levels in mice fed FO compared to n-6 PUFA control diets.  In contrast, other studies 
indicate that n-3 PUFA increase IFNg production (79,158,159).  There are several 
reasons for these apparent discrepancies.  Fritsche et al. (77) and Wallace et al. (78), who 
also reported decreased IFNg following FO-feeding, analyzed whole splenocyte 
populations and cultured cells in the presence of fetal bovine serum prior to IFNg 
analysis.  In contrast, Oarada et al. (158) and Fritsche et al. (79) detected enhanced IFNg 
when samples were assayed directly from n-3 PUFA fed animals, i.e., cells were not 
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maintained in culture.  The fact that a number of in vivo experiments show an increase in 
IFNg production following n-3 PUFA feeding support the conclusion that diet-induced 
changes in T cell cytokine production can be masked by culture conditions. 
 Since dietary lipids are incorporated into T cell membrane phospholipids (146), 
we investigated the effect of culture conditions on CD4+ T cell membranes.  Recent data 
generated in our lab have shown that n-3 PUFA remodel T cell lipid rafts (45), therefore 
we examined plasma membrane microdomains, i.e., rafts.  Interestingly, only in rafts 
isolated from CD4+ T cells from FO-fed mice did the addition of homologous MS 
prevent the culture-induced loss of cholesterol (Fig. 15).  Since cholesterol is critical for 
raft integrity (145), these results indicate that culture conditions have a profound effect 
on lipid raft composition and structure.  These data are noteworthy because perturbations 
in lipid raft integrity/composition directly mediate T cell AICD (107).  Rafts play an 
important role in cell signaling, particularly through the organization and distribution of 
surface receptors, including Fas, at specific sites in the plasma membrane (107,109).  
Recent studies have shown that the formation of macromolecular complexes containing 
the T cell receptor, CD4, and CD45 is believed to contribute to sustained TCR 
interaction with its ligand (44).  Lipid rafts are important for the formation and 
stabilization of these TCR signaling complexes, acting as platforms that facilitate 
intramolecular associations and propagation of signal transduction cascades (44).  
Interestingly, conditions that modify raft structure can disrupt early steps in T cell 
activation (160).  Rafts appear to differ depending on the developmental state of the T 
cell and these differences probably contribute to markedly different outcomes of 
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signaling (67).  Effector and memory T cells have more surface rafts compared to naïve 
T cells and activated Th1 cells differ from activated Th2 cells in raft organization.  
Stimulation of Th1 cells results in a stable association of TCR components with raft 
domains, while Th2 stimulation fails to form these signaling complexes (67).  Therefore, 
our data are noteworthy, because this is one of the first studies to examine the effect of 
diet on raft modification and its relationship to T cell activation. 
 With respect to AICD, raft structures are required for efficient propagation of 
apoptotic signals.  The death receptor and primary initiator of AICD, Fas, has been 
shown to require clustering and capping at the membrane to effectively signal to 
downstream apoptotic molecules (110).  This clustering and capping occurs in rafts; a 
location that best facilitates the trapping of Fas, recruitment of additional intracellular 
molecules of the DISC, and exclusion of inhibitory pathways.  Th1 and Th2 cells have 
different susceptibilities to AICD possibly explained, in part, by their distinct lipid raft 
compositions (67).  Our analysis showed that CD4+ T cells from FO-fed mice cultured in 
the presence of homologous MS exhibited significantly enhanced AICD (Fig. 11), i.e., 
the diet and culture conditions that promoted the greatest number of Th1 cells also 
enhanced AICD to the greatest extent.  These data extend our earlier findings where we 
demonstrated that alterations in dietary lipid composition can directly influence AICD 
(146).  In these experiments, following a 2 week feeding period, T cells were isolated 
from mice on diet and subsequently cultured for 3 days in the presence of FBS.  Only T 
cells from n-3 PUFA-fed mice had increased levels of AICD.  These observations clearly 
indicate that the tendency to undergo AICD is already established in vivo.  Therefore, the 
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use of homologous mouse serum does not create a new phenotype.  Interestingly, there 
was a significant positive correlation between the polarization status of the cell and the 
amount of AICD induced in homologous MS cells (Fig. 12).  The enhancement of AICD 
was not observed in FBS cultures where IFNg was suppressed.  Since Th1 cells are 
susceptible to AICD (112), our data suggest that n-3 PUFA may indirectly enhance 
AICD via promotion of a Th1 phenotype. 
 It has been reported that IFNg is required for T cell AICD (161).  IFNg signaling 
results in activation of Stat-1, which translocates to the nucleus and induces expression 
of caspase 8, the initiator caspase associated with the DISC.  Thus, IFNg and Stat-1 are 
involved in apoptosis mediated by death receptors.  Refaeli et al. (161) showed that T 
cells from IFNg -/- or Stat-1 -/- mice are unable to undergo apoptosis.  Our data 
indicating that dietary FO enhances the number of IFNg-producing CD4+ T cells relative 
to dietary CO (Fig. 10) suggests that IFNg may mediate the n-3 PUFA enhancement of 
AICD.  Figure 16 illustrates the putative mechanisms by which IFNg may mediate the n-
3 PUFA enhancement of AICD. 
 The IFNg receptor (IFNgR) has recently been found to be recruited to raft-like 
domains in T cells following IFNg stimulation (162).  IFNg binding and receptor 
relocalization to rafts is followed by IFNgR endocytosis and translocation of the 
IFNg/IFNgR/Stat-1 complex to the nucleus (162).  Since our data clearly show that 
dietary n-3 PUFA remodel CD4+ T cell lipid rafts (Fig. 14 & 15, Table 9), it is possible 
that n-3 PUFA modulate IFNg signaling by enhancing IFNgR raft localization due to 
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alterations in raft composition (Fig. 16).  Experiments are in progress in order to test this 
hypothesis. 
 Alterations in the methylation status of the IFNg promoter plays a critical role in 
regulating IFNg production (163).  For example, DNA methylation may interfere with 
transcription by preventing the recruitment of acetylase to the local chromatin, thereby 
inhibiting acquisition of the open conformation suitable for recruitment of transcription 
factors (163).  Recently, it has been shown that the IFNg promoter undergoes differential 
methylation during in vitro differentiation, with the promoter being in a hypomethylated 
state in Th1 cells, whereas it is hypermethylated in Th2 cells (163).  Interestingly, 
prostaglandin E2 (PGE2) inhibits IFNg promoter hypomethylation (164).  This is 
noteworthy, because n-3 PUFA decrease PGE2 production (39), whereas n-6 PUFA 
promote the synthesis of PGE2  (165).  Overall, these data suggest that the reduced IFNg 
expression in n-6 PUFA-fed mice in our studies (Fig. 10) might be due to reduced IFNg 
hypomethylation mediated by PGE2 (Fig. 16).  Additional studies to address the 
involvement of this mechanism are in progress. 
 Another mechanism by which n-3 PUFA could alter CD4+ T cell polarization 
might involve peroxisome proliferator-activated receptors (PPARs), specifically PPARg. 
PPARg has been shown to inhibit IL-4 production in CD4+ T cells (166).  However, 
PPARg also reduces IFNg and IL-2 in human T cells (167), indicating that PPARg is not 
selective in T cell subset repression.  Additionally, PPARg binds both n-3 and n-6 PUFA 
with equal affinity and lacks fatty acid class specificity (59,168).  Finally, we have 
already shown that our short-term feeding of n-3 PUFA does not induce increased 
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PPARg mRNA (Table 6).  Therefore, the effects of n-3 PUFA observed in this study are 
likely not mediated by PPARs. 
 In conclusion, our data support the hypothesis that dietary n-3 PUFA promote 
AICD in CD4+ T cells which are polarized toward the Th1 phenotype in vitro.  
Susceptibility to AICD in T cells from FO-fed mice appears to be an indirect result of 
the propensity of those cells to be induced to acquire a Th1 phenotype, i.e., produce 
IFNg.  We demonstrated the requirement for homologous MS in long-term cultures in 
order to preclude the loss of diet-derived n-3 PUFA from lipid rafts.  Furthermore, we 
have shown for the first time that the maintenance of diet-induced membrane alterations 
in vitro is required to observe the biological impact of diet on CD4+ T cell function. 
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Figure 16.  Scheme depicting the putative mechanisms by which IFNg may mediate the n-3 PUFA 
enhancement of AICD.  [A] n-3 polyunsaturated fatty acid (PUFA) induced alteration of lipid raft 
composition may promote IFNg receptor (IFNgR) localization to rafts, thereby permitting endocytosis and 
nuclear translocation of the IFNg/IFNgR/Stat-1 complex (162), resulting in enhanced IFNg expression 
(Th1 polarization).  [B] Alternatively, n-3 PUFA may promote IFNg expression through the reduction of 
prostaglandin E2 (PGE2), an inhibitor of IFNg transcription (164).  [C] The enhancement of IFNg 
expression by n-3 PUFA may promote the activation of caspase 8, resulting in increased activation-
induced cell death (AICD) (161).  Plasma membrane represents the phospholipid-rich phase of the 
membrane.  Lipid raft represents the sphingolipid and cholesterol enriched portion of the membrane.  LA, 
linoleic acid (n-6 PUFA); EPA, eicosapentaenoic acid (n-3 PUFA); DHA, docosahexaenoic acid (n-3 
PUFA); DISC, death-inducing signaling complex. 
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CHAPTER IV 
 
 
 
SUMMARY AND CONCLUSIONS 
 
 
Among dietary factors, n-3 PUFA found in fish oil (FO) have been shown to 
attenuate T cell-mediated inflammatory diseases in humans and experimental model 
systems (34,35,127).  The primary effector molecules are thought to be eicosapentaenoic 
acid [20:5n-3, EPA] and docosahexaenoic acid [22:6n-3, DHA].  In general, 
consumption of diets rich in n-3 PUFA are associated with a reduced pro-inflammatory 
T cell response due, in part, to a decreased proliferative capacity attributed to a reduction 
in IL-2 production and/or function (74,75,83).  Additionally, we have previously 
observed that the dietary effect of n-3 PUFA on T cell proliferation depends upon the 
propensity of the in vitro stimulus to bias T cells towards a predominant IL-2/IFNg 
producing population (a putative Th1-like subset) or an IL-4/IL-10 producing population 
(a putative Th2-like subset) (83).  Since the suppressive effects of n-3 PUFA on the 
accumulation of inflammatory T cells could result from either reduced proliferation, 
enhanced apoptosis of activated T cells, or both, we investigated the effect of dietary n-3 
PUFA on T cell apoptosis.  We specifically examined AICD since it is the form of 
apoptosis associated with the deletion of cells involved in chronic inflammation and 
autoimmune disease.  Consistent with this thinking, we focused on the CD4+ Th1 cell 
subset, as it is the cell mediator of chronic inflammation.   
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Our initial investigation of the effect of dietary n-3 PUFA on T cell apoptosis 
showed that n-3 PUFA enhanced T cell apoptosis following in vitro incubation with 
selective stimuli.  Purified splenic T cells from SAF, OO, and FO2-fed mice were 
cultured in aCD3/aCD28, aCD3/PMA, or PMA/Ionomycin for 24 h.  FO2 significantly 
increased the percentage of apoptotic cells relative to both SAF and OO only in 
PMA/Ionomycin stimulated T cells (Fig. 3B).  Cytokine analyses of cell culture 
supernatants revealed that aCD3/PMA stimulated T cells secreted significantly more IL-
4 and IL-10, Th2 cytokines (Fig. 5).  In comparison, PMA/Ionomycin stimulated T cells 
secreted significantly more IL-2, and much less IL-4, indicative of a Th1 phenotype.  
Thus, in agreement with previous studies (83), aCD3/PMA drove T cells towards a Th2-
like cytokine profile, while PMA/Ionomycin drove T cells towards a Th1-like cytokine 
profile.  Additionally, splenic T cells from FO2-fed mice had a modest increase in 
apoptosis following incubation in FasL + aFLAG (Fig. 3C), suggesting that n-3 PUFA 
are capable of modulating Fas signaling pathways.   
Since AICD is primarily regulated by Fas and FasL (96,120,121), we next 
determined the effect of n-3 PUFA on T cell AICD.  Similar to our initial apoptosis 
experiment, n-3 PUFA significantly increased AICD only following PMA/Ionomycin 
stimulation, or in Th1-like cells (Fig. 8D).  Furthermore, a comparison of dose (4% FO 
vs 9% FO) demonstrated that there was no difference in AICD, thus T cell AICD can 
occur just as efficiently at low n-3 PUFA intakes.  Th1 effectors are more susceptible to 
AICD (112,113), therefore we hypothesized that the ability of n-3 PUFA to enhance 
AICD following PMA/Ionomycin stimulation was due to the induction of a biased 
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pattern of cytokine production in T cells.  In an attempt to determine whether the pro-
apoptotic effects of dietary FO were mediated by DHA, we fed mice diets composed of 
1% DHA ethyl esters or CO.  To our surprise, DHA did not enhance apoptosis (Fig. 9), 
suggesting that DHA, by itself, is not the active molecule in FO with respect to AICD. 
Next, we wanted to determine whether the ingestion of different lipid sources 
altered systemic oxidative stress, since long chain n-3 PUFA are highly susceptible to 
peroxidation.  This is significant because the formation of reactive oxygen species and/or 
glutathione depletion can regulate signals involved in AICD (144).  Our results indicate 
that there was no change in oxidative status (Table 6), suggesting that short-term 
feeding of n-3 PUFA did not promote the generation of pro-apoptotic reactive oxygen 
species in our model. 
Based on our results that n-3 PUFA enhanced AICD in T cells induced to secrete 
a Th1-biased cytokine profile, we hypothesized that n-3 PUFA would also promote 
AICD in CD4+ T cells driven to differentiate in vitro towards a Th1 cytokine pole using 
standard polarization methodology.  Due to the extended time in culture to achieve 
polarization, a set of cells from each diet group were cultured in diet-matched 
homologous MS, rather than fetal bovine serum (FBS).  This approach prevented 
culture-induced loss of n-3 PUFA from membrane phospholipids.  Following 
verification that the cells were appropriately polarized towards a Th1 phenotype, it was 
demonstrated that dietary CO suppressed Th1 polarization relative to FO and that this 
effect only occurred in cells cultured in the presence of homologous MS (Fig. 10).  
Analysis of AICD in CD4+ T cells from FO-fed mice cultured in the presence of 
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homologous MS had significantly enhanced AICD (Fig. 11).  Therefore the diet and 
culture conditions that promoted the greatest number of Th1 cells also enhanced AICD 
to the greatest extent.  Since Th1 cells are susceptible to AICD (112,113), our data 
suggest that n-3 PUFA may indirectly enhance AICD via promotion of a Th1 phenotype. 
That the phenotypes were lost when cells were cultured in FBS led us to 
hypothesize that homologous MS maintained diet-induced changes in membrane fatty 
acid composition.  In addition, recent data have shown that n-3 PUFA remodel T cell 
lipid rafts (45), therefore we examined the effect of culture conditions on CD4+ T cell 
plasma membrane microdomains, i.e., rafts.  Analysis of the fatty acid composition of 
cell phospholipids showed that the inclusion of MS prevented the culture-induced 
rearrangement of T cell lipids (Table 9).  Detailed examination of membrane 
microdomains revealed that the significant enhancement of EPA and DHA in the CD4+ 
T cells from FO-fed mice, compared to CO-fed mice, was lost in cells cultured in FBS 
(Fig. 14).  Cholesterol analysis revealed that only in rafts isolated from CD4+ T cells 
from FO-fed mice did the addition of homologous MS prevent the culture-induced loss 
of cholesterol (Fig. 15).  Since cholesterol is critical for raft integrity (145), these results 
indicate that culture conditions have a profound effect on lipid raft composition and 
structure. 
In summary, our results add to the wealth of clinical and experimental data 
describing the anti-inflammatory properties of n-3 PUFA.  Our novel findings contribute 
significantly to the elucidation of mechanisms by which dietary n-3 PUFA selectively 
modulate T cell subset function.  Furthermore, we have shown that cell culture 
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conditions (e.g., serum source) are critical to observe the biological impact of diet on cell 
function in vitro.  Studies such as these will aid in the establishment of dietary guidelines 
designed to promote a balanced immune system, so that protective host responses (e.g., 
to infectious agents) can be maintained, while potentially detrimental host responses 
(e.g., chronic inflammation and hypersensitivity) can be controlled. 
Future studies are needed to determine the precise cellular and molecular 
mechanisms by which dietary n-3 PUFA promote Th1 polarization and subsequent 
AICD. 
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Means ± SEM for Fig. 3         
Early apoptosis  SAF  OO  FO2 
RPMI 3.35 ± 0.39 2.68 ± 0.22 2.13 ± 0.24 
CD3/CD28 3.74 ± 0.35 3.80 ± 0.32 2.67 ± 0.50 
CD3/PMA 5.24 ± 0.24 4.35 ± 0.50 4.21 ± 0.27 
PMA/Iono 9.19 ± 0.50 8.84 ± 0.28 10.09 ± 0.65 
Dexamethasone 1.53 ± 0.11 1.68 ± 0.10 1.42 ± 0.15 
FasL + aFLAG 1.91 ± 0.15 2.01 ± 0.14 2.71 ± 0.46 
values expressed as % AV+/PI-        
          
Late apoptosis  SAF  OO  FO2 
RPMI 54.06 ± 3.82 53.83 ± 4.56 46.07 ± 3.46 
CD3/CD28 48.23 ± 8.04 48.94 ± 9.17 38.65 ± 6.02 
CD3/PMA 50.29 ± 8.01 46.11 ± 6.73 36.43 ± 2.23 
PMA/Iono 24.55 ± 1.55 26.42 ± 1.47 25.82 ± 0.30 
Dexamethasone 91.41 ± 0.66 91.04 ± 1.49 92.28 ± 1.23 
FasL + aFLAG 85.29 ± 0.37 86.26 ± 1.77 85.42 ± 0.64 
values expressed as % AV+/PI+        
 
 Means ± SEM for Fig. 2      
 Early apoptosis 
4h 
Late apoptosis 
4h 
RPMI 8.18 ± 0.17 11.54 ± 0.32 
DMSO 8.46 ± 0.00 12.02 ± 0.00 
aFLAG 8.56 ± 0.17 12.56 ± 0.32 
FasL 9.89 ± 0.35 17.52 ± 0.38 
FasL + ZVAD 50 9.24 ± 0.23 10.13 ± 0.04 
FasL + ZVAD 20 9.45 ± 0.20 11.58 ± 0.06 
ZVAD 20 8.97 ± 0.00 10.83 ± 0.00 
       
 Early apoptosis 
24h 
Late apoptosis  
24h 
RPMI 3.55 ± 0.18 43.07 ± 0.54 
DMSO 3.41 ± 0.00 41.70 ± 0.00 
aFLAG 3.49 ± 0.10 42.74 ± 0.56 
FasL 2.42 ± 0.13 71.75 ± 0.51 
FasL + ZVAD 50 3.61 ± 0.12 39.73 ± 0.88 
FasL + ZVAD 20 3.56 ± 0.08 41.04 ± 1.15 
ZVAD 20 3.35 ± 0.20 42.32 ± 0.79 
values expressed as % AV+/PI- or %AV+/PI+   
118 
CHAPTER II - MEANS ± SEM (cont.) 
 
 
 
 
 
 
 
Means ± SEM for Fig. 7      
 Early apoptosis    Late apoptosis  
PMA/Iono 99.92 ± 1.31 100.01 ± 3.34 
P/I + Fas-Fc 81.77 ± 1.99 95.48 ± 4.27 
P/I + IgG 91.32 ± 4.88 101.91 ± 2.05 
P/I + ZVAD 95.25 ± 3.21 96.10 ± 0.94 
RPMI 54.27 ± 2.00 72.80 ± 2.86 
values expressed as % AV+/PI- or %AV+/PI+   
 
Means ± SEM for Fig. 5         
 CD3/CD28  CD3/PMA  PMA/Iono  
IFNg 233302.50 ± 5021.16 224857.7 ± 6193.46 94209.24± 2420.00 
IL-10 200.63 ± 19.01 752.35 ± 94.26 125.47 ± 4.30 
IL-2 3424.87 ± 207.50 586.16 ± 83.88 20920.6 ± 827.41 
IL-4 837.39 ± 48.17 1345.62 ± 116.16 36.79 ± 15.45 
values expressed as pg/ml         
          
Means ± SEM for Fig. 6         
 CD3/CD28  CD3/PMA  PMA/Iono  
IL-4          
SAF 780.33 ± 31.04 1010.73 ± 37.37 64.90 ± 35.13 
FO4 882.93 ± 114.94 1503.53 ± 155.28 11.03 ± 6.16 
FO9 848.90 ± 104.58 1522.60 ± 228.49 34.43 ± 29.37 
IFNg          
SAF 230270.0 ± 7707.49 210515.3 ± 9866.03 98070.2 ± 2420.34 
FO4 235705.8 ± 5258.06 220641.6 ± 6428.63 97628.3 ± 3903.71 
FO9 233931.7 ± 12924.3 242713.4 ± 10725.2 85473.2 ± 4576.23 
IL-10          
SAF 155.82 ± 39.62 719.79 ± 97.32 133.79 ± 8.49 
FO2 148.84 ± 8.90 564.13 ± 32.64 113.31 ± 4.94 
FO4 263.81 ± 35.12 1026.91 ± 226.10 129.32 ± 6.77 
IL-2          
SAF 3228.25 ± 358.63 848.54 ± 131.79 19106.9 ± 1070.33 
FO2 3432.54 ± 288.70 580.12 ± 129.26 22421.5 ± 1118.47 
FO4 3581.04 ± 458.19 329.81 ± 103.77 21233.3 ± 1859.70 
values expressed as pg/ml         
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Means ± SEM for Fig. 8         
  SAF  FO4  FO9 
CD3/CD28 30.32 ± 2.57 26.62 ± 1.43 29.65 ± 1.42 
CD3/PMA 44.33 ± 1.76 43.45 ± 1.05 42.33 ± 1.15 
PMA/Iono 6.66 ± 0.66 8.14 ± 0.42 9.47 ± 0.38 
          
  TOTAL       
CD3/CD28 30.24 ± 0.62       
CD3/PMA 42.93 ± 0.52       
PMA/Iono 8.23 ± 0.27       
values expressed as % AV+/PI-         
          
Means ± SEM for Fig. 9         
  CO  DHA    
CD3/CD28 29.02 ± 1.10 29.02 ± 1.28    
CD3/PMA 27.62 ± 0.98 25.92 ± 0.64    
PMA/Iono 5.55 ± 0.34 6.02 ± 0.27    
values expressed as % AV+/PI-        
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CHAPTER III - MEANS ± SEM 
 
 
 
 
 
 
 
 
 
 
 
 
Means ± SEM for Fig. 13   
  chol/PL  
Raft 0.031 ± 0.007  
Soluble 0.020 ± 0.006  
values are expressed as a cholesterol to  
phospholipid molar ratio (chol/PL)  
 
Means ± SEM for Fig. 11B   
   Total apoptosis  
FBS-CO 54.27 ± 2.45  
FBS-FO 50.83 ± 0.99  
MS-CO 55.87 ± 0.92  
MS-FO 69.32 ± 0.35  
values are expresssed as % apoptotic cells 
(AV+/PI- + AV+/PI+)    
 
Means ± SEM for Fig. 10B   
   Intracellular cytokines  
FBS-CO 58.18 ± 2.14  
FBS-FO 58.85 ± 1.64  
MS-CO 36.93 ± 2.36  
MS-FO 55.05 ± 1.12  
values are expresssed as %IFNg +/IL-4 - 
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Means ± SEM for Fig. 15        
  Day 0  Day 5 FBS  Day 5 MS 
CO          
raft 0.077 ± 0.030 0.012 ± 0.001 0.018 ± 0.009 
soluble 0.029 ± 0.004 0.008 ± 0.003 0.008 ± 0.002 
FO          
raft 0.033 ± 0.006 0.015 ± 0.002 0.032 ± 0.010 
soluble 0.050 ± 0.029 0.009 ± 0.002 0.014 ± 0.008 
values are expressed as mean chol/PL ratio      
 
Means ± SEM for Fig. 14        
20:5n-3  Day 0  Day 5 FBS  Day 5 MS 
CO          
raft 0.00 ± 0.00 0.00 ± 0.00 0.29 ± 0.16 
soluble 0.45 ± 0.45 0.00 ± 0.00 0.00 ± 0.00 
FO          
raft 0.83 ± 0.66 0.00 ± 0.00 0.26 ± 0.14 
soluble 1.14 ± 0.62 0.26 ± 0.13 0.96 ± 0.50 
          
22:6n-3  Day 0  Day 5 FBS  Day 5 MS 
CO          
raft 0.61 ± 0.31 1.01 ± 0.17 1.95 ± 0.12 
soluble 2.42 ± 0.50 1.29 ± 0.14 3.80 ± 0.24 
FO          
raft 2.47 ± 1.27 1.17 ± 0.06 3.61 ± 0.38 
soluble 4.54 ± 0.34 1.92 ± 0.04 6.26 ± 1.31 
values are expressed as mol%       
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EXPT. 1 – APOPTOSIS DATA 
 
 
 
 
Diet Mouse Stimulus %Early %Late %Total
SAF 1 CD3/CD28 2.72 26.65 29.37
SAF 2 CD3/CD28 4.11 46.36 50.47
SAF 3 CD3/CD28 3.4 56.05 59.45
SAF 4 CD3/CD28 3.92 66.74 70.66
SAF 5 CD3/CD28 5.14 69.83 74.97
SAF 6 CD3/CD28 3.13 23.77 26.9
OO 7 CD3/CD28 5.25 63.91 69.16
OO 8 CD3/CD28 3.49 39.75 43.24
OO 9 CD3/CD28 2.89 18.95 21.84
OO 10 CD3/CD28 3.76 67.88 71.64
OO 11 CD3/CD28 3.87 73.27 77.14
OO 12 CD3/CD28 3.54 29.9 33.44
FO 13 CD3/CD28 5.05 63.07 68.12
FO 14 CD3/CD28 1.94 29.92 31.86
FO 15 CD3/CD28 2.24 35.06 37.3
FO 16 CD3/CD28 2.68 29.29 31.97
FO 17 CD3/CD28 2.41 49.72 52.13
FO 18 CD3/CD28 1.71 24.84 26.55
Diet Mouse Stimulus %Early %Late %Total
SAF 1 CD3/PMA 5.1 57.96 63.06
SAF 2 CD3/PMA 5.91 69.76 75.67
SAF 3 CD3/PMA 5.41 62.32 67.73
SAF 4 CD3/PMA 5.86 23.05 28.91
SAF 5 CD3/PMA 4.46 28.07 32.53
SAF 6 CD3/PMA 4.71 60.6 65.31
OO 7 CD3/PMA 3.42 35.75 39.17
OO 8 CD3/PMA 6.17 64.38 70.55
OO 9 CD3/PMA 4.14 27.67 31.81
OO 10 CD3/PMA 3.04 36.59 39.63
OO 11 CD3/PMA 3.88 68.06 71.94
OO 12 CD3/PMA 5.44 44.23 49.67
FO 13 CD3/PMA 4.76 28.34 33.1
FO 14 CD3/PMA 3.57 40.16 43.73
FO 15 CD3/PMA 4.13 37.1 41.23
FO 16 CD3/PMA 5.11 31.98 37.09
FO 17 CD3/PMA 4.24 37.66 41.9
FO 18 CD3/PMA 3.45 43.36 46.81
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Diet Mouse Stimulus %Early %Late %Total
SAF 1 PMA/Iono 8.85 23.3 32.15
SAF 2 PMA/Iono 9.89 27.08 36.97
SAF 3 PMA/Iono 9.46 19.96 29.42
SAF 4 PMA/Iono 11.06 21.85 32.91
SAF 5 PMA/Iono 8.3 30.56 38.86
SAF 6 PMA/Iono 7.56 24.53 32.09
OO 7 PMA/Iono 9.67 31.76 41.43
OO 8 PMA/Iono 8.65 30.06 38.71
OO 9 PMA/Iono 8.13 25.02 33.15
OO 10 PMA/Iono 9.21 22.73 31.94
OO 11 PMA/Iono 7.97 24.76 32.73
OO 12 PMA/Iono 9.38 24.21 33.59
FO 13 PMA/Iono 11.11 26.44 37.55
FO 14 PMA/Iono 10.14 25.32 35.46
FO 15 PMA/Iono 10.27 24.85 35.12
FO 16 PMA/Iono 10.78 26.48 37.26
FO 17 PMA/Iono 11.27 26.48 37.55
FO 18 PMA/Iono 6.98 25.35 32.33
Diet Mouse Stimulus %Early %Late %Total
SAF 1 RPMI 3.43 57.6 61.03
SAF 2 RPMI 3.68 56.16 59.84
SAF 3 RPMI 4.99 69.03 74.02
SAF 4 RPMI 2.45 42.97 45.42
SAF 5 RPMI 2.43 53.11 55.54
SAF 6 RPMI 3.09 45.5 48.59
OO 7 RPMI 1.82 38.41 40.23
OO 8 RPMI 3.44 71.14 74.58
OO 9 RPMI 2.95 59.39 62.34
OO 10 RPMI 2.45 49.82 52.27
OO 11 RPMI 2.57 56.15 58.72
OO 12 RPMI 2.87 48.05 50.92
FO 13 RPMI 3.13 47.12 50.25
FO 14 RPMI 1.75 40.57 42.32
FO 15 RPMI 2.52 59.25 61.77
FO 16 RPMI 1.97 52.09 54.06
FO 17 RPMI 1.77 40.9 42.67
FO 18 RPMI 1.65 36.49 38.14
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Diet Mouse Stimulus %Early %Late %Total
SAF 1 Dexameth 1.5 92.18 93.68
SAF 2 Dexameth 2.04 90.33 92.37
SAF 3 Dexameth 1.42 88.79 90.21
SAF 4 Dexameth 1.53 93.45 94.98
SAF 5 Dexameth 1.44 91.88 93.32
SAF 6 Dexameth 1.24 91.81 93.05
OO 7 Dexameth 1.63 94.17 95.8
OO 8 Dexameth 1.81 91.96 93.77
OO 9 Dexameth 1.69 89.04 90.73
OO 10 Dexameth 1.28 92.47 93.75
OO 11 Dexameth 1.67 93.97 95.64
OO 12 Dexameth 2.01 84.6 86.61
FO 13 Dexameth 2.13 89.01 91.14
FO 14 Dexameth 1.34 94.65 95.99
FO 15 Dexameth 1.44 91.1 92.54
FO 16 Dexameth 1.23 89.7 90.93
FO 17 Dexameth 1.05 96.86 97.91
FO 18 Dexameth 1.31 92.35 93.66
Diet Mouse Stimulus %Early %Late %Total
SAF 1 FasL/FLAG 2.25 84.17 86.42
SAF 2 FasL/FLAG 2.22 86.14 88.36
SAF 3 FasL/FLAG 1.81 84.07 85.88
SAF 4 FasL/FLAG 2.16 85.82 87.98
SAF 5 FasL/FLAG 1.71 85.85 87.56
SAF 6 FasL/FLAG 1.29 85.67 86.96
OO 7 FasL/FLAG 1.78 86.63 88.41
OO 8 FasL/FLAG 1.96 86.9 88.86
OO 9 FasL/FLAG 1.88 81.5 83.38
OO 10 FasL/FLAG 1.61 92.81 94.42
OO 11 FasL/FLAG 2.32 88.33 90.65
OO 12 FasL/FLAG 2.53 81.41 83.94
FO 13 FasL/FLAG 2.43 83.67 86.1
FO 14 FasL/FLAG 4.07 85.32 89.39
FO 15 FasL/FLAG 1.86 87.03 88.89
FO 16 FasL/FLAG 2.54 83.51 86.05
FO 17 FasL/FLAG 4.05 86.99 91.04
FO 18 FasL/FLAG 1.33 86.01 87.34
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EXPT. 2 – APOPTOSIS DATA 
 
 
 
 
Diet Mouse Stimulus % Early % Late % Total
SAF 1 RPMI 1.7 68.7 70.4
SAF 2 RPMI 1.44 64.9 66.3
SAF 3 RPMI 1.97 72.9 74.9
SAF 4 RPMI 1.72 70.8 72.5
SAF 5 RPMI 0.82 61 61.8
SAF 6 RPMI 2.32 74.5 76.8
OO 7 RPMI 0.88 70.5 71.4
OO 8 RPMI 1.02 70.5 71.5
OO 9 RPMI 0.97 71.5 72.5
OO 10 RPMI 0.75 66.5 67.3
OO 11 RPMI 0.97 58.2 59.2
OO 12 RPMI 0.97 69.1 70.1
FO 13 RPMI 0.98 69.2 70.2
FO 14 RPMI 0.92 71.9 72.8
FO 15 RPMI 0.97 69.1 70.1
FO 16 RPMI 0.94 68.2 69.1
FO 17 RPMI 0.67 69.4 70.1
FO 18 RPMI 2.07 66.8 68.9
Diet Mouse Stimulus % Early % Late % Total
SAF 1 CD3/CD28 3.89 36.8 40.7
SAF 2 CD3/CD28 1.62 15.4 17.0
SAF 3 CD3/CD28 2.37 28.8 31.2
SAF 4 CD3/CD28 3.95 28.8 32.8
SAF 5 CD3/CD28 2.6 32 34.6
SAF 6 CD3/CD28 3.19 31.1 34.3
OO 7 CD3/CD28 2.93 27.5 30.4
OO 8 CD3/CD28 1.84 28.1 29.9
OO 9 CD3/CD28 1.68 26.8 28.5
OO 10 CD3/CD28 4.3 37.3 41.6
OO 11 CD3/CD28 2.01 23.9 25.9
OO 12 CD3/CD28 1.63 32.6 34.2
FO 13 CD3/CD28 3.5 32.8 36.3
FO 14 CD3/CD28 1.66 23.3 25.0
FO 15 CD3/CD28 2.11 27.3 29.4
FO 16 CD3/CD28 2.12 25.5 27.6
FO 17 CD3/CD28 1.91 27.1 29.0
FO 18 CD3/CD28 2.21 32 34.2
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Diet Mouse Stimulus % Early % Late % Total
SAF 1 PMA/Iono 2.19 17.2 19.4
SAF 2 PMA/Iono 1.61 15.5 17.1
SAF 3 PMA/Iono 1.28 14.5 15.8
SAF 4 PMA/Iono 2.51 17.8 20.3
SAF 5 PMA/Iono 2.31 22.3 24.6
SAF 6 PMA/Iono 1.84 19.7 21.5
OO 7 PMA/Iono 1.38 11.7 13.1
OO 8 PMA/Iono 5.84 26.2 32.0
OO 9 PMA/Iono 1.47 15.2 16.7
OO 10 PMA/Iono 1.21 13 14.2
OO 11 PMA/Iono 1.18 13.4 14.6
OO 12 PMA/Iono 4.14 20.5 24.6
FO 13 PMA/Iono 0.93 12.8 13.7
FO 14 PMA/Iono 1.37 16.2 17.6
FO 15 PMA/Iono 1.19 15 16.2
FO 16 PMA/Iono 1.25 15.2 16.5
FO 17 PMA/Iono 1.74 17.1 18.8
FO 18 PMA/Iono 1.13 15.9 17.0
Diet Mouse Stimulus % Early % Late % Total
SAF 1 CD3/PMA 3 21 24.0
SAF 2 CD3/PMA 6.12 30.3 36.4
SAF 3 CD3/PMA 4.49 22.4 26.9
SAF 4 CD3/PMA 4.47 24.2 28.7
SAF 5 CD3/PMA 4.63 24.4 29.0
SAF 6 CD3/PMA 3.15 24.2 27.4
OO 7 CD3/PMA 3.62 19.9 23.5
OO 8 CD3/PMA 4.73 28 32.7
OO 9 CD3/PMA 3.43 22.3 25.7
OO 10 CD3/PMA 6.91 32.9 39.8
OO 11 CD3/PMA 4.75 21.7 26.5
OO 12 CD3/PMA 2.9 24.7 27.6
FO 13 CD3/PMA 0.087 0.52 0.6
FO 14 CD3/PMA 0.68 4.88 5.6
FO 15 CD3/PMA 13.2 41.4 54.6
FO 16 CD3/PMA 5.39 26 31.4
FO 17 CD3/PMA 5.03 27.1 32.1
FO 18 CD3/PMA 2.99 24.1 27.1
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Diet Mouse Stimulus % Early % Late % Total
SAF 1 FasL/FLAG 0.63 78.7 79.3
SAF 2 FasL/FLAG 0.66 71.4 72.1
SAF 3 FasL/FLAG 0.61 80.3 80.9
SAF 4 FasL/FLAG 0.54 78.7 79.2
SAF 5 FasL/FLAG 0.47 85.9 86.4
SAF 6 FasL/FLAG 1.02 76.2 77.2
OO 7 FasL/FLAG 0.58 74 74.6
OO 8 FasL/FLAG 0.7 76.3 77.0
OO 9 FasL/FLAG 0.46 77.6 78.1
OO 10 FasL/FLAG 0.56 82 82.6
OO 11 FasL/FLAG 0.44 74.2 74.6
OO 12 FasL/FLAG 0.53 85.4 85.9
FO 13 FasL/FLAG 0.32 82.2 82.5
FO 14 FasL/FLAG 0.37 77.2 77.6
FO 15 FasL/FLAG 0.54 83.5 84.0
FO 16 FasL/FLAG 0.49 77.6 78.1
FO 17 FasL/FLAG 0.47 82.7 83.2
FO 18 FasL/FLAG 0.53 79.2 79.7
Diet Mouse Stimulus % Early % Late % Total
SAF 1 P/I/F/F 3.13 18.1 21.2
SAF 2 P/I/F/F 2.86 31.3 34.2
SAF 3 P/I/F/F 3.3 18 21.3
SAF 4 P/I/F/F 3.16 15.1 18.3
SAF 5 P/I/F/F 1.05 10.6 11.7
SAF 6 P/I/F/F 2.95 18.3 21.3
OO 7 P/I/F/F 2.65 14.6 17.3
OO 8 P/I/F/F 4.26 21.8 26.1
OO 9 P/I/F/F 4.13 19 23.1
OO 10 P/I/F/F 1.49 15.6 17.1
OO 11 P/I/F/F 2.74 18.5 21.2
OO 12 P/I/F/F 1.75 13.3 15.1
FO 13 P/I/F/F 2.38 17.2 19.6
FO 14 P/I/F/F 2.7 20.1 22.8
FO 15 P/I/F/F 3.42 22.7 26.1
FO 16 P/I/F/F 3.58 20.5 24.1
FO 17 P/I/F/F 3.21 21 24.2
FO 18 P/I/F/F 4.68 24.9 29.6
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Diet Mouse Stimulus % Early % Late % Total
SAF 1 3/P/F/F 10.1 42.4 52.5
SAF 2 3/P/F/F 7.85 37.2 45.1
SAF 3 3/P/F/F 9.46 38.8 48.3
SAF 4 3/P/F/F 10.9 41.5 52.4
SAF 5 3/P/F/F 10 42.6 52.6
SAF 6 3/P/F/F 8.02 42.8 50.8
OO 7 3/P/F/F 8.75 38.8 47.6
OO 8 3/P/F/F 7.91 43.3 51.2
OO 9 3/P/F/F 9.6 39.7 49.3
OO 10 3/P/F/F 9.32 44.7 54.0
OO 11 3/P/F/F 10.6 36.9 47.5
OO 12 3/P/F/F 7.58 46.1 53.7
FO 13 3/P/F/F 7.25 39.8 47.1
FO 14 3/P/F/F 8.52 38.9 47.4
FO 15 3/P/F/F 8.72 41.7 50.4
FO 16 3/P/F/F 9.74 44.9 54.6
FO 17 3/P/F/F 8.67 45.8 54.5
FO 18 3/P/F/F 8.36 46 54.4
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T cells CD3+ CD3+ CD3+ CD3+
AV-/7AAD- AV+/7AAD- AV+/7AAD+ AV-/7AAD+ Median
Stimulus Mouse %CD3+ LIVE EARLY LATE DEAD CD3 Fluor.
RPMI 1 40.1            42.8            2.2              49.4            5.6              703.0           
RPMI 2 33.7            42.1            1.1              51.1            5.7              455.0           
RPMI 3 40.1            54.9            1.2              40.5            3.4              765.0           
RPMI 4 36.9            45.2            1.1              46.7            7.0              527.0           
RPMI 5 35.4            46.5            1.5              48.7            3.3              677.0           
RPMI 6 32.8            39.4            1.3              55.7            3.6              735.0           
RPMI 7 36.5            44.3            1.5              50.0            4.3              780.0           
RPMI 8 36.6            36.3            1.1              53.1            9.5              716.0           
RPMI 9 35.1            48.2            0.9              45.7            5.2              744.0           
RPMI 10 39.5            47.7            1.2              47.2            4.0              593.0           
RPMI 11 34.5            46.3            1.0              48.2            4.5              667.0           
RPMI 12 33.9            41.6            1.5              48.2            8.7              610.0           
RPMI 13 36.8            53.0            1.5              40.7            4.8              615.0           
RPMI 14 37.7            41.6            1.0              43.2            14.3            607.0           
RPMI 15 31.3            49.2            1.0              45.2            4.7              506.0           
RPMI 16 32.5            48.9            1.2              44.5            5.5              524.0           
RPMI 17 32.1            41.8            0.8              49.9            7.5              621.0           
RPMI 18 39.3            42.7            0.6              49.9            6.7              503.0           
Median
Stimulus Mouse %CD3+ LIVE EARLY LATE DEAD CD3 Fluor.
CD3/CD28 1 32.5            64.4            17.4            12.5            5.6              175.0           
CD3/CD28 2 26.9            63.4            21.8            9.9              5.0              128.0           
CD3/CD28 3 28.7            74.3            12.8            10.0            2.9              127.0           
CD3/CD28 4 27.2            66.8            14.8            11.7            6.7              140.0           
CD3/CD28 5 26.5            70.1            16.0            9.5              4.4              150.0           
CD3/CD28 6 27.7            68.1            15.4            11.0            5.5              148.0           
CD3/CD28 7 27.3            70.1            12.3            12.5            5.2              158.0           
CD3/CD28 8 28.1            63.4            14.4            11.3            10.8            126.0           
CD3/CD28 9 28.9            73.8            11.9            10.3            3.9              145.0           
CD3/CD28 10 30.4            72.0            13.2            10.4            4.5              115.0           
CD3/CD28 11 30.2            70.2            16.1            9.3              4.4              147.0           
CD3/CD28 12 29.5            63.5            16.3            12.8            7.4              146.0           
CD3/CD28 13 29.2            65.9            15.4            12.3            6.5              166.0           
CD3/CD28 14 31.7            61.6            15.9            9.6              13.0            115.0           
CD3/CD28 15 28.7            67.4            16.2            10.0            6.5              129.0           
CD3/CD28 16 27.9            71.4            12.4            9.3              6.8              129.0           
CD3/CD28 17 30.1            69.8            12.7            11.0            6.4              160.0           
CD3/CD28 18 27.8            68.2            10.2            12.5            9.1              145.0           
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Median
Stimulus Mouse %CD3+ LIVE EARLY LATE DEAD CD3 Fluor.
CD3/PMA 1 30.5            65.1            14.1            12.9            7.9              151.0           
CD3/PMA 2 25.2            66.2            19.3            9.4              5.1              109.0           
CD3/PMA 3 25.8            73.3            13.5            8.9              4.3              132.0           
CD3/PMA 4 28.2            68.7            13.2            10.3            7.8              141.0           
CD3/PMA 5 25.8            72.8            11.3            9.7              6.3              174.0           
CD3/PMA 6 24.2            73.9            11.0            8.7              6.5              116.0           
CD3/PMA 7 26.3            64.4            16.0            12.3            7.4              167.0           
CD3/PMA 8 29.1            64.0            15.2            13.5            7.3              150.0           
CD3/PMA 9 26.9            68.7            14.8            10.3            6.2              141.0           
CD3/PMA 10 31.2            71.2            15.8            7.3              5.7              124.0           
CD3/PMA 11 27.0            70.2            17.0            7.8              5.0              139.0           
CD3/PMA 12 26.3            58.9            18.9            14.5            7.7              181.0           
CD3/PMA 13 27.8            60.8            19.5            14.1            5.7              166.0           
CD3/PMA 14 27.8            55.4            18.0            12.6            13.9            129.0           
CD3/PMA 15 25.6            66.6            15.4            13.2            4.8              172.0           
CD3/PMA 16 28.9            71.1            12.0            11.6            5.3              233.0           
CD3/PMA 17 25.6            64.5            16.9            11.8            6.8              158.0           
CD3/PMA 18 29.1            63.3            11.9            14.1            10.6            195.0           
Median
Stimulus Mouse %CD3+ LIVE EARLY LATE DEAD CD3 Fluor.
ConA 1 38.2            42.7            16.9            36.5            4.0              282.0           
ConA 2 35.7            42.9            19.4            33.5            4.1              279.0           
ConA 3 36.0            47.4            18.4            31.3            2.9              303.0           
ConA 4 34.0            41.0            13.7            40.2            5.1              265.0           
ConA 5 31.8            49.3            13.2            32.9            4.7              280.0           
ConA 6 31.4            45.1            14.1            37.3            3.5              289.0           
ConA 7 33.4            43.3            12.5            40.2            3.9              300.0           
ConA 8 36.3            43.1            12.6            37.7            6.7              290.0           
ConA 9 33.8            44.3            17.7            34.2            3.7              305.0           
ConA 10 40.2            43.0            15.1            37.7            4.3              299.0           
ConA 11 36.2            43.6            15.6            35.2            5.6              293.0           
ConA 12 33.4            40.7            19.0            33.9            6.3              283.0           
ConA 13 33.8            39.3            21.4            33.4            5.9              263.0           
ConA 14 39.8            40.8            17.1            34.1            8.1              307.0           
ConA 15 35.0            42.8            19.5            32.8            4.9              332.0           
ConA 16 36.9            47.4            18.3            30.8            3.5              275.0           
ConA 17 34.7            44.7            16.0            33.8            5.5              302.0           
ConA 18 33.9            42.6            10.6            40.8            6.1              305.0           
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Accessory Cells CD3- CD3- CD3- CD3-
AV-/7AAD- AV+/7AAD- AV+/7AAD+ AV-/7AAD+ Median
Diet Stimulus Mouse %CD3- LIVE EARLY LATE DEAD CD3 Fluor.
SAF RPMI 1 59.3            25.4            5.0              68.2            1.4              2.2               
SAF RPMI 2 66.0            25.7            3.2              69.7            1.5              1.9               
SAF RPMI 3 59.1            25.5            2.4              71.3            0.8              1.7               
SAF RPMI 4 62.6            22.8            2.9              73.7            0.5              1.6               
SAF RPMI 5 64.2            25.5            5.0              68.7            0.7              1.7               
SAF RPMI 6 66.6            14.7            2.0              82.4            0.9              1.7               
FO2 RPMI 7 62.9            17.5            2.1              79.8            0.6              1.6               
FO2 RPMI 8 63.0            15.1            2.1              81.6            1.2              1.7               
FO2 RPMI 9 64.3            26.2            2.2              70.8            0.8              2.2               
FO2 RPMI 10 60.0            20.2            3.3              75.8            0.8              2.1               
FO2 RPMI 11 65.1            20.3            2.3              76.1            1.3              1.9               
FO2 RPMI 12 65.5            27.2            3.4              68.0            1.5              2.4               
FO4 RPMI 13 62.7            24.3            3.9              70.5            1.3              1.7               
FO4 RPMI 14 61.9            23.1            2.2              72.8            1.9              2.2               
FO4 RPMI 15 68.4            26.3            3.0              69.4            1.3              2.2               
FO4 RPMI 16 67.1            25.5            3.4              70.1            1.0              2.0               
FO4 RPMI 17 67.3            23.2            2.8              72.6            1.4              2.4               
FO4 RPMI 18 60.4            12.6            1.6              84.8            1.0              1.6               
Median
Diet Stimulus Mouse %CD3- LIVE EARLY LATE DEAD CD3 Fluor.
SAF CD3/CD28 1 67.0            55.6            5.0              37.7            1.8              3.1               
SAF CD3/CD28 2 72.8            54.6            5.6              38.9            0.9              3.8               
SAF CD3/CD28 3 70.8            53.5            4.8              41.1            0.7              2.9               
SAF CD3/CD28 4 72.2            47.9            5.0              46.2            0.9              3.0               
SAF CD3/CD28 5 73.1            52.3            5.7              40.5            1.6              2.6               
SAF CD3/CD28 6 72.0            39.6            4.2              55.2            1.1              2.2               
FO2 CD3/CD28 7 72.1            46.3            3.9              48.6            1.1              2.9               
FO2 CD3/CD28 8 71.2            41.0            4.7              52.6            1.7              2.6               
FO2 CD3/CD28 9 70.5            57.4            3.9              37.4            1.4              3.8               
FO2 CD3/CD28 10 69.1            47.3            4.1              47.8            0.7              3.4               
FO2 CD3/CD28 11 69.2            49.3            5.1              44.3            1.2              3.0               
FO2 CD3/CD28 12 70.1            49.4            6.3              42.9            1.4              3.7               
FO4 CD3/CD28 13 70.2            52.6            4.4              42.3            0.7              3.2               
FO4 CD3/CD28 14 67.8            51.6            6.4              40.4            1.6              2.9               
FO4 CD3/CD28 15 70.8            50.5            6.1              41.9            1.5              2.8               
FO4 CD3/CD28 16 71.7            53.5            4.9              40.2            1.3              3.2               
FO4 CD3/CD28 17 69.3            50.1            5.6              42.6            1.8              2.7               
FO4 CD3/CD28 18 71.6            36.6            3.8              58.6            0.9              2.6               
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Median
Diet Stimulus Mouse %CD3- LIVE EARLY LATE DEAD CD3 Fluor.
SAF CD3/PMA 1 69.1            59.6            5.0              33.4            1.9              3.8               
SAF CD3/PMA 2 74.5            59.6            6.3              33.0            1.2              3.6               
SAF CD3/PMA 3 73.7            56.0            4.2              39.3            0.6              3.2               
SAF CD3/PMA 4 71.2            59.1            4.1              36.1            0.7              3.8               
SAF CD3/PMA 5 73.6            62.2            4.6              32.1            1.1              4.0               
SAF CD3/PMA 6 75.4            61.7            3.1              33.9            1.2              3.9               
FO2 CD3/PMA 7 73.3            57.6            4.9              36.9            0.6              3.4               
FO2 CD3/PMA 8 70.3            62.2            5.9              30.3            1.6              4.3               
FO2 CD3/PMA 9 72.7            64.8            4.0              30.1            1.0              4.5               
FO2 CD3/PMA 10 68.0            55.7            5.3              38.4            0.7              3.3               
FO2 CD3/PMA 11 72.5            60.7            4.9              33.2            1.2              4.0               
FO2 CD3/PMA 12 73.0            58.1            6.3              34.4            1.1              4.0               
FO4 CD3/PMA 13 71.8            62.3            5.4              31.2            1.1              4.5               
FO4 CD3/PMA 14 71.7            59.0            5.5              32.8            2.8              4.7               
FO4 CD3/PMA 15 73.8            59.9            4.5              33.4            2.2              4.5               
FO4 CD3/PMA 16 70.3            62.1            5.0              31.3            1.6              5.0               
FO4 CD3/PMA 17 73.9            63.2            5.2              30.0            1.6              4.5               
FO4 CD3/PMA 18 70.4            56.0            4.2              38.9            0.9              4.0               
Median
Diet Stimulus Mouse %CD3- LIVE EARLY LATE DEAD CD3 Fluor.
SAF ConA 1 61.1            50.4            3.8              43.7            2.1              3.9               
SAF ConA 2 63.8            51.0            3.8              43.9            1.4              3.8               
SAF ConA 3 63.6            46.3            4.4              48.4            0.9              2.9               
SAF ConA 4 65.4            42.8            3.5              52.9            0.8              2.8               
SAF ConA 5 67.7            50.9            3.7              43.7            1.6              3.5               
SAF ConA 6 68.0            39.4            2.7              56.7            1.3              3.1               
FO2 ConA 7 66.0            40.7            3.5              54.8            1.0              3.1               
FO2 ConA 8 63.2            36.6            2.6              58.8            2.0              3.3               
FO2 ConA 9 65.6            49.4            3.3              46.0            1.3              4.0               
FO2 ConA 10 59.2            40.0            4.6              54.5            0.9              2.8               
FO2 ConA 11 63.5            50.6            3.4              44.3            1.7              4.1               
FO2 ConA 12 66.1            50.2            4.5              43.6            1.7              3.9               
FO4 ConA 13 65.7            45.7            4.4              49.0            0.8              3.4               
FO4 ConA 14 59.6            45.6            3.9              48.5            2.0              4.0               
FO4 ConA 15 64.4            44.7            4.1              49.4            1.8              3.4               
FO4 ConA 16 62.8            49.3            3.8              45.5            1.4              3.4               
FO4 ConA 17 64.8            51.4            4.4              42.9            1.3              3.7               
FO4 ConA 18 65.4            33.0            3.2              62.4            1.4              3.2               
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AV-/ PI- AV+/ PI- AV+/ PI+ AV-/ PI+
Diet Stimulus Mouse %Live %Early %Late %Dead
SAF aCD3/ aCD28 1 69.0           3.9             22.4           4.7             
SAF aCD3/ aCD28 2 66.4           12.5           19.2           1.8             
SAF aCD3/ aCD28 3 65.5           15.9           16.2           2.5             
SAF aCD3/ aCD28 4 62.7           21.5           14.8           1.1             
SAF aCD3/ aCD28 5 62.2           18.1           18.2           1.5             
SAF aCD3/ aCD28 6 62.1           17.7           18.0           2.2             
FO2 aCD3/ aCD28 7 67.6           11.8           18.7           1.9             
FO2 aCD3/ aCD28 8 67.0           15.6           16.0           1.4             
FO2 aCD3/ aCD28 9 60.3           16.9           20.2           2.5             
FO2 aCD3/ aCD28 10 58.4           21.7           18.5           1.4             
FO2 aCD3/ aCD28 11 68.1           14.3           15.5           2.0             
FO2 aCD3/ aCD28 12 57.8           24.5           16.4           1.3             
FO4 aCD3/ aCD28 13 64.7           17.1           16.8           1.4             
FO4 aCD3/ aCD28 14 65.1           16.3           17.2           1.5             
FO4 aCD3/ aCD28 15 65.6           13.9           17.7           2.8             
FO4 aCD3/ aCD28 16 58.6           19.4           20.2           1.8             
FO4 aCD3/ aCD28 17 63.8           16.7           17.8           1.7             
FO4 aCD3/ aCD28 18 45.7           33.3           20.0           1.1             
Diet Stimulus Mouse %Live %Early %Late %Dead
SAF aCD3/ PMA 1 65.3           14.5           18.9           1.3             
SAF aCD3/ PMA 2 61.9           15.6           20.7           1.7             
SAF aCD3/ PMA 3 63.6           12.4           21.8           2.2             
SAF aCD3/ PMA 4 61.8           13.9           20.2           4.1             
SAF aCD3/ PMA 5 60.0           16.7           21.6           1.8             
SAF aCD3/ PMA 6 53.3           20.4           23.5           2.9             
FO2 aCD3/ PMA 7 65.4           12.7           20.0           1.9             
FO2 aCD3/ PMA 8 61.1           16.2           20.2           2.6             
FO2 aCD3/ PMA 9 54.6           21.5           22.5           1.5             
FO2 aCD3/ PMA 10 54.2           20.5           23.5           1.8             
FO2 aCD3/ PMA 11 55.7           22.1           21.0           1.2             
FO2 aCD3/ PMA 12 59.6           14.9           23.5           2.0             
FO4 aCD3/ PMA 13 62.6           13.7           22.4           1.4             
FO4 aCD3/ PMA 14 59.0           18.6           20.8           1.5             
FO4 aCD3/ PMA 15 61.3           18.4           18.1           2.2             
FO4 aCD3/ PMA 16 52.0           20.9           24.5           2.6             
FO4 aCD3/ PMA 17 47.3           26.5           24.2           2.1             
FO4 aCD3/ PMA 18 47.6           24.3           26.2           1.9             
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Diet Stimulus Mouse %Live %Early %Late %Dead
SAF PMA/Iono 1 78.0           5.6             15.5           0.9             
SAF PMA/Iono 2 80.7           3.5             14.8           1.0             
SAF PMA/Iono 3 74.7           4.9             19.3           1.1             
SAF PMA/Iono 4 77.5           4.3             16.8           1.4             
SAF PMA/Iono 5 75.3           4.4             18.9           1.3             
SAF PMA/Iono 6 75.7           6.8             16.2           1.3             
FO2 PMA/Iono 7 79.3           4.0             15.9           0.8             
FO2 PMA/Iono 8 77.5           4.1             17.0           1.4             
FO2 PMA/Iono 9 78.7           4.6             15.7           1.0             
FO2 PMA/Iono 10 76.2           4.4             18.3           1.1             
FO2 PMA/Iono 11 79.5           4.1             15.3           1.1             
FO2 PMA/Iono 12 75.3           3.9             18.7           2.2             
FO4 PMA/Iono 13 74.7           4.5             19.4           1.5             
FO4 PMA/Iono 14 75.8           4.3             17.9           2.0             
FO4 PMA/Iono 15 72.5           6.5             19.8           1.3             
FO4 PMA/Iono 16 72.9           4.3             21.2           1.6             
FO4 PMA/Iono 17 74.9           4.6             18.8           1.7             
FO4 PMA/Iono 18 70.1           4.6             23.6           1.7             
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AV-/PI- AV+/PI- AV+/PI+ AV-/PI+ AV-/PI- AV+/PI- AV+/PI+ AV-/PI+
SAMPLE LIVE EARLY LATE DEAD SAMPLE LIVE EARLY LATE DEAD
S1-1 41 32.9 24.9 1.17 U1-1 75.7 9.74 14.2 0.43
S1-2 45.8 24 29.2 1.04 U1-2 77.3 10.3 12.1 0.36
S1-3 41.1 31.8 26 1.11 U1-3 77.9 8.35 13.1 0.63
S1-4 41.6 25.1 31.1 2.18 U1-4 78.1 9.83 11.4 0.65
S1-5 37.3 37.8 24.4 0.49 U1-5 75.5 11.5 12.5 0.53
S1-7 49.8 23.3 25.4 1.47 U1-7 76.7 9.44 13.6 0.28
S1-8 42.8 27.2 28.5 1.58 U1-8 77.7 9.38 12.1 0.83
S1-9 39.3 28.5 31.2 0.97 U1-9 77.6 9.76 12.2 0.43
S1-10 46.6 23.6 28.1 1.72 U1-10 76.6 10.1 13 0.44
S1-11 46.7 24.7 27.1 1.45 U1-11 77.1 8.58 13.7 0.69
S1-12 41.3 32.4 25 1.32 U1-12 76.9 10.1 12.6 0.34
S1-13 45.8 27.3 25.3 1.66 U1-13 77 9.93 12.4 0.65
S1-14 41 32.8 24.7 1.45 U1-14 77.2 9.38 12.8 0.63
S1-15 42.2 28.4 26.8 2.53 U1-15 76.8 8.5 13.6 1.06
S1-16 44.7 27.5 25.3 2.53 U1-16 77.1 8.9 12.9 1.05
S1-17 42.9 27.4 27.4 2.36 U1-17 75.8 9.54 13.7 0.96
S1-18 48.1 26.8 23.5 1.57 U1-18 73.7 10.7 14.6 0.94
S1-19 43.1 32 24 0.94 U1-19 76.3 10.4 12.9 0.38
S1-20 46.8 29.4 22.7 1.1 U1-20 78.9 7.67 12.9 0.55
S1-21 50.5 25.2 23.7 0.67 U1-21 80.7 7.61 11.3 0.32
S1-22 42.1 32.2 23.7 2.04 U1-22 75.3 9.9 14.2 0.61
S1-23 42.2 33.3 23.1 1.39 U1-23 74.1 11.5 13.8 0.57
S1-24 51.8 25.8 21.1 1.28 U1-24 75.2 9.89 14.3 0.63
S2-1 28 42.3 29.3 0.34 U2-1 54.7 20.8 24.2 0.33
S2-2 30.6 39.1 29.7 0.51 U2-2 55.9 21.2 22.7 0.29
S2-3 28.9 42 28.7 0.38 U2-3 56.6 20.9 22.3 0.18
S2-4 17.1 50.7 31.9 0.34 U2-4 60.2 18.5 21.1 0.16
S2-5 29.4 43.7 26.6 0.29 U2-5 63.8 16.7 19.2 0.31
S2-6 16.2 48.2 34.8 0.77 U2-6 57 19 23.7 0.33
S2-7 21.2 43.3 34.1 1.37 U2-7 59.5 16.8 23.1 0.57
S2-8 23.1 41.7 33.9 1.29 U2-8 63.8 16.7 19.1 0.39
S2-9 17.7 47.2 34.7 0.42 U2-9 59.5 20.7 19.5 0.35
S2-10 20.2 44.3 34.9 0.53 U2-10 52.2 22.4 25.2 0.2
S2-11 30 39.7 28.9 1.49 U2-11 58.1 19.5 21.8 0.6
S2-12 22.8 44.5 32.3 0.42 U2-12 53.1 21 25.7 0.12
S2-13 26.7 38.1 33.9 1.25 U2-13 57.3 19.1 23.1 0.45
S2-14 23.8 43.4 32.2 0.59 U2-14 54.8 20.2 24.8 0.23
S2-15 22.5 43.5 33.4 0.57 U2-15 52.8 21.1 25.8 0.37
S2-16 21.9 44 33.3 0.78 U2-16 58.6 21.8 19.3 0.39
S2-17 28 38 32.8 1.25 U2-17 61.7 17.5 20.6 0.31
S2-18 30.2 40.3 28.8 0.73 U2-18 57.7 20 21.9 0.35
S2-19 23 45.3 31.1 0.62 U2-19 59 17.7 23 0.35
S2-20 21.9 44.1 33 0.99 U2-20 59.6 18.3 21.7 0.41
S2-21 16.8 43.2 38.6 1.37 U2-21 56.1 17.2 26.1 0.59
S2-22 22.7 43.5 33.1 0.65 U2-22 54.7 20.5 24.5 0.29
S2-23 31.1 40.1 28.2 0.6 U2-23 60 18.5 21 0.41
S2-24 30.8 37.8 30.4 0.97 U2-24 60.9 17.5 21.1 0.51
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AV-/PI- AV+/PI- AV+/PI+ AV-/PI+ AV-/PI- AV+/PI- AV+/PI+ AV-/PI+
SAMPLE LIVE EARLY LATE DEAD SAMPLE LIVE EARLY LATE DEAD
S3-1 75.1 5.94 15.7 3.28 U3-1 83.9 6.95 8.9 0.22
S3-2 72.9 5.81 19.3 2 U3-2 82.5 8.69 8.39 0.48
S3-3 78.2 0.059 0.3 21.5 U3-3 83.5 6.45 9.35 0.75
S3-4 70.8 8.34 19.5 1.34 U3-4 84.7 6.12 9.02 0.18
S3-5 75.4 7.66 15.1 1.77 U3-5 83.8 6.38 8.78 1.01
S3-6 71.6 8.25 19.4 0.69 U3-6 85.2 6.2 8.42 0.2
S3-7 75.4 7.76 15.6 1.3 U3-7 86.6 5.66 6.84 0.85
S3-8 73.8 6.94 18 1.23 U3-8 86.6 5.7 7.35 0.38
S3-9 67.5 9.63 21.7 1.15 U3-9 83.8 6.39 9.43 0.4
S3-10 72 8.71 17.6 1.7 U3-10 82.2 6.62 10.5 0.65
S3-11 68 9.48 21.2 1.26 U3-11 83.3 6.7 9.46 0.58
S3-12 71.4 8.9 18.6 1.09 U3-12 83 6.26 10.2 0.57
S3-13 75.7 7.46 15.6 1.23 U3-13 85.2 5.66 8.81 0.36
S3-14 73.8 8.49 16.8 0.97 U3-14 83.7 5.97 9.92 0.44
S3-15 73.1 7.49 18.2 1.17 U3-15 83.7 6.12 9.67 0.48
S3-16 73.1 8.82 17.4 0.75 U3-16 85.4 5.91 8.23 0.48
S3-17 72.2 7.8 18.9 1.09 U3-17 85.3 6.01 8.41 0.24
S3-18 71.7 7.88 19.6 0.89 U3-18 85.1 6.17 8.28 0.4
S3-19 76.1 7.92 14.9 1.11 U3-19 85 5.3 9.33 0.42
S3-20 74.3 9.08 15.8 0.73 U3-20 85.4 5.86 8.28 0.44
S3-21 72.1 9.43 18.1 0.38 U3-21 87.2 4.74 7.94 0.1
S3-22 72.7 8.02 18.5 0.79 U3-22 85.9 5.64 8.12 0.3
S3-23 75.3 8.71 15.2 0.75 U3-23 84.7 5.68 9.23 0.36
S3-24 70.1 9.08 20 0.85 U3-24 84.9 5.24 9.46 0.38
AV-/PI- AV+/PI- AV+/PI+ AV-/PI+ AV-/PI- AV+/PI- AV+/PI+ AV-/PI+
SAMPLE LIVE EARLY LATE DEAD SAMPLE LIVE EARLY LATE DEAD
S1-1 45.3 31.3 22.4 1.03 U1-1 71.3 11.1 17 0.59
S1-2 43.5 27.1 27.4 1.96 U1-2 71.1 11.6 16.9 0.53
S1-3 41.4 33.1 24.6 0.92 U1-3 75 9.81 14.5 0.61
S1-4 42.9 32 24.4 0.71 U1-4 78.1 7.82 13.4 0.67
S1-5 35 34.1 29.8 1.03 U1-5 76.7 9.63 13.2 0.46
S1-7 33 36.2 30.2 0.55 U1-7 74 11.1 14.6 0.28
S1-8 41.1 31.7 26.5 0.63 U1-8 76.4 8.95 14.2 0.49
S1-9 35.4 36.2 27.7 0.63 U1-9 74.7 9.72 15.3 0.28
S1-10 40.8 30.3 28.3 0.59 U1-10 73.2 11.3 15.2 0.24
S1-11 40.5 31.7 26.8 1 U1-11 74.5 11.7 13.5 0.28
S1-12 40.2 35.1 24.1 0.55 U1-12 70.9 14 14.9 0.18
S1-13 44.9 25.3 28.3 1.44 U1-13 70.1 11.3 18 0.59
S1-14 42.6 26.5 29.7 1.21 U1-14 73.5 9.61 16.4 0.45
S1-15 43 28.5 27.2 1.28 U1-15 72.1 11.8 15.3 0.77
S1-16 39.1 33.1 27 0.86 U1-16 73.5 10.6 15.4 0.48
S1-17 45.3 24.7 28.8 1.22 U1-17 75.1 10.9 13.4 0.49
S1-18 43.5 27.2 28.2 1.06 U1-18 74.4 10 14.9 0.65
S1-19 39.4 31.6 28 1.02 U1-19 69 12.9 17.7 0.41
S1-20 39.2 29.6 30.3 0.9 U1-20 71.3 12 16.4 0.28
S1-21 38.8 32.3 28.1 0.77 U1-21 70.4 12.8 16.3 0.57
S1-22 33.6 36.5 29 0.86 U1-22 68.7 13.4 17.5 0.41
S1-23 31.7 39.7 28 0.63 U1-23 66.6 13.9 19.1 0.43
S1-24 37.2 37.7 24.5 0.66 U1-24 70.7 12.6 16.2 0.49
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EXPT. 5 – APOPTOSIS DATA (cont.) 
 
 
 
AV-/PI- AV+/PI- AV+/PI+ AV-/PI+ AV-/PI- AV+/PI- AV+/PI+ AV-/PI+
SAMPLE LIVE EARLY LATE DEAD SAMPLE LIVE EARLY LATE DEAD
S2-1 14.1 46.9 38.8 0.27 U2-1 55.2 16.4 27.5 0.87
S2-2 17 45.5 36.9 0.65 U2-2 57.7 12.5 29.3 0.43
S2-3 23.8 40.1 35 1.02 U2-3 62.1 14 23.5 0.43
S2-4 15.6 45.1 38.6 0.74 U2-4 62.3 14 23.3 0.35
S2-5 21.2 43.6 34.5 0.75 U2-5 61.5 13.5 24.5 0.47
S2-6 19.6 51.8 27.9 0.65 U2-6 61.6 14.5 23.5 0.31
S2-7 19 44.6 35.6 0.84 U2-7 63.8 13.1 22.8 0.31
S2-8 24.1 39.9 35.2 0.82 U2-8 59.3 13.8 26 0.86
S2-9 20.8 41.3 37.6 0.3 U2-9 61.3 15.7 22.9 0.18
S2-10 18.6 44.8 36.2 0.36 U2-10 58.2 17.1 24.3 0.41
S2-11 20.5 42.8 36.2 0.47 U2-11 61 14.2 24 0.76
S2-12 17.3 45.9 36.4 0.36 U2-12 54.9 16.1 28.5 0.52
S2-13 25.1 37.4 36.3 1.12 U2-13 59.1 14.5 26.1 0.37
S2-14 16 45.8 37.8 0.4 U2-14 57.1 18.1 24.4 0.39
S2-15 17.5 44.6 37.7 0.23 U2-15 56.9 17.2 25.6 0.31
S2-16 22 42.2 35.3 0.5 U2-16 61.3 14.5 23.8 0.37
S2-17 26.5 39.6 33 0.96 U2-17 63.5 14.1 21.9 0.59
S2-18 19.3 44.7 35.5 0.47 U2-18 60.3 17.2 22.1 0.35
S2-19 23.4 41 35.1 0.5 U2-19 56.7 15.9 27.1 0.23
S2-20 27.6 38.7 32.8 0.92 U2-20 61.9 14.5 23.1 0.49
S2-21 12.3 49.1 38.3 0.4 U2-21 61.4 15.1 22.9 0.63
S2-22 20.8 45.9 32.7 0.59 U2-22 58.7 15.5 25.4 0.45
S2-23 27.8 34.5 35 2.66 U2-23 57 15.6 26.9 0.41
S2-24 32 36.6 30.4 0.94 U2-24 60 15.5 24 0.51
S3-1 73.5 8.27 17.5 0.67 U3-1 84 6.63 9.02 0.3
S3-2 80.7 5.88 12.7 0.71 U3-2 85 5.32 9.52 0.18
S3-3 75.8 8.16 14.9 1.13 U3-3 83.5 6.47 9.69 0.3
S3-4 79.3 6.51 13.1 1.13 U3-4 90 0.02 0.2 9.81
S3-5 77.6 7.57 14.6 0.28 U3-5 85.4 6.57 7.93 0.12
S3-6 74.4 7.49 17.5 0.67 U3-6 86.7 5.93 7.24 0.18
S3-7 76.7 7.44 14.7 1.18 U3-7 85.8 5.97 8.03 0.18
S3-8 83.6 6.13 9.97 0.28 U3-8 85.4 6.69 7.7 0.16
S3-9 71.8 8.1 19.2 0.91 U3-9 84.1 5.99 9.68 0.22
S3-10 74.7 7.61 16.8 0.83 U3-10 86.6 5.03 8.19 0.16
S3-11 71.1 6.02 22 0.89 U3-11 84.5 6.1 9.31 0.099
S3-12 70.2 10.9 18.3 0.51 U3-12 83.4 6.32 10.2 0.099
S3-13 73.1 9.93 16.4 0.49 U3-13 84.1 7.06 8.71 0.18
S3-14 75.7 9.04 14.8 0.43 U3-14 86.3 5.63 7.94 0.12
S3-15 72.4 9.46 17.7 0.37 U3-15 84.9 5.98 8.86 0.24
S3-16 79 8.43 12 0.52 U3-16 86 5.3 8.48 0.22
S3-17 74.9 10.2 14.3 0.63 U3-17 85.2 5.86 8.65 0.34
S3-18 74 8.85 16.6 0.53 U3-18 86 5.13 8.54 0.34
S3-19 74.4 9.63 15.4 0.53 U3-19 85.5 5.16 9.15 0.24
S3-20 73.8 9.64 16.2 0.36 U3-20 84.8 6.22 8.82 0.14
S3-21 74 8.9 16.4 0.73 U3-21 86.2 5.27 8.19 0.36
S3-22 74.6 10.3 14.7 0.43 U3-22 84.9 5.43 9.35 0.28
S3-23 74.2 9.93 15.3 0.53 U3-23 86 4.4 9.41 0.22
S3-24 70.2 13 16.4 0.36 U3-24 83.5 7.5 8.8 0.18
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APPENDIX A-8 
 
EXPT. 6 – APOPTOSIS DATA 
 
 
 
 
AV-/PI- AV+/PI- AV+/PI+ AV-/PI+
SAMPLE LIVE EARLY LATE DEAD TOTAL Apop.
1-1 39.7 29.1 30.9 0.3 60.0
1-2 41.7 26.8 30.8 0.7 57.6
1-3 39.2 31.3 29.1 0.4 60.4
1-4 42.5 32.6 24.6 0.3 57.2
1-5 43.9 28.9 26.9 0.3 55.8
1-6 45.3 25.4 28.5 0.8 53.9
1-7 46.2 23.9 29.1 0.7 53.0
1-8 43.7 29.8 26.2 0.3 56.0
1-9 38.4 27.0 34.1 0.5 61.1
1-10 40.0 30.0 29.7 0.2 59.7
1-11 39.0 32.9 27.9 0.2 60.8
1-12 39.7 30.5 29.6 0.3 60.1
2-1 38.0 29.3 32.3 0.4 61.6
2-2 31.3 28.8 39.0 0.9 67.8
2-3 35.4 29.8 34.6 0.2 64.4
2-4 36.9 27.7 34.8 0.6 62.5
2-5 34.9 26.9 37.7 0.6 64.6
2-6 36.8 23.2 38.6 1.3 61.8
2-7 37.1 25.1 37.3 0.5 62.4
2-8 38.3 24.2 36.9 0.6 61.1
2-9 34.2 25.5 39.8 0.6 65.3
2-10 34.3 27.7 37.7 0.3 65.4
2-11 33.9 28.0 37.6 0.4 65.6
2-12 36.2 25.0 38.5 0.3 63.5
3-1 82.8 6.3 10.7 0.2 17.0
3-2 83.5 4.9 11.4 0.3 16.3
3-3 84.3 6.0 9.6 0.1 15.6
3-4 83.0 5.8 11.1 0.1 16.9
3-5 84.1 6.1 9.6 0.2 15.7
3-6 86.2 4.2 9.4 0.2 13.6
3-7 83.7 5.3 10.8 0.2 16.1
3-8 83.1 5.5 11.2 0.2 16.7
3-9 81.4 6.1 12.3 0.3 18.4
3-10 81.9 6.1 11.9 0.1 18.0
3-11 80.3 5.9 13.6 0.3 19.5
3-12 79.7 7.2 13.0 0.2 20.2
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APPENDIX A-9 
 
EXPT. 7 – DATA 
 
 
APOPTOSIS 
 
 
 
 
 
AV-/PI- AV+/PI- AV+/PI+ AV-/PI+
SAMPLE LIVE EARLY LATE DEAD TOTAL Apop.
FBS-CO 1 43.8 18.9 36.7 0.5 55.6
2 41.3 20.2 37.9 0.6 58.1
3 35.8 19.8 43.9 0.5 63.7
4 48.8 17.5 33.4 0.4 50.9
5 51.4 16.8 31.3 0.4 48.1
6 50.7 15.4 33.8 0.2 49.2
FBS-FO 7 51.8 14.0 32.8 1.3 46.8
8 47.8 16.1 35.6 0.5 51.7
9 47.5 15.2 36.4 0.9 51.6
10 48.1 15.2 35.7 1.0 50.9
11 49.4 15.2 34.7 0.6 49.9
12 44.9 15.7 38.4 1.0 54.1
MS-CO 1 43.7 16.5 39.5 0.2 56.0
2 45.1 15.4 39.3 0.2 54.7
3 45.6 18.3 35.9 0.2 54.2
4 42.7 14.9 42.1 0.3 57.0
5 45.9 14.9 38.7 0.5 53.6
6 39.6 15.3 44.4 0.6 59.7
MS-FO 7 30.8 19.5 49.1 0.5 68.6
8 30.2 19.4 49.8 0.5 69.2
9 30.5 17.5 50.7 1.3 68.2
10 29.2 18.3 51.5 1.0 69.8
11 27.6 19.1 51.5 1.8 70.6
12 29.0 19.1 50.4 1.4 69.5
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EXPT. 7 – DATA (cont.) 
 
 
INTRACELLULAR CYTOKINES 
 
 
 
SAMPLE IFNg-/IL4- IFNg+/IL4- IFNg-/IL4+ IFNg+/IL4+
FBS-CO 1 42.1 57.8 0.0 0.1
2 36.6 63.3 0.0 0.1
3 35.0 64.8 0.0 0.1
4 42.9 56.9 0.1 0.1
5 43.9 55.9 0.0 0.1
6 49.5 50.4 0.0 0.1
FBS-FO 7 41.8 58.1 0.0 0.1
8 37.4 62.6 0.0 0.1
9 45.1 54.8 0.0 0.2
10 41.6 58.2 0.0 0.1
11 45.2 54.8 0.0 0.1
12 35.3 64.6 0.0 0.1
MS-CO 1 63.8 36.0 0.0 0.2
2 63.4 36.5 0.0 0.1
3 51.8 48.1 0.0 0.2
4 67.7 32.2 0.0 0.1
5 63.8 36.1 0.0 0.1
6 67.2 32.7 0.0 0.1
MS-FO 7 48.2 51.2 0.0 0.6
8 44.4 54.8 0.0 0.8
9 41.6 57.4 0.0 1.0
10 45.6 53.5 0.0 0.9
11 40.0 58.9 0.0 1.0
12 44.5 54.5 0.0 1.0
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APPENDIX A-10 
 
EXPT. 8 – DATA 
 
 
Moles FA 
 
 
 
Cell # 19 x 10
6 19 x 106 30 x 106 30 x 106 38 x 106 38 x 106
DAY 0
1 raft 1 sol. 2 raft 2 sol. 3 raft 3 sol. 
Fatty Acid
17:0 ISD
14:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
14:10 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
15:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
16:00 2.41E-06 3.36E-06 1.77E-06 3.55E-06 2.86E-06 3.75E-06
16:1N-7 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:00 6.60E-07 1.18E-06 5.73E-07 1.49E-06 1.62E-06 2.29E-06
18:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:1N-7 4.89E-07 9.57E-07 3.65E-07 9.12E-07 5.08E-07 8.15E-07
18:2N-6 0.00E+00 6.43E-07 2.14E-07 5.40E-07 3.00E-07 7.36E-07
18:3N-6 1.59E-07 1.77E-07 1.34E-07 2.18E-07 2.49E-07 1.42E-07
18:3N-3 2.38E-07 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:4N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:2N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:3N-6 1.89E-07 8.56E-07 1.22E-08 5.93E-07 3.39E-07 1.06E-06
20:4N-6 1.54E-07 7.00E-07 1.54E-07 1.19E-06 3.74E-07 1.56E-06
20:3N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:5N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 1.57E-07
22:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:4N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-3 7.52E-08 5.95E-07 0.00E+00 1.38E-07 1.50E-08 3.36E-07
22:6N-3 4.20E-08 1.50E-07 2.85E-08 2.08E-07 0.00E+00 3.87E-07
24:0 0.00E+00 3.78E-07 0.00E+00 1.44E-07 0.00E+00 3.02E-07
24:1N-9 0.00E+00 1.34E-07 0.00E+00 1.65E-07 1.22E-07 0.00E+00
Total 4.42E-06 9.13E-06 9.15E-06 9.66E-06 6.38E-06 1.15E-05
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EXPT. 8 – DATA (cont.) 
Moles FA 
 
 
 
 
Cell # 54 x 10
6 54 x 106 47 x 106 47 x 106 72 x 106 72 x 106
DAY 0
4 raft 4 sol. 5 raft 5 sol. 6 raft 6 sol. 
Fatty Acid
17:0 ISD
14:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
14:10 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
15:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
16:00 2.90E-06 5.16E-06 5.71E-06 8.14E-06 2.30E-06 1.75E-06
16:1N-7 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:00 1.13E-06 2.64E-06 2.95E-06 3.79E-06 8.71E-07 8.06E-07
18:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:1N-7 3.22E-07 1.07E-06 2.09E-06 2.21E-06 5.55E-07 4.06E-07
18:2N-6 1.50E-07 3.53E-07 4.77E-07 7.24E-07 3.81E-07 2.90E-07
18:3N-6 1.17E-07 0.00E+00 5.06E-07 2.24E-07 0.00E+00 0.00E+00
18:3N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:4N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:2N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:3N-6 2.12E-07 1.70E-07 2.99E-07 2.04E-07 0.00E+00 0.00E+00
20:4N-6 1.71E-07 1.45E-06 4.16E-07 1.80E-06 3.81E-07 3.63E-07
20:3N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:5N-3 0.00E+00 1.55E-07 4.66E-08 4.13E-07 0.00E+00 0.00E+00
22:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:4N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-3 4.91E-08 3.78E-07 1.49E-07 5.67E-07 0.00E+00 0.00E+00
22:6N-3 5.93E-08 5.71E-07 1.72E-07 9.75E-07 8.30E-08 1.46E-07
24:0 7.93E-08 7.07E-08 1.72E-07 2.33E-07 0.00E+00 0.00E+00
24:1N-9 1.33E-07 8.53E-08 1.73E-07 1.71E-07 0.00E+00 0.00E+00
Total 5.32E-06 1.21E-05 1.32E-05 1.94E-05 4.57E-06 3.76E-06
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EXPT. 8 – DATA (cont.) 
Moles FA 
 
 
 
Cell # 14 x 10
6 14 x 106 17 x 106 17 x 106 15 x 106 15 x 106
       DAY 5 (FBS)
1 raft 1 sol. 2 raft 2 sol. 3 raft 3 sol. 
Fatty Acid
17:0 ISD
14:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
14:10 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
15:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
16:00 4.51E-06 7.80E-06 5.47E-06 4.61E-06 4.29E-06 6.85E-06
16:1N-7 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:00 1.84E-06 5.40E-06 2.63E-06 2.94E-06 2.03E-06 4.46E-06
18:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:1N-7 1.34E-06 8.89E-06 2.59E-06 3.89E-06 1.28E-06 5.83E-06
18:2N-6 2.09E-07 6.68E-07 2.68E-07 5.22E-07 3.23E-07 9.13E-07
18:3N-6 5.61E-08 7.63E-07 9.65E-08 0.00E+00 3.40E-07 4.38E-07
18:3N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:4N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:2N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:3N-6 5.10E-08 2.85E-07 1.58E-07 1.99E-07 0.00E+00 1.07E-06
20:4N-6 2.57E-07 1.23E-06 5.30E-07 7.61E-07 3.96E-07 1.12E-06
20:3N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:5N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:4N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-3 7.09E-08 1.89E-07 1.30E-07 1.66E-07 5.22E-08 3.32E-07
22:6N-3 9.51E-08 2.66E-07 1.64E-07 2.04E-07 6.56E-08 2.97E-07
24:0 2.44E-07 2.71E-07 3.79E-07 9.93E-08 2.11E-07 3.64E-07
24:1N-9 3.84E-07 3.41E-07 4.84E-07 1.50E-07 4.12E-07 3.66E-07
Total 9.06E-06 2.61E-05 1.29E-05 1.35E-05 9.40E-06 2.20E-05
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EXPT. 8 – DATA (cont.) 
Moles FA 
 
 
 
Cell # 12 x 10
6 12 x 106 14 x 106 14 x 106 21 x 106 21 x 106
       DAY 5 (FBS)
4 raft 4 sol. 5 raft 5 sol. 6 raft 6 sol. 
Fatty Acid
17:0 ISD
14:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
14:10 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
15:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
16:00 3.65E-06 2.83E-06 5.49E-06 6.10E-06 4.93E-06 4.84E-06
16:1N-7 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:00 1.94E-06 1.55E-06 2.72E-06 4.55E-06 2.33E-06 3.19E-06
18:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:1N-7 5.06E-07 2.33E-06 4.74E-07 6.19E-06 2.01E-06 4.39E-06
18:2N-6 1.41E-07 2.41E-07 1.29E-07 4.26E-07 3.19E-07 5.23E-07
18:3N-6 9.97E-08 2.99E-07 1.85E-08 1.56E-07 1.32E-07 9.58E-08
18:3N-3 0.00E+00 0.00E+00 0.00E+00 7.81E-08 0.00E+00 0.00E+00
18:4N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:2N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:3N-6 7.77E-08 1.29E-07 1.85E-07 3.90E-07 1.55E-07 2.39E-07
20:4N-6 3.26E-07 4.56E-07 2.20E-07 1.68E-06 4.32E-07 8.98E-07
20:3N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:5N-3 0.00E+00 0.00E+00 0.00E+00 7.19E-08 0.00E+00 6.61E-08
22:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:4N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-3 7.20E-08 9.61E-08 1.09E-07 5.92E-07 1.11E-07 2.22E-07
22:6N-3 8.46E-08 1.57E-07 1.10E-07 3.97E-07 1.44E-07 3.04E-07
24:0 1.94E-07 9.69E-08 3.36E-07 2.95E-07 2.86E-07 1.81E-07
24:1N-9 2.60E-07 1.41E-07 3.94E-07 3.26E-07 4.16E-07 2.00E-07
Total 7.35E-06 8.33E-06 1.02E-05 2.13E-05 1.13E-05 1.51E-05
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EXPT. 8 – DATA (cont.) 
Moles FA 
 
 
 
Cell # 19 x 10
6 19 x 106 16 x 106 16 x 106 17 x 106 17 x 106
      DAY 5 (MS)
1 raft 1 sol. 2 raft 2 sol. 3 raft 3 sol. 
Fatty Acid
17:0 ISD
14:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
14:10 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
15:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
16:00 1.06E-04 1.21E-05 4.42E-06 3.04E-06 3.67E-06 4.73E-06
16:1N-7 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:00 6.24E-05 7.56E-06 1.77E-06 2.41E-06 1.96E-06 4.41E-06
18:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:1N-7 2.12E-05 7.19E-06 8.26E-07 1.04E-06 7.24E-07 2.05E-06
18:2N-6 1.52E-05 6.32E-06 4.58E-07 1.01E-06 2.80E-07 2.00E-06
18:3N-6 9.87E-06 3.92E-06 8.55E-08 6.50E-08 7.90E-08 1.44E-07
18:3N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:4N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:2N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:3N-6 2.85E-06 6.92E-07 2.95E-07 0.00E+00 1.44E-07 3.05E-07
20:4N-6 1.93E-05 3.98E-06 5.16E-07 1.78E-07 4.96E-07 2.36E-06
20:3N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:5N-3 0.00E+00 0.00E+00 3.15E-08 0.00E+00 4.16E-08 0.00E+00
22:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:4N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-3 1.13E-06 2.75E-07 2.16E-07 8.77E-08 0.00E+00 1.41E-07
22:6N-3 4.57E-06 1.48E-06 1.74E-07 3.31E-07 1.72E-07 6.90E-07
24:0 3.05E-06 2.06E-07 9.05E-08 0.00E+00 0.00E+00 0.00E+00
24:1N-9 8.87E-06 6.61E-07 3.64E-07 5.93E-08 3.00E-07 2.36E-07
Total 2.55E-04 4.44E-05 9.25E-06 8.21E-06 7.86E-06 1.71E-05
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EXPT. 8 – DATA (cont.) 
Moles FA 
 
 
 
Cell # 10 x 10
6 10 x 106 10 x 106 10 x 106 21 x 106 21 x 106
      DAY 5 (MS)
4 raft 4 sol. 5 raft 5 sol. 6 raft 6 sol. 
Fatty Acid
17:0 ISD
14:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
14:10 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
15:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
16:00 2.01E-06 2.69E-06 3.39E-06 7.14E-06 3.91E-06 3.81E-06
16:1N-7 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:00 8.79E-07 1.65E-06 1.63E-06 5.47E-06 1.76E-06 2.94E-06
18:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:1N-7 7.20E-07 1.91E-06 6.61E-07 3.66E-06 6.42E-07 1.71E-06
18:2N-6 2.21E-07 2.91E-07 2.39E-07 1.66E-06 3.17E-07 9.66E-07
18:3N-6 3.71E-08 8.50E-08 8.85E-08 4.90E-07 1.99E-07 2.38E-07
18:3N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
18:4N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:2N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:3N-6 0.00E+00 0.00E+00 1.72E-07 3.71E-07 0.00E+00 2.16E-07
20:4N-6 1.25E-07 2.33E-07 1.62E-07 1.90E-06 1.95E-07 7.72E-07
20:3N-3 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
20:5N-3 0.00E+00 0.00E+00 2.33E-08 3.01E-07 3.67E-08 2.19E-07
22:00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:1N-9 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:4N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-6 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
22:5N-3 8.87E-08 1.19E-07 1.70E-07 1.68E-06 2.35E-07 8.57E-07
22:6N-3 1.73E-07 2.64E-07 2.04E-07 1.94E-06 3.16E-07 9.72E-07
24:0 0.00E+00 0.00E+00 1.72E-07 1.85E-07 1.61E-07 9.81E-08
24:1N-9 0.00E+00 0.00E+00 1.92E-07 3.41E-07 3.23E-07 2.79E-07
Total 4.25E-06 7.24E-06 7.11E-06 2.51E-05 8.10E-06 1.31E-05
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EXPT. 8 – DATA (cont.) 
 
 
Mole % 
 
 
 
 
Cell # 19 x 10
6 19 x 106 30 x 106 30 x 106 38 x 106 38 x 106
DAY 0
1 raft 1 sol. 2 raft 2 sol. 3 raft 3 sol. 
Fatty Acid
17:0 ISD
14:00 0.00 0.00 0.00 0.00 0.00 0.00
14:10 0.00 0.00 0.00 0.00 0.00 0.00
15:00 0.00 0.00 0.00 0.00 0.00 0.00
16:00 54.60 36.77 54.43 38.76 44.77 32.48
16:1N-7 0.00 0.00 0.00 0.00 0.00 0.00
18:00 14.94 12.94 17.63 16.30 25.35 19.83
18:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
18:1N-7 11.06 10.49 11.23 9.97 7.96 7.06
18:2N-6 0.00 7.04 6.58 5.90 4.70 6.38
18:3N-6 3.59 1.93 4.14 2.38 3.90 1.24
18:3N-3 5.39 0.00 0.00 0.00 0.00 0.00
18:4N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:00 0.00 0.00 0.00 0.00 0.00 0.00
20:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
20:2N-6 0.00 0.00 0.00 0.00 0.00 0.00
20:3N-6 4.28 9.38 0.38 6.48 5.31 9.21
20:4N-6 3.49 7.67 4.73 13.05 5.86 13.56
20:3N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:5N-3 0.00 0.00 0.00 0.00 0.00 1.36
22:00 0.00 0.00 0.00 0.00 0.00 0.00
22:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
22:4N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-3 1.70 6.52 0.00 1.50 0.23 2.92
22:6N-3 0.95 1.64 0.88 2.27 0.00 3.35
24:0 0.00 4.14 0.00 1.57 0.00 2.61
24:1N-9 0.00 1.47 0.00 1.81 1.90 0.00
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EXPT. 8 – DATA (cont.) 
Mole % 
 
 
 
 
Cell # 54 x 10
6 54 x 106 47 x 106 47 x 106 72 x 106 72 x 106
DAY 0
4 raft 4 sol. 5 raft 5 sol. 6 raft 6 sol. 
Fatty Acid
17:0 ISD
14:00 0.00 0.00 0.00 0.00 0.00 0.00
14:10 0.00 0.00 0.00 0.00 0.00 0.00
15:00 0.00 0.00 0.00 0.00 0.00 0.00
16:00 54.49 42.64 43.40 41.84 50.28 46.51
16:1N-7 0.00 0.00 0.00 0.00 0.00 0.00
18:00 21.23 21.78 22.38 19.49 19.07 21.44
18:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
18:1N-7 6.05 8.84 15.91 11.38 12.16 10.80
18:2N-6 2.83 2.92 3.62 3.72 8.34 7.71
18:3N-6 2.19 0.00 3.84 1.15 0.00 0.00
18:3N-3 0.00 0.00 0.00 0.00 0.00 0.00
18:4N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:00 0.00 0.00 0.00 0.00 0.00 0.00
20:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
20:2N-6 0.00 0.00 0.00 0.00 0.00 0.00
20:3N-6 3.98 1.40 2.27 1.05 0.00 0.00
20:4N-6 3.21 12.01 3.16 9.24 8.34 9.65
20:3N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:5N-3 0.00 1.28 0.35 2.13 0.00 0.00
22:00 0.00 0.00 0.00 0.00 0.00 0.00
22:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
22:4N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-3 0.92 3.13 1.13 2.92 0.00 0.00
22:6N-3 1.11 4.72 1.30 5.01 1.82 3.88
24:0 1.49 0.58 1.31 1.20 0.00 0.00
24:1N-9 2.50 0.70 1.31 0.88 0.00 0.00
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EXPT. 8 – DATA (cont.) 
Mole % 
 
 
 
 
Cell # 14 x 10
6 14 x 106 17 x 106 17 x 106 15 x 106 15 x 106
       DAY 5 (FBS)
1 raft 1 sol. 2 raft 2 sol. 3 raft 3 sol. 
Fatty Acid
17:0 ISD
14:00 0.00 0.00 0.00 0.00 0.00 0.00
14:10 0.00 0.00 0.00 0.00 0.00 0.00
15:00 0.00 0.00 0.00 0.00 0.00 0.00
16:00 49.79 29.87 42.43 34.08 45.61 31.07
16:1N-7 0.00 0.00 0.00 0.00 0.00 0.00
18:00 20.31 20.69 20.37 21.69 21.60 20.23
18:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
18:1N-7 14.81 34.06 20.07 28.70 13.64 26.44
18:2N-6 2.31 2.56 2.08 3.85 3.43 4.14
18:3N-6 0.62 2.92 0.75 0.00 3.62 1.99
18:3N-3 0.00 0.00 0.00 0.00 0.00 0.00
18:4N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:00 0.00 0.00 0.00 0.00 0.00 0.00
20:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
20:2N-6 0.00 0.00 0.00 0.00 0.00 0.00
20:3N-6 0.56 1.09 1.22 1.47 0.00 4.87
20:4N-6 2.83 4.72 4.11 5.62 4.22 5.09
20:3N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:5N-3 0.00 0.00 0.00 0.00 0.00 0.00
22:00 0.00 0.00 0.00 0.00 0.00 0.00
22:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
22:4N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-3 0.78 0.72 1.01 1.23 0.56 1.51
22:6N-3 1.05 1.02 1.27 1.51 0.70 1.35
24:0 2.69 1.04 2.94 0.73 2.24 1.65
24:1N-9 4.24 1.31 3.75 1.11 4.38 1.66
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EXPT. 8 – DATA (cont.) 
Mole % 
 
 
 
Cell # 12 x 10
6 12 x 106 14 x 106 14 x 106 21 x 106 21 x 106
       DAY 5 (FBS)
4 raft 4 sol. 5 raft 5 sol. 6 raft 6 sol. 
Fatty Acid
17:0 ISD
14:00 0.00 0.00 0.00 0.00 0.00 0.00
14:10 0.00 0.00 0.00 0.00 0.00 0.00
15:00 0.00 0.00 0.00 0.00 0.00 0.00
16:00 49.68 34.01 53.91 28.72 43.73 31.94
16:1N-7 0.00 0.00 0.00 0.00 0.00 0.00
18:00 26.37 18.59 26.69 21.39 20.69 21.05
18:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
18:1N-7 6.88 28.00 4.66 29.14 17.86 28.99
18:2N-6 1.92 2.89 1.26 2.01 2.83 3.45
18:3N-6 1.36 3.59 0.18 0.73 1.17 0.63
18:3N-3 0.00 0.00 0.00 0.37 0.00 0.00
18:4N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:00 0.00 0.00 0.00 0.00 0.00 0.00
20:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
20:2N-6 0.00 0.00 0.00 0.00 0.00 0.00
20:3N-6 1.06 1.55 1.82 1.84 1.37 1.58
20:4N-6 4.43 5.48 2.16 7.89 3.84 5.93
20:3N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:5N-3 0.00 0.00 0.00 0.34 0.00 0.44
22:00 0.00 0.00 0.00 0.00 0.00 0.00
22:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
22:4N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-3 0.98 1.15 1.07 2.79 0.99 1.47
22:6N-3 1.15 1.89 1.08 1.87 1.28 2.01
24:00:00 2.64 1.16 3.30 1.39 2.54 1.19
24:1N-9 3.53 1.69 3.87 1.53 3.70 1.32
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EXPT. 8 – DATA (cont.) 
Mole % 
 
 
 
 
Cell # 19 x 10
6 19 x 106 16 x 106 16 x 106 17 x 106 17 x 106
      DAY 5 (MS)
1 raft 1 sol. 2 raft 2 sol. 3 raft 3 sol. 
Fatty Acid
17:0 ISD
14:00 0.00 0.00 0.00 0.00 0.00 0.00
14:10 0.00 0.00 0.00 0.00 0.00 0.00
15:00 0.00 0.00 0.00 0.00 0.00 0.00
16:00 41.73 27.29 47.78 36.99 46.66 27.73
16:1N-7 0.00 0.00 0.00 0.00 0.00 0.00
18:00 24.50 17.04 19.18 29.31 24.89 25.81
18:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
18:1N-7 8.34 16.19 8.93 12.65 9.21 12.03
18:2N-6 5.95 14.24 4.95 12.27 3.57 11.70
18:3N-6 3.88 8.82 0.92 0.79 1.01 0.84
18:3N-3 0.00 0.00 0.00 0.00 0.00 0.00
18:4N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:00 0.00 0.00 0.00 0.00 0.00 0.00
20:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
20:2N-6 0.00 0.00 0.00 0.00 0.00 0.00
20:3N-6 1.12 1.56 3.19 0.00 1.83 1.78
20:4N-6 7.58 8.97 5.58 2.17 6.31 13.85
20:3N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:5N-3 0.00 0.00 0.34 0.00 0.53 0.00
22:00 0.00 0.00 0.00 0.00 0.00 0.00
22:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
22:4N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-3 0.45 0.62 2.34 1.07 0.00 0.83
22:6N-3 1.79 3.32 1.88 4.03 2.19 4.04
24:0 1.20 0.46 0.98 0.00 0.00 0.00
24:1N-9 3.48 1.49 3.93 0.72 3.82 1.39
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EXPT. 8 – DATA (cont.) 
Mole % 
 
 
 
Cell # 10 x 10
6 10 x 106 10 x 106 10 x 106 21 x 106 21 x 106
      DAY 5 (MS)
4 raft 4 sol. 5 raft 5 sol. 6 raft 6 sol. 
Fatty Acid
17:0 ISD
14:00 0.00 0.00 0.00 0.00 0.00 0.00
14:10 0.00 0.00 0.00 0.00 0.00 0.00
15:00 0.00 0.00 0.00 0.00 0.00 0.00
16:00 47.26 37.15 47.71 28.38 48.34 29.12
16:1N-7 0.00 0.00 0.00 0.00 0.00 0.00
18:00 20.65 22.75 22.98 21.77 21.70 22.51
18:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
18:1N-7 16.93 26.38 9.29 14.56 7.93 13.05
18:2N-6 5.20 4.02 3.35 6.61 3.91 7.39
18:3N-6 0.87 1.17 1.24 1.95 2.46 1.82
18:3N-3 0.00 0.00 0.00 0.00 0.00 0.00
18:4N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:00 0.00 0.00 0.00 0.00 0.00 0.00
20:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
20:2N-6 0.00 0.00 0.00 0.00 0.00 0.00
20:3N-6 0.00 0.00 2.42 1.47 0.00 1.65
20:4N-6 2.93 3.22 2.28 7.57 2.40 5.90
20:3N-3 0.00 0.00 0.00 0.00 0.00 0.00
20:5N-3 0.00 0.00 0.33 1.20 0.45 1.68
22:00 0.00 0.00 0.00 0.00 0.00 0.00
22:1N-9 0.00 0.00 0.00 0.00 0.00 0.00
22:4N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-6 0.00 0.00 0.00 0.00 0.00 0.00
22:5N-3 2.08 1.65 2.40 6.70 2.91 6.55
22:6N-3 4.07 3.65 2.86 7.71 3.90 7.43
24:0 0.00 0.00 2.42 0.74 1.99 0.75
24:1N-9 0.00 0.00 2.70 1.36 3.99 2.14
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EXPT. 8 – DATA (cont.) 
 
 
Cholesterol Data 
 
 
 
 
 
 
ug chol. ug chol/1x106 mol chol molchol/1x106 FA (total mol) PL (mol) molPL/1x106  chol/ PL (mol)
Day 0
1 R 44.9856 2.37 1.16E-07 6.12E-09 4.42E-09 2.21E-09 1.16E-10 52.65
1 S 43.0272 2.26 1.11E-07 5.86E-09 9.13E-09 4.56E-09 2.40E-10 24.39
2 R 85.9008 2.86 2.22E-07 7.41E-09 3.25E-09 1.62E-09 5.41E-11 136.85
2 S 64.7184 2.16 1.67E-07 5.58E-09 9.15E-09 4.57E-09 1.52E-10 36.60
3 R 51.1968 1.35 1.32E-07 3.48E-09 6.38E-09 3.19E-09 8.40E-11 41.50
3 S 57.9408 1.52 1.50E-07 3.94E-09 1.15E-08 5.77E-09 1.52E-10 25.99
4 R 21.9168 0.41 5.67E-08 1.05E-09 5.32E-09 2.66E-09 4.93E-11 21.31
4 S 69.4848 1.29 1.80E-07 3.33E-09 1.21E-08 6.05E-09 1.12E-10 29.70
5 R 92.8848 1.98 2.40E-07 5.11E-09 1.32E-08 6.58E-09 1.40E-10 36.51
5 S 51.096 1.09 1.32E-07 2.81E-09 1.94E-08 9.72E-09 2.07E-10 13.59
6 R 37.2192 0.52 9.63E-08 1.34E-09 4.57E-09 2.28E-09 3.17E-11 42.17
6 S 78.1536 1.09 2.02E-07 2.81E-09 3.76E-09 1.88E-09 2.61E-11 107.64
ug chol. ug chol/1x106 mol chol molchol/1x106 FA (total mol) PL (mol) molPL/1x106  chol/ PL (mol)
Day 5 FBS
1 R 18.2352 1.30 4.72E-08 3.37E-09 9.06E-09 4.53E-09 3.23E-10 10.42
1 S 31.9296 2.28 8.26E-08 5.90E-09 2.61E-08 1.31E-08 9.33E-10 6.33
2 R 33.9456 2.00 8.78E-08 5.17E-09 1.32E-08 6.58E-09 3.87E-10 13.34
2 S 14.4336 0.85 3.73E-08 2.20E-09 1.37E-08 6.87E-09 4.04E-10 5.44
3 R 21.384 1.43 5.53E-08 3.69E-09 9.40E-09 4.70E-09 3.13E-10 11.77
3 S 58.0464 3.87 1.50E-07 1.00E-08 2.20E-08 1.10E-08 7.35E-10 13.62
4 R 19.92 1.66 5.15E-08 4.29E-09 7.35E-09 3.68E-09 3.06E-10 14.02
4 S 17.2752 1.44 4.47E-08 3.72E-09 8.33E-09 4.16E-09 3.47E-10 10.73
5 R 38.2176 2.73 9.89E-08 7.06E-09 1.02E-08 5.09E-09 3.64E-10 19.42
5 S 44.8704 3.21 1.16E-07 8.29E-09 2.13E-08 1.06E-08 7.59E-10 10.92
6 R 24.8496 1.18 6.43E-08 3.06E-09 1.13E-08 5.63E-09 2.68E-10 11.41
6 S 15.3456 0.73 3.97E-08 1.89E-09 1.51E-08 7.57E-09 3.61E-10 5.24
ug chol. ug chol/1x106 mol chol molchol/1x106 FA (total mol) PL (mol) molPL/1x106  chol/ PL (mol)
Day 5 MS
1 MS R 17.0976 0.90 4.42E-08 2.33E-09 2.55E-07 1.27E-07 6.70E-09 0.35
1 MS S 28.6224 1.51 7.40E-08 3.90E-09 4.44E-08 2.22E-08 1.17E-09 3.34
2 MS R 37.32 2.33 9.65E-08 6.03E-09 9.25E-09 4.63E-09 2.89E-10 20.87
2 MS S 14.6928 0.92 3.80E-08 2.38E-09 8.21E-09 4.11E-09 2.57E-10 9.25
3 MS R 48.9024 2.88 1.26E-07 7.44E-09 7.86E-09 3.93E-09 2.31E-10 32.19
3 MS S 36.0384 2.12 9.32E-08 5.48E-09 1.71E-08 8.53E-09 5.02E-10 10.92
4 MS R 41.7504 4.18 1.08E-07 1.08E-08 4.25E-09 2.13E-09 2.13E-10 50.77
4 MS S 41.7696 4.18 1.08E-07 1.08E-08 7.24E-09 3.62E-09 3.62E-10 29.85
5 MS R 26.3568 2.64 6.82E-08 6.82E-09 7.11E-09 3.55E-09 3.55E-10 19.18
5 MS S 45.2832 4.53 1.17E-07 1.17E-08 2.51E-08 1.26E-08 1.26E-09 9.32
6 MS R 40.5744 1.93 1.05E-07 5.00E-09 8.10E-09 4.05E-09 1.93E-10 25.92
6 MS S 4.248 0.20 1.10E-08 5.23E-10 1.31E-08 6.54E-09 3.11E-10 1.68
154 
APPENDIX A-11 
 
CELL COUNTS 
 
 
 
 
Cell numbers (1 x 106 cells/ml) from all diet studies
Splenocytes T Cells CD4+ T Cells
SAF 64.75 ± 7.23 12.39 ± 0.55 ND
HFSAF ND 12.40 ± 0.66 ND
OO ND 14.39 ± 1.47 ND
CO ND 6.26 ± 0.38 7.74 ± 0.67
FO 2 85.88 ± 7.33 15.20 ± 1.60 ND
FO 4 92.75 ± 6.15 13.90 ± 1.70 8.92 ± 0.44
HFFO ND 13.80 ± 0.95 ND
DHA ND 8.65 ± 0.38 ND
Cell counts were obtained at Day 0.  Numbers represent 1 x 106 cells/ml
per mouse.  SAF, 2% Safflower oil + 3% corn oil; HFSAF, 4% safflower oil 
 + 6% corn oil; OO, 2% olive oil + 3% corn oil; CO, 5% corn oil; FO2, 
2% menhaden fish oil (fish oil) + 3% corn oil; FO4, 4% fish oil + 1% corn 
oil; HFFO, 9% fish oil + 1% corn oil; DHA, 1% DHA ethyl esters + 4% corn oil.  
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APPENDIX B-1 
 
EXPT. 1:  T cell Apoptosis - Experiment Description 
 
Diets: 
1. Safflower Oil Ethyl Esters (2% safflower oil + 3% corn oil) 
2. Olive Oil Ethyl Esters (2% olive oil + 3% corn oil) 
3. Fish Oil (2% menhaden fish oil + 3% corn oil) 
 
n = 6 mice per diet = 18 mice total 
 
Stimuli: 
- Untreated 
- aCD3/aCD28   (1mg/ml / 5mg/ml) 
- PMA/Ionomycin    (1ng/ml / 500nM) 
- PMA/ aCD3  (0.5ng/ml / 1mg/ml) 
- Dexamethasone   (330ng/ml) 
- FasL/aFLAG   (50ng/ml / 1mg/ml) 
 
6 treatments per mouse 
culture 500,000 cells per well (treatment) 
 so, need 3 x 106 cells per animal 
 
 
Purified T cells from column yields ~ 10 X 106  cells per animal 
Remaining T cells (~ 7 x 106) will be used for lipid extraction 
Pool 2 mice for n = 3 per diet group to have enough cells for lipid analysis 
 
 
Culture 1 treatment per 24-well plate = 6 plates 
Will use 18 wells per plate — 1 for each animal 
so, will have 108 total wells (samples) 
 
 
Analysis: 
1. Annexin V/ PI - at 24h for 108 samples 
2. Lipid extraction - at 0h (collect and pool remaining T cells from T cell columns) for 9 
samples 
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APPENDIX B-2 
 
EXPT. 1 - Diet Composition and Preparation 
Diet Composition: 
 
14g/mouse/day for 2 weeks 
6 mice per group x 14 days x 14g/m/day_____ 
  1176g per diet Þ make 1400g each diet 
 
3 Groups: 
1. 2% Olive Oil + 3% CO 
2. 2% Saf + 3% CO 
3. 2% FO + 3% CO 
 
                  Lot # L90325WF    Lot # L93271YF   Lot # L95108BB 
 g/100g OO   1.4kg Saf  1.4kg FO   1.4kg Total 
Casein 20 280 280 280 840 
Sucrose 42 588 588 588 1764 
Starch 21.98 307.7 307.7 307.7 923.1 
Cellulose 6 84 84 84 252 
Mineral 3.5 49 49 49 147 
Vitamin 1 14 14 14 42 
Met. 0.3 4.2 4.2 4.2 12.6 
Chol. Cl 0.2 2.8 2.8 2.8 8.4 
Tenox-20A 0.1 1.4 1.4 1.4 4.2 
OO 2 28   28 
Saf 2  28  28 
FO 2   28 28 
CO 3 42 42 42 126 
 
Tenox-20A =  Source of TBHQ 
32%  Glycerol 
30%  Corn Oil 
20%  TBHQ  
15%  Propylene glycol 
3%  Citric acid 
Amount of TBHQ = 0.02g/100g diet 
 
Sources of other dietary ingredients: 
-     Sucrose: product # 3900, Bioserv, lot # 1979.08, 10kg 
- Casein:  product # 1100, Bioserv, lot # 1589.01, 10kg 
- Choline Chloride: product # 30200, Harlan-Teklad, 500g 
- Tenox-20A: B&D Nutritional Ingredients, Inc., lot # 90114, 4oz 
- Salt Mix, AIN-76: product # F8505, Harlan-Teklad, lot # 30230, 4kg 
- Vitamin Mix, AIN-76A: product # 40077, Harlan-Teklad, Rx 993083, 1kg 
- Methionine: product # 1340, Bioserv, lot # 1806.02, 0.5kg 
- Cellulose: product # 3425, Bioserv, lot # 2667.01, 10kg 
- Corn Starch: product # 160170, Harlan-Teklad, lot # 96420, 25kg 
- Corn Oil: product # BLKC40, Traco Labs, Inc., lot # 99-017-22 
158 
Vitamin E content of diets 
A mouse requires 22mg Vit. E/ kg diet – NRC, Nutrient Requirements of Laboratory Animals, 1995 
Vitamin Mix: 
 
10g vit E/kg Vitamin mix 
 = 1% vit E 
 = 0.01g vit E/100g diet 
 = 100mg vit E/kg diet 
 
Olive Oil Ethyl Ester: 
 
2.05mg vit E/g OO 
 = 2050mg vit E/kg OO 
 since 2% of diet  
 = 41mg vit E/kg diet 
 
Safflower Oil Ethyl Ester: 
 
1.9mg vit E/g Saf 
 = 1900mg vit E/kg Saf 
 since 2% of diet 
 = 38mg vit E/kg diet 
 
Fish Oil: 
 
1.9mg vit E/g FO 
 = 1900mg vit E/kg FO 
 since 2% of diet 
 = 38mg vit E/kg diet 
 
Corn Oil: 
 
896ppm = 896 mg vit E/kg CO 
 since 3% of diet 
 = 26.88mg vit E/kg diet 
 
 
Total Vitamin E in each diet: 
 
OO diet: 
= 2% OO + 3% CO + Vitamin Mix 
= 41mg + 26.88mg + 100mg 
= 167.88mg vit E/kg diet 
 
Saf diet: 
= 2% Saf + 3% CO + Vitamin Mix 
= 38mg + 26.88mg + 100mg 
= 164.88mg vit E/kg diet 
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FO diet: 
=2% FO + 3% CO + Vitamin Mix 
= 38mg + 26.88mg + 100mg 
= 164.88mg vit E/kg diet 
 
 
Diet Preparation 
 
Remove Menhaden oil and Olive oil from freezer and place in warm H2O bath to thaw 
 
q Bring downstairs:  scale, bowls, mixing bowl w/ beaters, plastic containers, tape, markers, spoons, 
scoops, gloves, scissors, vitamin, methionine, choline chloride, detergent, EtOH 
q Weigh 5kg mixing bowl before adding any ingredients.  WEIGHT______ 
 
Label large containers as follows: 
 Casein   840g 
 Sucrose   1764g 
 Starch   923.1g 
 Cellulose   252g 
 
Label small containers as follows: 
 Mineral   147g 
 Vitamin   42g 
 Met   12.6g 
 Chol. Cl   8.4g 
 
Label containers as follows: 
___OO (green), Saf (red), FO (blue) 
___Add 42g CO to each of these containers 
___Cover and put on ice 
 
**Note: Flush all containers with Nitrogen after use 
 
OO Prep: 
Add the following to the CO: 
___Olive Oil – 28g 
___Tenox-20A – 1.4g 
___ Cover and put on ice 
 
Saf Prep: 
Add the following to the CO: 
___Safflower Oil – 28g 
___ Tenox-20A – 1.4g 
___ Cover and put on ice 
 
FO Prep: 
Add the following to the CO: 
___Menhaden Oil – 28g 
___ Tenox-20A – 1.4g 
___ Cover and put on ice 
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Weigh out the following dry ingredients and mix together in one large mixing bowl: 
___ Casein   840g 
___Sucrose   1764g 
___Starch   923.1g 
___Cellulose   252g 
 
Mix with the 5kg Hobart mixer for 5 min 
 
Weigh out the following dry ingredients.  Sift the ingredients and mix together in one small bowl: 
___Mineral   147g 
___Vitamin   42g 
___Met   12.6g 
___Chol. Cl   8.4g 
 
Once these ingredients are mixed, add them to the large mixing bowl containing the other dry ingredients.  
Mix for 10 min with the Hobart mixer 
 
q Weigh the total diet (should be 3989g + weight of bowl). 
q Divide the diet three ways into labeled plastic containers marked “OO”, “Saf”, or “FO” 
q Add all of the OO mixture to 1/3 the dry diet.  Mix for 5 min with Hobart mixer 
q Remove OO diet from bowl and put into labeled plastic container.  Cover. 
q Wash mixing bowl well 
q Add all of the Saf oil mixture to 1/3 the dry diet.  Mix for 5 min with Hobart mixer 
q Remove Saf diet from bowl and put into labeled plastic container.  Cover. 
q Wash mixing bowl well 
q Add all of the FO mixture to 1/3 the dry diet.  Mix for 5 min with Hobart mixer 
q Remove FO diet from bowl and put into labeled plastic container.  Cover. 
q Wash mixing bowl well 
q Aliquot diets into plastic cups at 84g per cup (enough for 6 mice per day) 
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APPENDIX B-3 
 
DIETARY LIPID EXTRACTION 
 
To extract lipid from mixed diet which will be analyzed via Gas Chromatography 
 
q Obtain prepared 12ml leak-proof vials 
q If not available:  Put acetone into 12ml glass screw-top vials. 
§ Mark the acetone level.   Put lids on and place in 80°C oven for 1h. 
§ Remove and note the acetone level.  Discard vials that evaporated acetone. 
q Pour off acetone from vials and drain upside down 
q Put each diet (0.5-1g, amount not critical) into 25ml glass screw-top vials. 
q Add 5ml Folch (CHCl3/ Methanol – 2:1 v:v) to each tube 
q Add 1ml 0.1 M KCl to each tube 
q Vortex for 1 min 
q Centrifuge at 4000rpm for 5 min at 4°C  Make sure to put glass tubes in a rubber holder before 
placing in the centrifuge 
q Transfer the lower phase to a 12ml leak-proof vial 
q -Using a Pasteur pipet bubble through the fat layer so as not to contaminate the extraction 
q Dry down with Nitrogen 
-Wipe each needle with EtOH 
-Do not put the needle into the solution 
-Do not turn the Nitrogen on too high otherwise the solution will bubble out 
-Dry until no liquid remains 
q Add 3ml fresh 6% HCl/MeOH to each tube 
For 20ml, use 1.2ml concentrated HCl in 18.8ml MeOH.  This solution is light sensitive, so put 
foil around the container 
q Flush with Nitrogen and cap tightly 
q Vortex for 1 min 
q Put in an 80°C oven for 14-16h (overnight) 
q Take tubes out of oven, put on ice 
q Add 1ml of 0.1 M KCl and 2ml Hexane to each tube 
q Vortex for 1 min 
q Label 4ml glass screw-top vials: “FAME” for Fatty Acid Methyl Esters 
 Make sure to replace normal black lids with green lids for organic solvents 
q Transfer upper phase to 4ml glass vials 
q Vortex for 1 min 
q Dry down with Nitrogen - see above description 
q Redissolve the FAME extract into 500ul of CH2Cl2.   
Use extra if the oil looks concentrated (yellowish).  Remove 100ul of the concentrated oil and 
add it to 1ml of CH2Cl2 
q Flush with Nitrogen 
q Store at -20°C or analyze immediately on GC 
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APPENDIX B-4 
 
EXPT. 1 Cell Preparation 
Take out T cell columns and buffer, Lympholyte  M, and 10% FBS-RPMI and warm to room 
temperature. 
 
Necropsy 
Þ Fill 15ml tubes (one for each animal) with 3ml of 10% FBS-RPMI  
Þ Assemble necessary equipment to take over to LARR: 
__labcoat 
__sterile scissors and forceps 
__gloves 
__EtOH 
__15ml tubes 
__keys, ID card 
Þ Go to LARR, room 202 to get mice 
Þ Get scale and take to necropsy room 
Þ Asphyxiate mice (1 cage at a time) with CO2, then weigh each individually 
Þ Remove spleens aseptically and place in 15ml tubes 
 
Homogenization  
Þ Have the following equipment ready and in the hood: 
__sterile glass homogenizers (1 per spleen) 
__10cc syringes 
__20 gauge needles 
__wire filters 
Þ Take out the bottom portion of the homogenizer from the sterile pouch –be careful to not touch any 
part of the homogenizer that will come in contact with the spleen 
Þ Pour the spleen and RPMI into the homogenizer 
Þ Homogenize with the top portion of the homogenizer until no spleen is visible (~5-7 strokes) 
Þ Pass homogenate through wire filter and 20 gauge needle to produce a single cell suspension 
· Screw a 20 gauge needle into the smaller opening of the filter 
· Screw a 10cc syringe into the larger opening of the filter 
· Remove the syringe plunger 
· Place assembly over 15cc tube 
· Pour homogenate into syringe and reinsert plunger to push all cells gently through the filter 
Þ Fill tube with RPMI to wash 
Þ Centrifuge at 200g for 5 min 
Þ Aspirate supernatant 
 
RBC Removal 
Þ Resuspend cells in 3ml RPMI 
Þ Add an equal amount of Lympholyte M 
· Using a 2ml pipet, insert the tip into the bottom of the tube 
· Layer Lympholyte M underneath the cell suspension by slowly adding it to the bottom of the tube 
· Should have two distinct layers 
Þ Careful not to knock the tubes, centrifuge at 500g for 15 min with the brake turned OFF 
Þ Carefully remove from centrifuge 
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Þ Pipet off the lymphocyte layer (layer at the interface between the two layers) by using a slow swirling 
motion with the pipet  
Þ Place lymphocytes into a new 15ml tube, fill with RPMI and spin at 300g for 5 min 
Þ Aspirate 
Þ Resuspend cells in 2ml of 1x R&D wash buffer (see below) 
 
Column Loading for T Cell Purification 
Begin preparing columns during 15 min spin from above 
Þ Dilute 10x R&D wash buffer to 1x using sterile H2O (Will need 18ml/column) 
Þ Place columns in the R&D column rack 
Þ Remove the TOP cap first – to avoid drawing air into the bottom of the column 
Þ Remove the bottom cap 
Þ Rinse tip with EtOH while column drains into a waste receptacle (a 50ml tube) 
Þ Wash the column with 8ml of 1x wash buffer by applying the buffer to the top of the column 
Þ Replace the waste receptacle with a sterile 15cc tube 
Þ Apply the 2ml cell suspension to the top of the column.  The cells will enter the column and displace 
the wash buffer in the column.  This is collected in the 15cc tube. 
Þ Incubate the cells within the column at room temperature for 10 min 
Þ Elute the T cells from the column with 8ml of 1x wash buffer 
Þ Centrifuge the collected T cells at 200g for 5min 
Þ Aspirate and resuspend in 1ml of RPMI for counting 
 
Cell Counting with Trypan Blue 
Þ Add 198ul of Trypan Blue to a 12x75mm tube with cap 
Þ Mix the cells by pipetting 
Þ Add 2ul of cells to 198ul Trypan Blue and resuspend 
Þ Resuspend the cells without forming bubbles and add to one side of a hemocytometer 
Þ Add the next sample to the other side of the hemocytometer 
Þ Using a 10x or 20x magnification look at the entire grid to make sure the cells are evenly distributed 
Þ Count the viable cells in one of the four 16-square grids 
Þ Write down number and repeat 
Þ 1 16-square grid = ___x106 cells/ml.  Take the average of the two counts 
Þ Culture cells at 2 x 106/ml  
Calculation: 
(___x106 cells/ml)(1ml) = (2x106 cells/ml)(X) – 1ml 
 
Example: 
Count 7x106 cells/ml 
(7x106 cells/ml)(1ml) = (2x106 cells/ml)(X) 
 X = 3.5 – 1ml (volume cells are presently in), so add 2.5ml 10%FBS-RPMI to cell suspension 
 
Cell Culture 
Þ Label 24-well plates (one plate per stimulus) 
Þ Rinse plates containing incubating aCD3 from day before (day before add 300ul 1ug/ml aCD3 to 
each well of plates using the aCD3 stimulus) 
· Forcefully flick out aCD3 solution 
· Add 300ul RPMI to each well with a repeator pipet  
· Shake briefly and flick out 
· Repeat 2 more times 
Þ Add stimuli solutions in the appropriate volumes to the appropriate wells 
Þ Add the cells at the 2x106 cells/ml concentration to the wells with the solutions 
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Þ Place in 37°C incubator for 24h incubation 
Þ Perform day 0 lipid extraction on remaining cells set aside for that purpose 
 
 
STIMULI CALCULATIONS 
aCD3  1ug/ml 
-Need 12ml, make 1ug/ml sol’n 
(1000ug/ml)(x) = (1ug/ml)(12000ul) 
 12ul stock into 12,000ul PBS  Þ  300ul/well 
 
aCD28  5ug/ml 
-Need 6ml, make 10ug/ml sol’n 
(1000ug/ml)(x) = (10ug/ml)(6000ul) 
 60ul stock into 5940ul RPMI  Þ  250ul/well 
 
Ionomycin  500nM 
-Need 5ml, make 2000nM sol’n 
(1000uM)(x) = (2uM)(5000ul) 
 10ul stock into 5000ul RPMI  Þ  add to PMA (1ng/ml)  Þ  add 250ul/well 
 
PMA  1ng/ml 
-Need 5ml, make 4ng/ml sol’n 
[1] (1000ug/ml)(x) = (2ug/ml)(2000ul) 
4ul stock into 2000ul RPMI 
[2] (2000ng/ml)(x) = (4ng/ml)(5000ul) 
10ul [1] into 5000ul RPMI  Þ  add to Ionomycin  Þ  add 250ul/well 
 
PMA  0.5ng/ml 
-Need 6ml, make 1ng/ml sol’n 
[1] See Above 
[2] (2000ng/ml)(x) = (1ng/ml)(6000ul) 
3ul [1] into 6000ul RPMI  Þ  add 250ul/well 
 
Dexamethasone  330ng/ml 
-Need 6ml, make 660ng/ml sol’n 
[1] (1000ug/ml)(x) = (10ug/ml)(1000ul) 
10ul stock into 990ul RPMI 
[2] (10000ng/ml)(x) = (660ng/ml)(6000ul) 
396ul [1] into 5600ul RPMI  Þ  add 250ul/well 
 
FasL  50ng/ml 
-Need 3ml, make 200ng/ml sol’n 
(100,000ng/ml)(x) = (200ng/ml)(3000ul) 
 6ul stock into 3000ul RPMI  Þ  add to aFLAG  Þ  add 250ul/well 
 
aFLAG  1ug/ml 
-Need 3ml, make 4ug/ml sol’n 
(1000ug/ml)(x) = (4ug/ml)(3000ul) 
 12ul stock into 2988ul RPMI  Þ  add to FasL  Þ  add 250ul/well 
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APPENDIX B-5 
 
Annexin V-FITC/ PI Protocol for Flow Cytometry 
 
Solutions and Equipment: 
 
· Following 3 reagents from Pharmingen’s Annexin V Kit 1 (# 6693KK) 
· FITC-conjugated Annexin V 
· Annexin V Binding Buffer, 10x concentrate (0.1M HEPES, pH 7.4; 1.4M NaCl; 25nM CaCl2).  
Dilute to 1x with sterile H2O prior to use. 
· Propidium Iodide Staining Solution (50ug/ml stock in 1x PBS) 
· 1xPBS, stored at 4°C  
· 1.5ml tubes 
· 12x75mm Polystyrene tubes (for the flow cytometer) 
· Aluminum foil 
 
** Make a flow cytometry appointment with Roger Smith:  rosmith@tamu.edu 
 
Protocol: 
 
1. Remove 24-well plates containing 24h-stimulated lymphocytes at a concentration of 2x106 
cells/ml in 500ul from incubator. 
2. For each well:  
a. Resuspend cells in well several times forcefully and aspirate using a p1000 pipettor set at 
500ul. 
b. Transfer aspirated cells to a 1.5ml tube. 
c. Rinse wells by resuspending forcefully several times with 500ul cold 1xPBS and add to 
the1.5ml tube. 
3. Centrifuge cells at 200xg, 5 min. 
4. Aspirate supernatant leaving cell pellets behind. 
5. Resuspend pellets in 100ul of 1x Binding Buffer and transfer to 12x75mm polystyrene tubes.  
(This should be ~1x105 cells) 
6. In the dark add to each tube:  
5ul of Annexin V-FITC  
2ul of Propidium Iodide  
7. Resuspend after adding each solution  
8. Wrap tubes in aluminum foil and incubate in the dark for 15 min at room temperature. 
9. After the 15 min. incubation, add 400ul of 1x Binding Buffer to each tube.  No need to mix—
samples will be vortexed before loading into flow cytometer 
10. Cover tubes in aluminum foil again 
11. Promptly take samples to the Vet. School flow cytometer in Dr. Smith’s lab.   
 
**Samples need to be analyzed within 1 hour of staining** 
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APPENDIX B-6 
 
Thin Layer Chromatography (TLC) 
Quantitating fatty acid mass of major phospholipids of T cells 
 
After lipid extraction of the samples: 
 
Þ Prepare 12ml glass screw-top leak-proof vials (will need 7/sample) 
§ Put 1ml Acetone into each vial 
§ Mark Acetone level  and tightly screw a black vinyl lid on 
§ Place at 80°C for 1h 
§ Use only vials that didn’t evaporate 
Þ Pre-activate TLC plate by heating at 110°C for 1h 
Þ Remove extracts from -20°C and place on ice 
Þ Dry the samples under N2  
Þ Redissolve the sample in 25ul FOLCH (MeOH/CHCl3, 1:2, v:v) and place on ice 
§ Use a 25ul Wiretrol to add the FOLCH, then vortex thoroughly (make sure to vortex along sides 
of vial) 
§ Flush with N2 
Þ Make-up TLC system solvents  
(CHCl3/MeOH/Acetic Acid/H2O,  50 : 37.5 : 3.5 : 2, v/v) 
· Make ~100ml per TLC tank 
· Use HPLC-grade H2O and Tracepur Acetic Acid, MeOH and CHCl3 
· Use glass pipets to add all solvents 
Þ Pour solvent mixture into a TLC tank  
Þ Gently place 1/3 sheet of filter paper into tank width-side up to equilibrate the solvents 
Þ Place glass lid onto the top of tank and a heavy object (e.g. the top from the N2 tank) on top of the lid 
to prevent evaporation 
Þ Allow solvents to equilibrate for at least 30 min 
Þ Spot the TLC plate after it has cooled from the pre-activation 
· Lie plate silica-side up 
· Using the extra wiretrol needle scrape a line across the plate 1/2” from the top 
· Place the TLC “plate grid” on top of the plate and mark evenly spaced lines for the number of 
lanes needed.  Scrape lines from top to bottom of the plate.  (make sure to leave ~1/2” on both 
sides of the plate) 
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· Put “plate grid” back onto plate and use the shadow of the edge of the grid to spot the sample 
(make sure the shadow falls ~1” from the bottom of the plate) 
· Vortex sample well and aspirate sample into the 25ul Wiretrol 
· Spot the sample in one lane by releasing droplets, one-after-another, onto shadow-line 
-Spot in the center of the lane, staying away from the edges 
-Be sure not to touch the plate with tip of the Wiretrol 
-If needed, respot over previous spot once dry 
· After spotting add 25ul additional FOLCH to sample, vortex and repot in same lane 
· Wipe Wiretrol needle with FOLCH between each sample 
· Include a standard (such as rat liver extract) on each plate 
Þ Place TLC plate, top side up, into tank.  Replace glass cover and heavy object. 
· Place the plate’s edge in the middle of the bottom of the tank  
Þ Run for about 2h or until solvents reach <0.5cm from the top line 
Þ While the plate is running prepare leak-proof tubes 
· Will need 7 tubes per sample spotted 
· Label the tubes for: Sphingosine, PC, PS, PI, PE, Cardiolipin, and Neutral lipids 
· Pour off the Acetone.  Dry by inverting tubes in rack 
· Rinse tubes and lids with 1ml MeOH (Tracepur grade) and pour off.  Dry by inverting in rack 
-Invert and rotate tube to thoroughly rinse   
-Make sure not to mix up lids (tubes are only guaranteed to be leak-proof w/ the corresponding 
lids) 
Þ Add 500ng (10ul of the 50ng/ul stock) of 17:0 free fatty acid.  This serves as an internal standard. 
-To determine the amount of internal std to add to PL tubes:  pmoles/106 cells of PL = 2.9 
 Breakdown by PL:  
 pmoles/106 cells MW 
PC 1.53 760 
PE 0.60 770 
PS 0.26 810 
PI 0.36 900 
Sph 0.14 750 
CL 0.14 1500 
Calculation:  PC = (1.53 x 10-9)(760) = 1.16 x 10-6,  Sph = (0.14 x 10-9)(750) = 0.1 x 10-6  
Range is ~1 mg-0.1 mg, so add 500ng internal std. 
· Add 3ml 6% HCl/MeOH and invert tube to mix with the ISD 
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· Keep tubes in dark until ready to use 
Þ Once plate in done running remove from tank and dry for ~5 min 
Þ In dark spray plate with 0.1% ANS (8-Anilino-1-naphthalene-sulfonic acid) to view bands 
· 0.1% ANS is stored at 4°C and is light sensitive 
· Place plate inside 3-sided box to contain ANS 
· Spray plate by attaching flask container (containing 0.1% ANS) to N2 
· Spray evenly, but not so much as to soak the plate 
Þ View the plate with UV (if unable to see the bands clearly, spray again) 
Þ Circle the bands with pencil while viewing under UV 
Þ Bands should be located similar to illustration below: 
 
                                                                                     Top 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Þ Scrape the circled bands into the appropriate leak-proof tubes 
· Use a TLC scraper blade  (similar to an Exacto knife) 
· Scrape in an upward motion so as not to lose the band 
· Scrape over a funnel into tube 
· Tap out all remaining pieces of plate caught in funnel into tube 
Þ Flush with N2 and vortex for 1 min 
Þ Methylate at 76°C for 15h 
Þ Extract FAME: 
· Add 2ml Hexane and 1ml 0.1M KCl to the leak-proof tubes 
· Vortex for 1 min 
· Centrifuge for 5 min at 3000rpm at 4°C (Jouan centrifuge) –use rubber tube inserts to prevent 
tubes from breaking  
· Transfer upper phase, using Pasteur pipet, to a labeled 4ml glass vial- be sure to replace black 
lids with green lids for organic solvents 
 
                               
 
 
                                 
                                 
 
 
                                  
 
                               
 
  
 
NL 
CL 
PE 
PI 
PS 
PC 
Sph 
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· Repeat the 2ml Hexane extract 
Þ Dry down the FAME under N2 
Þ Redissolve in 25ul CH2Cl2, flush with N2 and vortex 
Þ Run GC to calculate the mass of the phospholipids 
 
 
Item                                                   Company                                            Catalog # 
TLC plate                                              VWR Scientific                                       EM5721-7 
Omnisolv MeOH                                    EM                                                         MX0480-1 
Omnisolv CHCl3                                     EM                                                         CX1054-1 
Tracepur Acetic Acid                             EM                                                          AX0077-1 
HCl                                                       Aldrich Chem. Co.                                   25,814-8 
Filter paper                                           Whatman                                                1001-917 
17:0 Free Fatty Acid                            Sigma                                                      T-2151 
ANS                                                     Aldrich Chem. Co.                                   13,992-0 
Omnisolv Hexane                                   EM                                                         HX0297-1 
Acetone                                                  Fisher                                                    A929-4 
Omnisolv CH2Cl2                                     EM                                                         DX0837-1 
KCl 
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APPENDIX B-7 
 
EXPT. 2: T cell Apoptosis 48h - Experiment Description 
 
Diets: 
1. Olive Oil Ethyl Esters (2% olive oil + 3% corn oil) 
2. Safflower Oil Ethyl Esters (2% safflower oil + 3% corn oil) 
3. Fish Oil (2% menhaden fish oil + 3% corn oil) 
 
n = 6 mice per diet = 18 mice total 
 
Stimuli: 
- Untreated 
- aCD3/aCD28   (1ug/ml / 5ug/ml) 
- PMA/Ionomycin    (1ng/ml / 500nM) 
- PMA/ aCD3  (0.5ng/ml / 1ug/ml) 
- FasL/aFLAG   (50ng/ml / 1ug/ml) 
- PMA/Ionomycin   (1ng/ml / 500nM)  + FasL/aFLAG   (50ng/ml / 1ug/ml) 
- PMA/ aCD3  (0.5ng/ml / 1ug/ml)  + FasL/aFLAG   (50ng/ml / 1ug/ml) 
 
7 treatments per mouse 
culture 500,000 cells per well (treatment) 
 so, need 3.5 x 106 cells per animal 
 
 
Purified T cells from column yields ~ 10 X 106  cells per animal 
 
 
Culture 1 treatment per 24-well plate = 7 plates 
Will use 18 wells per plate — 1 for each animal     
so, will have 126 total wells (samples) 
 
 
Analysis: 
Annexin V/ PI - at 48h for 126 samples 
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APPENDIX B-8 
 
EXPT. 2 - Diet Composition and Preparation 
 
Diet Composition: 
 
14g/mouse/day for 2 weeks 
6 mice per group x 14 days x 14g/m/day_____ 
  1176g per diet Þ make 1400g each diet 
 
3 Groups: 
1. 2% Olive Oil + 3% CO 
2. 2% Saf + 3% CO 
3. 2% FO + 3% CO 
 
                    Lot # L90325WF  Lot # L93271YF  Lot # L95108BB 
 g/100g OO   1.4kg Saf   1.4kg FO   1.4kg Total 
Casein 20 280 280 280 840 
Sucrose 42 588 588 588 1764 
Starch 21.98 307.7 307.7 307.7 923.1 
Cellulose 6 84 84 84 252 
Mineral 3.5 49 49 49 147 
Vitamin 1 14 14 14 42 
Met. 0.3 4.2 4.2 4.2 12.6 
Chol. Cl 0.2 2.8 2.8 2.8 8.4 
Tenox-20A 0.1 1.4 1.4 1.4 4.2 
OO 2 28   28 
Saf 2  28  28 
FO 2   28 28 
CO 3 42 42 42 126 
 
Tenox-20A =  Source of TBHQ 
32%  Glycerol 
30%  Corn Oil 
20%  TBHQ 
15%  Propylene glycol 
3%  Citric acid 
Amount of TBHQ = 0.02g/100g diet 
 
Sources of other dietary ingredients: 
-     Sucrose: product # 3900, Bioserv, lot # 1979.08, 10kg 
- Casein:  product # 1100, Bioserv, lot # 1589.01, 10kg 
- Choline Chloride: product # 30200, Harlan-Teklad, 500g 
- Tenox-20A: B&D Nutritional Ingredients, Inc., lot # 90114, 4oz 
- Salt Mix, AIN-76: product # F8505, Harlan-Teklad, lot # 30230, 4kg 
- Vitamin Mix, AIN-76A: product # 40077, Harlan-Teklad, Rx 993083, 1kg 
- Methionine: product # 1340, Bioserv, lot # 1806.02, 0.5kg 
- Cellulose: product # 3425, Bioserv, lot # 2667.01, 10kg 
- Corn Starch: product # 160170, Harlan-Teklad, lot # 96420, 25kg 
- Corn Oil: product # BLKC40, Traco Labs, Inc., lot # 29025 
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Vitamin E content of diets 
A mouse requires 22mg Vit. E/ kg diet – NRC, Nutrient Requirements of Laboratory Animals, 1995 
Vitamin Mix: 
10g vit E/kg Vitamin mix 
 = 1% vit E 
 = 0.01g vit E/100g diet 
 = 100mg vit E/kg diet 
 
Olive Oil Ethyl Ester: 
2.05mg vit E/g OO 
 = 2050mg vit E/kg OO 
 since 2% of diet  
 = 41mg vit E/kg diet 
 
Safflower Oil Ethyl Ester: 
1.9mg vit E/g Saf 
 = 1900mg vit E/kg Saf 
 since 2% of diet 
 = 38mg vit E/kg diet 
 
Fish Oil: 
1.9mg vit E/g FO 
 = 1900mg vit E/kg FO 
 since 2% of diet 
 = 38mg vit E/kg diet 
 
Corn Oil: 
896ppm = 896 mg vit E/kg CO 
 since 3% of diet 
 = 26.88mg vit E/kg diet 
 
Total Vitamin E in each diet: 
 
OO diet: 
= 2% OO + 3% CO + Vitamin Mix 
= 41mg + 26.88mg + 100mg 
= 167.88mg vit E/kg diet 
 
Saf diet: 
= 2% Saf + 3% CO + Vitamin Mix 
= 38mg + 26.88mg + 100mg 
= 164.88mg vit E/kg diet 
 
FO diet: 
=2% FO + 3% CO + Vitamin Mix 
= 38mg + 26.88mg + 100mg 
= 164.88mg vit E/kg diet 
 
See Appendix B-2 for Diet Preparation details 
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EXPT. 2 Cell Preparation 
 
Take out T cell columns and buffer, Lympholyte M, and 10% FBS-RPMI and warm to room 
temperature. 
 
Necropsy 
Þ Fill 15ml tubes (one for each animal) with 3ml of 10% FBS-RPMI  
Þ Assemble necessary equipment to take over to LARR: 
__labcoat 
__sterile scissors and forceps 
__gloves 
__EtOH 
__15ml tubes 
__keys, ID card 
Þ Go to LARR, room 202 to get mice 
Þ Get scale and take to necropsy room 
Þ Asphyxiate mice (1 cage at a time) with CO2, then weigh each individually 
Þ Remove spleens aseptically and place in 15ml tubes 
 
Homogenization  
Þ Have the following equipment ready and in the hood: 
__sterile glass homogenizers (1 per spleen) 
__10cc syringes 
__20 gauge needles 
__wire filters 
Þ Take out the bottom portion of the homogenizer from the sterile pouch –be careful to not touch any 
part of the homogenizer that will come in contact with the spleen 
Þ Pour the spleen and RPMI into the homogenizer 
Þ Homogenize with the top portion of the homogenizer until no spleen is visible (~5-7 strokes) 
Þ Pass homogenate through wire filter and 20 gauge needle to produce a single cell suspension 
· Screw a 20 gauge needle into the smaller opening of the filter 
· Screw a 10cc syringe into the larger opening of the filter 
· Remove the syringe plunger 
· Place assembly over 15cc tube 
· Pour homogenate into syringe and reinsert plunger to push all cells gently through the filter 
Þ Fill tube with RPMI to wash 
Þ Centrifuge at 200g for 5 min 
Þ Aspirate supernatant 
 
RBC Removal 
Þ Resuspend cells in 3ml RPMI 
Þ Add an equal amount of Lympholyte M 
· Using a 2ml pipet, insert the tip into the bottom of the tube 
· Layer Lympholyte M underneath the cell suspension by slowly adding it to the bottom of the 
tube 
· Should have two distinct layers 
Þ Careful not to knock the tubes, centrifuge at 500g for 15 min with the brake turned OFF 
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Þ Carefully remove from centrifuge 
Þ Pipet off the lymphocyte layer (layer at the interface between the two layers) by using a slow swirling 
motion with the pipet  
Þ Place lymphocytes into a new 15ml tube, fill with RPMI and spin at 300g for 5 min 
Þ Aspirate 
Þ Resuspend cells in 2ml of 1x R&D wash buffer (see below) 
 
Column Loading for T Cell Purification 
Begin preparing columns during 15 min spin from above 
Þ Dilute 10x R&D wash buffer to 1x using sterile H2O (Will need 18ml/column) 
Þ Place columns in the R&D column rack 
Þ Remove the TOP cap first – to avoid drawing air into the bottom of the column 
Þ Remove the bottom cap 
Þ Rinse tip with EtOH while column drains into a waste receptacle (a 50ml tube) 
Þ Wash the column with 8ml of 1x wash buffer by applying the buffer to the top of the column 
Þ Replace the waste receptacle with a sterile 15cc tube 
Þ Apply the 2ml cell suspension to the top of the column.  The cells will enter the column and displace 
the wash buffer in the column.  This is collected in the 15cc tube. 
Þ Incubate the cells within the column at room temperature for 10 min 
Þ Elute the T cells from the column with 8ml of 1x wash buffer 
Þ Centrifuge the collected T cells at 200g for 5min 
Þ Aspirate and resuspend in 1ml of RPMI for counting 
 
Cell Counting with Trypan Blue 
Þ Add 198ul of Trypan Blue to a 12x75mm tube with cap 
Þ Mix the cells by pipetting 
Þ Add 2ul of cells to 198ul Trypan Blue and resuspend 
Þ Resuspend the cells without forming bubbles and add to one side of a hemocytometer 
Þ Add the next sample to the other side of the hemocytometer 
Þ Using a 10x or 20x magnification look at the entire grid to make sure the cells are evenly distributed 
Þ Count the viable cells in one of the four 16-square grids 
Þ Write down number and repeat 
Þ 1 16-square grid = ___x106 cells/ml.  Take the average of the two counts 
Þ Culture cells at 2 x 106/ml  
Calculation: 
(___x106 cells/ml)(1ml) = (2x106 cells/ml)(X) – 1ml 
 
Example: 
Count 7x106 cells/ml 
(7x106 cells/ml)(1ml) = (2x106 cells/ml)(X) 
 X = 3.5 – 1ml (volume cells are presently in), so add 2.5ml 10%FBS-RPMI to cell suspension 
 
Cell Culture 
Þ Label 24-well plates (one plate per stimulus) 
Þ Rinse plates containing incubating aCD3 from day before (day before add 300ul 1ug/ml aCD3 to 
each well of plates using the aCD3 stimulus) 
· Forcefully flick out aCD3 solution 
· Add 300ul RPMI to each well with a repeator pipet  
· Shake briefly and flick out 
· Repeat 2 more times 
Þ Add stimuli solutions in the appropriate volumes to the appropriate wells 
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Þ Add the cells at the 2x106 cells/ml concentration to the wells with the solutions 
Þ Place in 37°C incubator for 48h incubation 
 
 
STIMULI CALCULATIONS 
 
aCD3  1ug/ml 
-Need 18ml, make 1ug/ml sol’n 
(1000ug/ml)(x) = (1ug/ml)(18000ul) 
 18ul stock into 18,000ul PBS  Þ  300ul/well 
 
 
 
aCD28  5ug/ml 
-Need 6ml, make 10ug/ml sol’n 
(1000ug/ml)(x) = (10ug/ml)(6000ul) 
 60ul stock into 5940ul RPMI  Þ  250ul/well 
 
 
 
 
 
 
PMA  1ng/ml 
-Need 4ml, make 4ng/ml sol’n 
[2] (2000ng/ml)(x) = (4ng/ml)(4000ul) 
8ul [1] into 4000ul RPMI  Þ  add to Ionomycin (2000nM sol’n) 
 
Ionomycin  500nM 
-Need 4ml, make 2000nM sol’n 
(1000uM)(x) = (2uM)(4000ul) 
 8ul stock into 4000ul RPMI  Þ  add to PMA (4ng/ml sol’n)  Þ  add 250ul/well 
 
 
 
PMA  0.5ng/ml 
-Need 6ml, make 1ng/ml sol’n 
[2] (2000ng/ml)(x) = (1ng/ml)(6000ul) 
3ul [1] into 6000ul RPMI  Þ  add 250ul/well 
 
 
 
FasL  50ng/ml 
-Need 3ml, make 200ng/ml sol’n 
(100,000ng/ml)(x) = (200ng/ml)(6000ul) 
 12ul stock into 6000ul RPMI  Þ  add 3000ul to aFLAG  
 **** Use remaining for plate 7 
 
 
Plates 2, 4, 7 
Plate 2 
PMA  1st dilution 
[1] (1000ug/ml)(x) = (2ug/ml)(4000ul) 
 8ul stock into 4000ul RPMI 
Plate 3 
Plate 4 
Plate 5 
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aFLAG  1ug/ml 
-Need 3ml, make 4ug/ml sol’n 
(1000ug/ml)(x) = (4ug/ml)(3000ul) 
 12ul stock into 2988ul RPMI  Þ  add to FasL  Þ  add 250ul/well 
 
 
 
PMA  1ng/ml    
-Need 2ml, make 6ng/ml sol’n 
(2000ng/ml)(x) = (6ng/ml)(2000ul) 
6ul [1] into 2000ul RPMI  Þ  add to Iono, FasL, and aFLAG  
 
Ionomycin  500nM    
-Need 2ml, make 3000nM sol’n 
(1000uM)(x) = (3uM)(2000ul) 
6ul stock into 2000ul RPMI  Þ  add to PMA, FasL, and aFLAG 
 
FasL  50ng/ml   
-Need 2ml, make 300ng/ml sol’n 
(100,000ng/ml)(x) = (300ng/ml)(2000ul) 
6ul stock into 2000ul RPMI  Þ  add to PMA, Iono, and aFLAG 
 
aFLAG  1ug/ml    
-Need 2ml, make 8ug/ml sol’n 
(1000ug/ml)(x) = (8ug/ml)(2000ul) 
16ul stock into 1984ul RPMI  Þ  add to PMA, Iono and FasL 
 
 
 
PMA  0.5ng/ml    
-Need 6ml, make 2ng/ml sol’n 
(2000ng/ml)(x) = (2ng/ml)(3000ul) 
3ul [1] into 3000ul RPMI  Þ  add to FasL and aFLAG  
 
FasL  50ng/ml    
 Þ  add 3ml to PMA and aFLAG 
 
aFLAG  1ug/ml    
-Need 3ml, make 6ug/ml sol’n 
(1000ug/ml)(x) = (6ug/ml)(3000ul) 
18ul stock into 2982ul RPMI  Þ  add to PMA and FasL  
 
 
 
Plate 6 
Plate 7 
Plate 5 (cont.) 
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APPENDIX B-10 
 
EXPT 3: Whole Splenocyte - Experiment Description 
 
Diets: 
1. Safflower Oil Ethyl Esters (2% safflower oil + 3% corn oil) 
2. Fish Oil 2% (2% menhaden fish oil + 3% corn oil) 
3. Fish Oil 4% (4% menhaden fish oil + 1% corn oil) 
 
n = 6 mice per diet = 18 mice total 
 
Stimuli: 
- Untreated 
- aCD3/aCD28   (1ug/ml / 5ug/ml) 
- PMA/ aCD3  (0.5ng/ml / 1ug/ml) 
- ConA   (2.5ug/ml) 
 
4 treatments per mouse 
culture 5 x 105  cells per well (treatment)______ 
 so, need 2 x 106 cells per animal 
 
 
Culture 1 treatment per 24-well plate = 4 plates 
Will use 18 wells per plate — 1 for each animal______ 
           so, will have 72 total wells (samples) 
 
 
Analysis: 
1. aCD3-PE/AnnexinV-FITC/ 7AAD - at 24h for 72 samples 
- Gate on T cell population and accessory cell population for separate apoptosis readouts 
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EXPT. 3 & 4 - Diet Composition and Preparation 
Diet Composition: 
 
EXPT. 3: 
14g/mouse/day for 2 weeks 
6 mice per group x 14 days x 14g/m/day_____ 
  1176g per diet  
EXPT. 4: 
14g/mouse/day for 2 weeks 
12 mice per group x 14 days x 14g/m/day_____ 
  2352g per diet  
 
3 Groups: 
1. 2% Saf + 3% CO 
2. 2% FO + 3% CO 
3. 4% FO + 1% CO 
 
                 Lot # L90325WF    Lot # L93271YF   Lot # L95108BB 
 g/100g SAF   3.9kg FO2%  3.9kg FO4%  3.9kg Total 
Casein 20 780 780 780 2340 
Sucrose 42 1638 1638 1638 4914 
Starch 21.98 857.2 857.2 857.2 2571.6 
Cellulose 6 234 234 234 702 
Mineral 3.5 136.5 136.5 136.5 409.5 
Vitamin 1 39 39 39 117 
Met. 0.3 11.7 11.7 11.7 35.1 
Chol. Cl 0.2 7.8 7.8 7.8 23.4 
Tenox-20A 0.1 3.9 3.9 3.9 11.7 
SAF 2 78   78 
FO 2% 2  78  78 
FO 4% 4   156 156 
CO 3/1(FO 4%) 117 117 39 273 
 
Tenox-20A =  Source of TBHQ 
32%  Glycerol 
30%  Corn Oil 
20%  TBHQ  
15%  Propylene glycol 
3%  Citric acid 
Amount of TBHQ = 0.02g/100g diet 
 
 
Total: 3528g per diet 
 make 3900g each diet 
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Sources of other dietary ingredients: 
-     Sucrose: product # 3900, Bioserv, lot # 1979.08, 10kg 
- Casein:  product # 1100, Bioserv, lot # 1589.01, 10kg 
- Choline Chloride: product # 30200, Harlan-Teklad, 500g 
- Tenox-20A: B&D Nutritional Ingredients, Inc., lot # 90114, 4oz 
- Salt Mix, AIN-76: product # F8505, Harlan-Teklad, lot # 30230, 4kg 
- Vitamin Mix, AIN-76A: product # 40077, Harlan-Teklad, Rx 993083, 1kg 
- Methionine: product # 1340, Bioserv, lot # 1806.02, 0.5kg 
- Cellulose: product # 3425, Bioserv, lot # 2667.01, 10kg 
- Corn Starch: product # 160170, Harlan-Teklad, lot # 96420, 25kg 
- Corn Oil: product # BLKC40, Traco Labs, Inc., lot # 99-017-22 
 
 
See Appendix B-2 for diet preparation details 
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EXPT. 3 Cell Preparation 
 
Take out T cell columns and buffer, Lympholyte M, and 10% FBS-RPMI and warm to room 
temperature. 
 
Necropsy 
Þ Fill 15ml tubes (one for each animal) with 3ml of 10% FBS-RPMI  
Þ Assemble necessary equipment to take over to LARR: 
__labcoat 
__sterile scissors and forceps 
__gloves 
__EtOH 
__15ml tubes 
__keys, ID card 
Þ Go to LARR, room 202 to get mice 
Þ Get scale and take to necropsy room 
Þ Asphyxiate mice (1 cage at a time) with CO2, then weigh each individually 
Þ Remove spleens aseptically and place in 15ml tubes 
 
Homogenization  
Þ Have the following equipment ready and in the hood: 
__sterile glass homogenizers (1 per spleen) 
__10cc syringes 
__20 gauge needles 
__wire filters 
Þ Take out the bottom portion of the homogenizer from the sterile pouch –be careful to not touch any 
part of the homogenizer that will come in contact with the spleen 
Þ Pour the spleen and RPMI into the homogenizer 
Þ Homogenize with the top portion of the homogenizer until no spleen is visible (~5-7 strokes) 
Þ Pass homogenate through wire filter and 20 gauge needle to produce a single cell suspension 
· Screw a 20 gauge needle into the smaller opening of the filter 
· Screw a 10cc syringe into the larger opening of the filter 
· Remove the syringe plunger 
· Place assembly over 15cc tube 
· Pour homogenate into syringe and reinsert plunger to push all cells gently through the filter 
Þ Fill tube with RPMI to wash 
Þ Centrifuge at 200g for 5 min 
Þ Aspirate supernatant 
 
RBC Removal 
Þ Resuspend cells in 3ml RPMI 
Þ Add an equal amount of Lympholyte M 
· Using a 2ml pipet, insert the tip into the bottom of the tube 
· Layer Lympholyte M underneath the cell suspension by slowly adding it to the bottom of the 
tube 
· Should have two distinct layers 
Þ Careful not to knock the tubes, centrifuge at 500g for 15 min with the brake turned OFF 
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Þ Carefully remove from centrifuge 
Þ Pipet off the lymphocyte layer (layer at the interface between the two layers) by using a slow swirling 
motion with the pipet  
Þ Place lymphocytes into a new 15ml tube, fill with RPMI and spin at 300g for 5 min 
Þ Aspirate 
Þ Resuspend cells in 1ml of RPMI 
 
Cell Counting with Trypan Blue 
Þ Add 198ul of Trypan Blue to a 12x75mm tube with cap 
Þ Mix the cells by pipetting 
Þ Add 2ul of cells to 198ul Trypan Blue and resuspend 
Þ Resuspend the cells without forming bubbles and add to one side of a hemocytometer 
Þ Add the next sample to the other side of the hemocytometer 
Þ Using a 10x or 20x magnification look at the entire grid to make sure the cells are evenly distributed 
Þ Count the viable cells in one of the four 16-square grids 
Þ Write down number and repeat 
Þ 1 16-square grid = ___x106 cells/ml.  Take the average of the two counts 
Þ Culture cells at 2 x 106/ml  
Calculation: 
(___x106 cells/ml)(1ml) = (2x106 cells/ml)(X) – 1ml 
 
Example: 
Count 7x106 cells/ml 
(7x106 cells/ml)(1ml) = (2x106 cells/ml)(X) 
 X = 3.5 – 1ml (volume cells are presently in), so add 2.5ml 10%FBS-RPMI to cell suspension 
 
Cell Culture 
Þ Label 24-well plates (one plate per stimulus) 
Þ Rinse plates containing incubating aCD3 from day before (day before add 300ul 1ug/ml aCD3 to 
each well of plates using the aCD3 stimulus) 
· Forcefully flick out aCD3 solution 
· Add 300ul RPMI to each well with a repeator pipet  
· Shake briefly and flick out 
· Repeat 2 more times 
Þ Add stimuli solutions in the appropriate volumes to the appropriate wells 
Þ Add the cells at the 2x106 cells/ml concentration to the wells with the solutions 
Þ Place in 37°C incubator for 24h incubation 
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STIMULI CALCULATIONS 
aCD3  1ug/ml 
Need 10.8ml for 2 plates x 18 wells 
Make 12ml, 1ug/ml sol’n 
(1000ug/ml)(x) = (1ug/ml)(12000ul) 
 12ul stock into 12,000ul PBS  Þ    300ul/well - Plates 2 & 3 
 
aCD28  5ug/ml 
Need 4.5ml for 1 plate x 18 wells 
Make 6ml, 10ug/ml sol’n 
(1000ug/ml)(x) = (10ug/ml)(6000ul) 
 60ul stock into 5940ul RPMI  Þ   250ul/well – Plate 2 
 
PMA  0.5ng/ml 
Need 4.5ml for 1 plate x 18 wells 
Make 6ml, 1ng/ml sol’n 
(2000ug/ml)(x) = (1ng/ml)(6000ul) 
3ul stock into 6000ul RPMI  Þ   250ul/well – Plate 3 
 
ConA  2.5ug/ml 
Need 4.5ml for 1 plate x 18 wells 
Make 6ml, 5ug/ml sol’n 
(10000ug/ml)(x) = (5ug/ml)(6000ul) 
3ul stock into 6000ul RPMI  Þ   250ul/well – Plate 4 
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Three color staining for flow cytometry 
(aCD3-PE/AnnexinV-FITC/7AAD) 
 
Reagents and Equipment: 
§ aCD3-PE  (0.1mg/ml) Pharmingen #553063 
§ dilute to 10ug/ml in Wash Buffer 
§ FC Block  (0.5mg/ml) Pharmingen #01241D 
§ dilute to 5ug/ml in Wash Buffer 
§ AnnexinV-FITC (200 tests) Pharmingen #556419 
§ 7AAD  (100 tests) Pharmingen #555816 
§ AnnexinV Binding Buffer, 10x concentrate (0.1M HEPES, pH 7.4; 1.4M NaCl; 25nM CaCl2)  
 Pharmingen #556454 
-  dilute to 1x concentrate with sterlie H2O 
§ Wash Buffer (pH 7.4): 
- 100ml PBS 
- 0.5g BSA (Boehringer Mannheim #100030) 
- 0.1g NaN3  
§ 1xPBS, stored at 4°C  
§ 2.0ml microtubes 
§ 12x75mm Polystyrene FACS tubes (for the flow cytometer) 
§ Aluminum foil 
 
Protocol: 
1. Remove 24-well plates containing 24h-stimulated splenocytes at a concentration of 2x106 cells/ml in 
500ul from incubator. 
2. For each well:  
· Resuspend cells in well several times forcefully and aspirate using a p1000 pipettor set at 500ul. 
· Transfer aspirated cells to a 2.0ml tube. 
· Rinse wells by resuspending forcefully several times with 500ul cold 1xPBS and add to the 2.0ml 
tube. 
3. Centrifuge cells at 200xg, 5 min. 
4. Aspirate supernatant leaving cell pellets behind. 
5. Resuspend cells in 50ul Wash Buffer 
6. Add 10ul FC Block [5ug/ml] and shake at RT for 10 min. 
7. In the dark add 10ul aCD3-PE [10ug/ml] and incubate in the dark for 30 min. 
8. Wash with 1xPBS.   
9. Centrifuge at 200xg, 5 min., asprirate supernatant 
10. Resuspend cells in 100ul 1x Binding Buffer 
-  transfer cells to 12x75mm FACS tubes 
11. In the dark add to each tube: 
5ul AnnexinV-FITC 
20ul 7AAD 
12. Wrap tubes in Aluminum foil and incubate in the dark for 10-15 min 
13. Add 400ul 1x Binding Buffer to each tube.  No need to mix—samples will be vortexed before loading 
into the flow cytometer 
14. Cover tubes in Aluminum foil again 
15. Promptly take samples to the Vet school’s flow cytometer facility  
 
**Samples need to be analyzed within 1 hour of staining with Annexin V** 
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EXPT. 4: AICD - Experiment Description 
 
Diets: 
1. Safflower Oil Ethyl Esters (2% safflower oil + 3% corn oil) 
2. Fish Oil 2% (2% menhaden fish oil + 3% corn oil) 
3. Fish Oil 4% (4% menhaden fish oil + 1% corn oil) 
 
n = 6 mice per diet , pool 2 spleens per n = 36 mice total 
 
Stimuli: 
1. aCD3/aCD28   (1ug/ml / 5ug/ml) 
2. PMA/aCD3  (0.5ng/ml / 1ug/ml) 
3. PMA/Iono  (1ng/ml / 500nM) 
 
3 treatments per mouse (n) 
culture 2 wells of 3 x 106 cells per well per treatment at d0 
 so, need 18 x 106 cells per n 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses: 
1. AnnexinV/PI – for 54 samples 
2. Cytokine quantitation via ELISA 
stim. 
T cells Collect sup 
Reculture 
Wash 
Reculture 
Analyze 
stim. rest 
D 0 48h O/N 5h 
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APPENDIX B-15 
 
EXPT. 4  AICD – Cell Preparation  
 
DAY 0 
 
Take out T cell columns and buffer, Lympholyte M, and 10% FBS-RPMI and warm to room 
temperature. 
 
Necropsy 
Þ Fill 15ml tubes (one for each pair of animal) with 3ml of 10% FBS-RPMI  
Þ Assemble necessary equipment to take downstairs to basement: 
__labcoat 
__sterile scissors and forceps 
__gloves 
__EtOH 
__15ml tubes 
__keys 
Þ Asphyxiate mice (1 cage at a time) with CO2, then weigh mice in pairs 
Þ Remove spleens aseptically and place 2 each in 15cc tubes 
 
Homogenization  
Þ Have the following equipment ready and in the hood: 
__sterile glass homogenizers (1 per 2 spleens) 
__5cc syringes 
__20 gauge needles 
__wire filters 
Þ Take out the bottom portion of the homogenizer from the sterile pouch –be careful to not touch any 
part of the homogenizer that will come in contact with the spleen 
Þ Pour the spleen and RPMI into the homogenizer 
Þ Homogenize with the top portion of the homogenizer until no spleen is visible (~5-7 strokes) 
Þ Pass homogenate through wire filter and 20 gauge needle to produce a single cell suspension 
· Screw a 20 gauge needle into the smaller opening of the filter 
· Screw a 10cc syringe into the larger opening of the filter 
· Remove the syringe plunger 
· Place assembly over 15cc tube 
· Pour homogenate into syringe and reinsert plunger to push all cells gently  through the filter 
Þ Fill tube with RPMI to wash 
Þ Centrifuge at 200g for 5 min 
Þ Aspirate supernatant 
 
RBC Removal 
Þ Resuspend cells in 3ml RPMI 
Þ Add an equal amount of Lympholyte M 
· Using a 2ml pipet, insert the tip into the bottom of the tube 
· Layer Lympholyte M underneath the cell suspension by slowly adding it to the bottom of the 
tube 
· Should have two distinct layers 
Þ Careful not to knock the tubes, centrifuge at 500g for 15 min with the brake turned OFF 
Þ Carefully remove from centrifuge 
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Þ Pipet off the lymphocyte layer (layer at the interface between the two layers) by using a slow swirling 
motion with the pipet  
Þ Place lymphocytes into a new 15cc tube, fill with RPMI and spin at 300g for 5 min 
Þ Aspirate 
Þ Resuspend cells in 2ml of 1x R&D wash buffer (see below) 
 
Column Loading for T Cell Purification 
Begin preparing columns during 15 min spin from above 
Þ Dilute 10x R&D wash buffer to 1x using sterile H2O (Will need 18ml/column) 
Þ Place columns in the R&D column rack 
Þ Remove the TOP cap first – to avoid drawing air into the bottom of the column 
Þ Remove the bottom cap 
Þ Rinse tip with EtOH while column drains into a waste receptacle (a 50cc tube) 
Þ Wash the column with 8ml of 1x wash buffer by applying the buffer to the top of the column 
Þ Replace the waste receptacle with a sterile 15cc tube 
Þ Apply the 2ml cell suspension to the top of the column.  The cells will enter the column and displace 
the wash buffer in the column.  This is collected in the 15cc tube. 
Þ Incubate the cells within the column at room temperature for 10 min 
Þ Elute the T cells from the column with 8ml of 1x wash buffer 
Þ Centrifuge the collected T cells at 200g for 5min 
Þ Aspirate and resuspend in 1ml of RPMI for counting 
 
Cell Counting with Trypan Blue 
Þ Add 198ul of Trypan Blue to a 12x75mm tube with cap 
Þ Mix the cells by pipetting 
Þ Add 2ul of cells to 198ul Trypan Blue and resuspend 
Þ Resuspend the cells without forming bubbles and add to one side of a hemocytometer 
Þ Add the next sample to the other side of the hemocytometer 
Þ Using a 10x or 20x magnification look at the entire grid to make sure the cells are evenly distributed 
Þ Count the viable cells in one of the four 16-square grids 
Þ Write down number and repeat 
Þ 1 16-square grid = ___x106 cells/ml.  Take the average of the two counts 
Þ Culture cells at 3 x 106/ml  
Calculation: 
(___x106 cells/ml)(1ml) = (3x106 cells/ml)(X) – 1ml 
 
Example: 
Count 7x106 cells/ml 
(18x106 cells/ml)(1ml) = (3x106 cells/ml)(X) 
 X = 6 – 1ml (volume cells are presently in), so add 5ml 10%FBS-RPMI to cell suspension 
 
Cell Culture 
Þ Have the following solutions prepared ahead of time (in the AM): 
· aCD3/aCD28  (1ug/ml / 5ug/ml) 
· aCD3/PMA  (1ug/ml / 0.5ng/ml) 
· PMA/Iono  (1ng/ml / 500nM) 
Þ Label 24-well plates (for large experiments label ahead of time) 
Þ Rinse plates containing incubating aCD3 from day before 
· Forcefully flick out aCD3 solution 
· Add 300ul RPMI to each well with a repeator pipet  
· Shake briefly and flick out 
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· Repeat 2 more times 
Þ Add 1ml stimuli solutions to the appropriate wells 
Þ Add 1ml cells at 3x106 cells/ml concentration to the wells with the solutions 
· Culture 2 wells / sample for each stimulation 
Þ Place in 37°C incubator for 48h incubation 
 
 
48 HOUR 
 
Þ Remove 24-well plates from incubator and harvest cells into 15cc tubes (2 wells/tube) 
Þ Centrifuge the collected T cells at 200g for 5min 
Þ Collect 2 x 500ul supernatant from the centrifuged samples and place each one of 500ul aliquots into 
a sterile microtube 
· Store supernatants at -80°C 
Þ Aspirate remaining sup. and resuspend cells in1ml RPMI for counting 
Þ Count cells in 200ul Trypan Blue 
Þ Bring cells to a concentration of 2x106 cells/ml 
Þ Add 1ml cells/well, 1 well per sample to 24-well plates containing 1ml/well RPMI 
Þ Place in 37°C incubator overnight 
 
 
DAY 3 
 
Þ Remove 24-well plates from incubator and harvest cells into 15cc tubes 
Þ Centrifuge the collected T cells at 200g for 5min 
Þ Aspirate sup. and resuspend cells in 1ml RPMI 
Þ Add an equal amount of Lympholyte M 
· Using a 2ml pipet, insert the tip into the bottom of the tube 
· Layer Lympholyte M underneath the cell suspension by slowly adding it to the bottom of the tube 
· Should have two distinct layers 
Þ Careful not to knock the tubes, centrifuge at 500g for 15 min with the brake turned OFF 
Þ Carefully remove from centrifuge 
Þ Pipet off the lymphocyte layer (layer at the interface between the two layers) by using a slow swirling 
motion with the pipet  
Þ Place lymphocytes into a new 15cc tube, fill with RPMI and spin at 300g for 5 min 
Þ Aspirate sup. 
Þ Resuspend cells in 1ml RPMI for counting 
Þ Count cells in 200ul Trypan Blue 
Þ Bring cells to a concentration of 2x106 cells/ml 
Þ Add 500ul cells/well, 1 well per sample to 24-well plates containing 500ul/well of initial (Day0) 
stimulus 
Þ Place in 37°C incubator 4-5h 
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STIMULI CALCULATIONS 
 
DAY 0 
 
aCD3  1ug/ml 
Will have 72 wells, 500ul/well 
Make 40ml, 1ug/ml sol’n 
(1000ug/ml)(x) = (1ug/ml)(40000ul) 
 40ul stock into 40,000ul PBS  Þ   500ul/well,  Plates 1 & 2 a-b 
 
aCD28  5ug/ml 
Will have 36 wells, 1ml/well 
Make 40ml, 10ug/ml sol’n 
(1000ug/ml)(x) = (10ug/ml)(40000ul) 
 400ul stock into 39,600ul RPMI  Þ  1ml/well,  Plates 1 a-b 
 
PMA  0.5ng/ml 
Will have 36 wells, 1ml/well 
Make 40ml, 1ng/ml sol’n 
(2000ng/ml)(x) = (1ng/ml)(40000ul) 
20ul stock into 40,000ul RPMI  Þ  1ml/well,  Plates 2 a-b 
 
PMA  1ng/ml 
Will have 36 wells, Comb. w/ Iono = 500ul/well 
Make 20ml, 4ng/ml sol’n 
(2000ng/ml)(x) = (4ng/ml)(20000ul) 
40ul stock  
 
Ionomycin  500nM 
Will have 36 wells, Comb. w/ PMA (1ng/ml) = 500ul/well 
Make 20ml, 2uM sol’n  
(1000uM)(x) = (2uM)(20000ul) 
 40ul stock  
 
 
 
DAY 3 
 
aCD3  1ug/ml 
Will have 36 wells, 300ul/well 
Make 12ml, 1ug/ml sol’n 
(1000ug/ml)(x) = (1ug/ml)(12000ul) 
 12ul stock into 12,000ul PBS  Þ   300ul/well,  Plates 1 & 2 
 
aCD28  5ug/ml 
Will have 18 wells, 500ul/well 
Make 10ml, 10ug/ml sol’n 
(1000ug/ml)(x) = (10ug/ml)(10000ul) 
 100ul stock into 9,900ul RPMI  Þ  500ul/well,  Plate 1 
 
Add both to 20ml RPMI 
1ml/well 
Plates 3 a-b 
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PMA  0.5ng/ml 
Will have 18 wells, 500ul/well 
Make 10ml, 1ng/ml sol’n 
(2000ng/ml)(x) = (1ng/ml)(10000ul) 
5ul stock into 10,000ul RPMI  Þ  500ul/well,  Plate 2 
 
PMA  1ng/ml 
Will have 18 wells, Comb. w/ Iono = 250ul/well 
Make 5ml, 4ng/ml sol’n 
(2000ng/ml)(x) = (4ng/ml)(5000ul) 
10ul stock  
 
Ionomycin  500nM 
Will have 18 wells, Comb. w/ PMA (1ng/ml) = 250ul/well 
Make 5ml, 2uM sol’n  
(1000uM)(x) = (2uM)(5000ul) 
 10ul stock   
 
 
Add both to 5ml RPMI 
500ul/well 
Plate 3  
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APPENDIX B-16 
 
ELISA (Enzyme-Linked Immunosorbent Assay)  
 
R&D Systems Quantikine M kit  
 IL-2:  cat # M2000 
 IL-4:  cat # M4000 
 IL-10:  cat # M1000 
 IFNg:  cat # MIF00 
 
Reagent Preparation 
 
Bring all reagents to room temp before use 
 
Mouse cytokine (refers to either IL-2, IL-4, IL-10, or IFNg) Kit Control 
Reconstitute with 1.0 ml deionized/distilled water. 
 
Mouse cytokine Conjugate Concentrate 
For each plate make 10 ml.  Add 450 ml Conjugate Concentrate to 9550 ml Conjugate Diluent. 
 
Wash Buffer 
For each plate make 500 ml.  Add 20 ml Wash Buffer Concentrate (25X) to 480 ml deionized/distilled 
water. 
 
Substrate Solution 
For each plate make 10 ml.  Mix Reagent A and Reagent B together in equal volumes (i.e., 5 ml/5 ml).  
Protect from light and use within 15 min. 
 
Mouse cytokine Standard 
Reconstitute Standard with 2-5 ml (varies with cytokine) of Calibrator Diluent (for cell culture supernatant 
samples).  Allow to sit for 5 min with gentle mixing prior to making dilutions.  This reconstitution 
produces a stock solution. 
Standard dilutions:   
Use polypropylene tubes 
Pipet 200 ml Calibrator diluent into 7 tubes labeled for decreasing dilution series.  Use the stock to make a 
dilution series (see below).  Mix thoroughly before each transfer.  Use Calibrator diluent for 0 pg/ml Std. 
 
Example: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stock 
500 
pg/ml 
250  
pg/ml 
125  
pg/ml 
62.5  
pg/ml 
31.2 
 pg/ml 
15.6  
pg/ml 
7.8  
pg/ml 
200 ml 200 ml 
200 ml 200 ml 200 ml 200 ml 
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Assay Protocol (as per Kit instructions): 
 
· Bring kit reagents and 96-well plates to room temp.  Thaw supernatant samples on ice. 
 
· Prepare reagents and standard dilutions as previously described.  Prepare supernatant samples to 
predetermined dilutions (dilute with Calibrator Diluent) so that expected absorbances will fall 
within the Standard ranges. 
 
· Add 50 ml Assay Diluent to each well of the 96-well plate precoated with monoclonal antibody 
specific for the cytokine of interest. 
 
· Add 50 ml Standards, Control, or Samples to each well.  Tap plate gently for 1 min.  Cover with 
the adhesive strip provided.  Incubate at room temp for 2h. 
 
· Wash:  Dump-out plate contents into the sink and wash by adding 400 ml of Wash Buffer to each 
well using a multipipettor.  Dump-out Wash Buffer after gentle shaking and blot plate against a 
clean paper towel to insure complete content removal.  Repeat process 4 more times for a total of 
5 washes. 
 
· Add 100 ml Mouse cytokine conjugate to each well.  Cover with a new adhesive strip.  Incubate at 
room temp for 2h. 
 
· Repeat wash step as described above. 
 
· Prepare Substrate Solution as described above.  Add 100 ml Substrate Solution to each well and 
cover plate with foil to protect from light.  Incubate at room temp for 30 min. 
 
· Add 100 ml Stop Solution to each well.  Gently tap the plate to ensure thorough mixing. 
 
· Determine the optical density of each well within 30 min using a spectraphotometer set at 450 nm, 
with wavelength correction set at 540 nm. 
 
· Generate a standard curve (optical density vs the concentration of the Standards) and calculate the 
Sample concentrations from this curve. 
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APPENDIX B-17 
 
EXPT. 5 Part I and II:  AICD - Experiment Description 
 
Diets: 
1. LFSAF, lowfat safflower oil (2% safflower oil + 3% corn oil) 
2. LFFO, lowfat fish oil (4% menhaden fish oil + 1% corn oil) 
3. HFSAF, highfat safflower oil (4% safflower oil + 6% corn oil) 
4. HFFO, highfat fish oil (9% menhaden fish oil + 1% corn oil) 
 
For each Part:  n = 6 mice/diet, 3 spleens/n = 72 mice/Part = 144 mice total 
 
Stimuli: 
1. aCD3/aCD28   (1ug/ml / 5ug/ml) 
2.    “ unstim. 2º 
3. aCD3/PMA (1.0ug/ml / 0.5ng/ml) 
4.  “ unstim. 2º 
5. PMA/Iono  (1ng/ml / 500nM) 
6.  “ unstim. 2º 
 
***Stagger Parts by one week 
 
6 samples/4 diets = 24 samples x 6 treatments = 144 FACS samples/Part 
 
Analyses: 
1. AnnexinV/PI  
2. Cytokine quantitation via ELISA (48h. d3) 
3. mRNA for FasL and Fas (d3 AM and PM) 
 
Experimental design for EXPT. 5  
T cells
aCD3/ aCD28
aCD3/PMA
PMA/ Iono
Activation
      48h
RPMI-complete
    medium
   Rest
overnight
5h
aCD3/ aCD28
    aCD3/PMA
        PMA/ Iono
RPMI-complete
   medium
“U
nr
ea
cti
va
ted
”“Reactivated”
Apoptosis Analysis
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EXPT. 5 - Diet Composition and Preparation 
14g/mouse/day for 2 weeks for 2 parts  
18 mice per group x 14 d x 14g/m/d x 2 parts_____ 
  7056g per diet   Þ  make 8000g per diet 
 
4  Diet Groups: 
1. 2% SAF + 3% CO  SAF LF 
2. 4% FO + 1% CO  FO LF 
3. 4% SAF + 6% CO  SAF HF 
4. 9% FO + 1% CO  FO HF 
 
 
 LF HF  
 g/100g SAF 8.0kg FO 8.0kg g/100g 
SAF 
8.0kg 
FO  
8.0kg Total 
Casein 20 1600 1600 20 1600 1600 6400 
Sucrose 42 3360 3360 37 2960 2960 12640 
Starch 21.9 1752 1752 21.9 1752 1752 7008 
Cellulose 6 480 480 6 480 480 1920 
Mineral 3.5 280 280 3.5 280 280 1120 
Vitamin 1 80 80 1 80 80 320 
Met. 0.3 24 24 0.3 24 24 96 
Chol. Cl 0.2 16 16 0.2 16 16 64 
Tenox-
20A* 
0.1 8.0 8.0 0.1 8.0 8.0 32 
SAF  160   320  480 
FO    320   720 1040 
CO  240 80  480 80 880 
 
*Tenox-20A =  Source of TBHQ 
 32%  Glycerol 
 30%  Corn Oil 
 20%  TBHQ 
 15%  Propylene Glycol 
 3%  Citric Acid 
Amount of TBHQ = 0.02g/100g diet 
 
Sources of other dietary ingredients: 
-      Sucrose: product # 3900, Bioserv, lot # 1979.08, 10kg 
- Casein:  product # 1100, Bioserv, lot # 1589.01, 10kg 
- Choline Chloride: product # 30200, Harlan-Teklad, 500g 
- Tenox-20A: B&D Nutritional Ingredients, Inc., lot # 90114, 4oz 
- Salt Mix, AIN-76: product # F8505, Harlan-Teklad, lot # 30230, 4kg 
- Vitamin Mix, AIN-76A: product # 40077, Harlan-Teklad, Rx 993083, 1kg 
- Methionine: product # 1340, Bioserv, lot # 1806.02, 0.5kg 
- Cellulose: product # 3425, Bioserv, lot # 2667.01, 10kg 
- Corn Starch: product # 160170, Harlan-Teklad, lot # 96420, 25kg 
- Corn Oil: product # BLKC40, Traco Labs, Inc., lot # 01-010-07 
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LF vs HF diets 
 
A mouse requires 22mg Vit. E/ kg diet – NRC, Nutrient Requirements of Laboratory Animals, 1995 
 
      
       
LFSAF diet:    LFFO diet:   
= 2% SAF + 3% CO + Vitamin Mix  =4% FO + 1% CO + Vitamin Mix 
 = 38mg + 22.8mg + 100mg    = 76mg + 7.6mg + 100mg  
 = 160.8mg vit E/kg diet    = 183.6mg vit E/kg diet  
       
HFSAF diet:    HFFO diet:   
 =4% SAF + 6% CO + Vitamin Mix  =9% FO + 1% CO + Vitamin Mix 
 = 76mg + 45.6mg + 100mg    = 171mg + 7.6mg + 100mg  
 = 221.6mg vit E/kg diet     = 278.6mg vit E/kg diet  
       
       
 To equalize to 278.6g Vit E/kg diet need to add 0.006g Vit E/100g diet 
(6mg/100g) 
 
 
 
 
 
LF diets   
Casein = 20g x 4kcal/g = 80 
Sucrose = 42 x 4  = 168  
Starch = 21.9 x 4 = 87.6  
Lipids = 5 x 9 = 45  
 380.6 kcal/100g 
   
   
HF diets   
Casein = 20 x 4 = 80  
Sucrose = 37 x 4 = 148  
Starch = 21.9 x 4 = 87.6  
Lipids = 10 x 9 = 90  
 405.6 kcal/100g 
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EXPT. 5 (Parts I and II)  AICD – Cell Preparation  
 
DAY 0 
 
Take out T cell columns and buffer, Lympholyte M, and 10% FBS-RPMI and warm to room 
temperature. 
 
Necropsy 
Þ Fill 15ml tubes (one for each pair of animal) with 3ml of 10% FBS-RPMI  
Þ Assemble necessary equipment to take downstairs to basement: 
__labcoat 
__sterile scissors and forceps 
__gloves 
__EtOH 
__15ml tubes 
__keys 
Þ Asphyxiate mice (1 cage at a time) with CO2, then weigh mice per cage 
Þ Remove spleens aseptically and place 3 each in 15ml tubes 
 
Homogenization  
Þ Have the following equipment ready and in the hood: 
__sterile glass homogenizers (1 per 3 spleens) 
__5cc syringes 
__20 gauge needles 
__wire filters 
Þ Take out the bottom portion of the homogenizer from the sterile pouch –be careful to not touch any 
part of the homogenizer that will come in contact with the spleen 
Þ Pour the spleen and RPMI into the homogenizer 
Þ Homogenize with the top portion of the homogenizer until no spleen is visible (~5-7 strokes) 
Þ Pass homogenate through wire filter and 20 gauge needle to produce a single cell suspension 
· Screw a 20 gauge needle into the smaller opening of the filter 
· Screw a 10cc syringe into the larger opening of the filter 
· Remove the syringe plunger 
· Place assembly over 15cc tube 
· Pour homogenate into syringe and reinsert plunger to push all cells gently  through the filter 
Þ Fill tube with RPMI to wash 
Þ Centrifuge at 200g for 5 min 
Þ Aspirate supernatant 
 
RBC Removal 
Þ Resuspend cells in 3ml RPMI 
Þ Add an equal amount of Lympholyte M 
· Using a 2ml pipet, insert the tip into the bottom of the tube 
· Layer Lympholyte M underneath the cell suspension by slowly adding it to the bottom of the 
tube 
· Should have two distinct layers 
Þ Careful not to knock the tubes, centrifuge at 500g for 15 min with the brake turned OFF 
Þ Carefully remove from centrifuge 
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Þ Pipet off the lymphocyte layer (layer at the interface between the two layers) by using a slow swirling 
motion with the pipet  
Þ Place lymphocytes into a new 15cc tube, fill with RPMI and spin at 300g for 5 min 
Þ Aspirate 
Þ Resuspend cells in 2ml of 1x R&D wash buffer (see below) 
 
Column Loading for T Cell Purification 
Begin preparing columns during 15 min spin from above 
Þ Dilute 10x R&D wash buffer to 1x using sterile H2O (Will need 18ml/column) 
Þ Place columns in the R&D column rack 
Þ Remove the TOP cap first – to avoid drawing air into the bottom of the column 
Þ Remove the bottom cap 
Þ Rinse tip with EtOH while column drains into a waste receptacle (a 50cc tube) 
Þ Wash the column with 8ml of 1x wash buffer by applying the buffer to the top of the column 
Þ Replace the waste receptacle with a sterile 15cc tube 
Þ Apply the 2ml cell suspension to the top of the column.  The cells will enter the column and displace 
the wash buffer in the column.  This is collected in the 15cc tube. 
Þ Incubate the cells within the column at room temperature for 10 min 
Þ Elute the T cells from the column with 8ml of 1x wash buffer 
Þ Centrifuge the collected T cells at 200g for 5min 
Þ Aspirate and resuspend in 1ml of RPMI for counting 
 
Cell Counting with Trypan Blue 
Þ Add 198ul of Trypan Blue to a 12x75mm tube with cap 
Þ Mix the cells by pipetting 
Þ Add 2ul of cells to 198ul Trypan Blue and resuspend 
Þ Resuspend the cells without forming bubbles and add to one side of a hemocytometer 
Þ Add the next sample to the other side of the hemocytometer 
Þ Using a 10x or 20x magnification look at the entire grid to make sure the cells are evenly distributed 
Þ Count the viable cells in one of the four 16-square grids 
Þ Write down number and repeat 
Þ 1 16-square grid = ___x106 cells/ml.  Take the average of the two counts 
Þ Culture cells at 5 x 106/ml  
Calculation: 
(___x106 cells/ml)(1ml) = (5x106 cells/ml)(X) – 1ml 
 
Example: 
Count 7x106 cells/ml 
(20x106 cells/ml)(1ml) = (5x106 cells/ml)(X) 
 X = 4 – 1ml (volume cells are presently in), so add 3ml 10%FBS-RPMI to cell suspension 
 
Cell Culture 
Þ Have the following solutions prepared ahead of time (in the AM): 
· aCD3/aCD28  (1ug/ml / 5ug/ml) 
· aCD3/PMA  (1ug/ml / 0.5ng/ml) 
· PMA/Iono  (1ng/ml / 500nM) 
Þ Label 24-well plates (for large experiments label ahead of time) 
Þ Rinse plates containing incubating aCD3 from day before 
· Forcefully flick out aCD3 solution 
· Add 300ul RPMI to each well with a repeator pipet  
· Shake briefly and flick out 
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· Repeat 2 more times 
Þ Add 1ml stimuli solutions to the appropriate wells 
Þ Add 1ml cells at 5x106 cells/ml concentration to the wells with the solutions 
· Culture 2 wells / sample for each stimulation 
Þ Place in 37°C incubator for 48h incubation 
 
 
48 HOUR 
 
Þ Remove 24-well plates from incubator and harvest cells into 15cc tubes (2 wells/tube) 
Þ Centrifuge the collected T cells at 200g for 5min 
Þ Collect 2 x 500ul supernatant from the centrifuged samples and place each one of 500ul aliquots into 
a sterile microtube (Part I only) 
- Store supernatants at -80°C 
Þ Aspirate remaining sup. and resuspend cells in1ml RPMI for counting 
Þ Count cells in 200ul Trypan Blue 
Þ Bring cells to a concentration of 2x106 cells/ml 
Þ Add 1ml cells/well, 1 well per sample to 24-well plates containing 1ml/well RPMI 
Þ Place in 37°C incubator overnight 
 
 
DAY 3 
 
Þ Remove 24-well plates from incubator and harvest cells into 15cc tubes 
Þ Centrifuge the collected T cells at 200g for 5min 
Þ Aspirate sup. and resuspend cells in 1ml RPMI 
Þ Add an equal amount of Lympholyte M 
· Using a 2ml pipet, insert the tip into the bottom of the tube 
· Layer Lympholyte M underneath the cell suspension by slowly adding it to the bottom of the tube 
· Should have two distinct layers 
Þ Careful not to knock the tubes, centrifuge at 500g for 15 min with the brake turned OFF 
Þ Carefully remove from centrifuge 
Þ Pipet off the lymphocyte layer (layer at the interface between the two layers) by using a slow swirling 
motion with the pipet  
Þ Place lymphocytes into a new 15cc tube, fill with RPMI and spin at 300g for 5 min 
Þ Aspirate sup. 
Þ Resuspend cells in 1ml RPMI for counting 
Þ Count cells in 200ul Trypan Blue 
Þ Bring cells to a concentration of 2x106 cells/ml 
Þ Add 500ul cells/well, 1 well per sample to 24-well plates containing 500ul/well of initial (Day0) 
stimulus 
Þ Place in 37°C incubator 4-5h 
Þ Save remaining cells for mRNA extraction (Part II only) 
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STIMULI CALCULATIONS 
 
DAY 0 
 
aCD3  1ug/ml 
Make 50ml, 1ug/ml sol’n 
(1000ug/ml)(x) = (1ug/ml)(50000ul) 
 50ul stock into 50ml PBS  Þ   500ul/well 
 
aCD28  5ug/ml 
Make 50ml, 10ug/ml sol’n 
(1000ug/ml)(x) = (10ug/ml)(50000ul) 
 500ul stock into 49.5ml RPMI  Þ  1ml/well 
 
PMA  0.5ng/ml 
Make 50ml, 1ng/ml sol’n 
(2000ng/ml)(x) = (1ng/ml)(50000ul) 
25ul stock into 50ml RPMI  Þ  1ml/well 
 
PMA  1ng/ml 
Make 50ml, 2ng/ml sol’n 
(2000ng/ml)(x) = (2ng/ml)(50000ul) 
50ul stock  
 
Ionomycin  500nM 
Make 50ml, 1000uM sol’n  
(1000uM)(x) = (1uM)(50000ul) 
 50ul stock  
 
 
 
DAY 3 
 
aCD3  1ug/ml 
Make 50ml, 1ug/ml sol’n 
(1000ug/ml)(x) = (1ug/ml)(50000ul) 
 50ul stock into 50ml PBS  Þ   500ul/well 
 
aCD28  5ug/ml 
Make 50ml, 10ug/ml sol’n 
(1000ug/ml)(x) = (10ug/ml)(50000ul) 
 500ul stock into 49.5ml RPMI  Þ  500ul/well 
 
PMA  0.5ng/ml 
Make 50ml, 1ng/ml sol’n 
(2000ng/ml)(x) = (1ng/ml)(50000ul) 
25ul stock into 50ml RPMI  Þ  500ul/well 
Add both to 
50ml RPMI 
1ml/well 
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PMA  1ng/ml 
Make 50ml, 2ng/ml sol’n 
(2000ng/ml)(x) = (2ng/ml)(50000ul) 
50ul stock  
 
Ionomycin  500nM 
Make 50ml, 1000uM sol’n  
(1000uM)(x) = (1uM)(50000ul) 
 50ul stock  
 
 
 
Add both to 
50ml RPMI 
500ul/well 
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APPENDIX B-20 
 
EXPT. 6:  DHA AICD – Experiment Description 
 
Diets: 
1. Corn oil (5%) 
2. DHA ethyl esters (1% DHA + 4% corn oil) 
 
n = 6 mice per diet, pool 3 spleens per n = 36 mice total 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T cells 
aCD3/aCD28 (1ug/ml / 5ug/ml) 
aCD3/PMA (1ug/ml / 500nM) 
PMA/Iono (1ng/ml / 500nM) 
10% FBS-RPMI complete 
aCD3/aCD28  
aCD3/PMA  
PMA/Iono  
48h 
O/N 
5h 
APOPTOSIS analysis 
(AV/PI) 
3 stim. X 12 n = 36 samples 
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APPENDIX B-21 
 
EXPT. 6 Diet Composition and Preparation 
 
14g/mouse/day for 2 weeks  
18 mice per group x 14 d x 14g/m/d _____ 
  3528g per diet   Þ  make 3800g per diet 
 
2  Diet Groups: 
1. 5% Corn Oil 
2. 1% DHA ethyl ester + 4% CO 
 
 
 g/100g CO 3.8kg DHA 3.8kg TOTAL 
Casein 20 760 760 1520 
Sucrose 42 1596 1596 3192 
Starch 21.9 832.2 832.2 1664.4 
Cellulose 6 228 228 456 
Mineral 3.5 133 133 266 
Vitamin 1 38 38 76 
Met. 0.3 11.4 11.4 22.8 
Chol. Cl 0.2 7.6 7.6 15.2 
Tenox-20A* 0.1 3.8 3.8 7.6 
CO  190 152 342 
DHA  --- 38 38 
 
*Tenox-20A =  Source of TBHQ 
 32%  Glycerol 
 30%  Corn Oil 
 20%  TBHQ 
 15%  Propylene Glycol 
 3%  Citric Acid 
Amount of TBHQ = 0.02g/100g diet 
 
Sources of other dietary ingredients: 
-     Sucrose: product # 3900, Bioserv, lot # 1979.08, 10kg 
- Casein:  product # 1100, Bioserv, lot # 1589.01, 10kg 
- Choline Chloride: product # 30200, Harlan-Teklad, 500g 
- Tenox-20A: B&D Nutritional Ingredients, Inc., lot # 90114, 4oz 
- Salt Mix, AIN-76: product # F8505, Harlan-Teklad, lot # 30230, 4kg 
- Vitamin Mix, AIN-76A: product # 40077, Harlan-Teklad, Rx 993083, 1kg 
- Methionine: product # 1340, Bioserv, lot # 1806.02, 0.5kg 
- Cellulose: product # 3425, Bioserv, lot # 2667.01, 10kg 
- Corn Starch: product # 160170, Harlan-Teklad, lot # 96420, 25kg 
- Corn Oil: product # BLKC40, Traco Labs, Inc., lot # 01-010-07 
- 4 oz. Storage containers: # 02-544-216A, Fisher Sci., 300/cs 
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Vitamin E content of diets 
 
A mouse requires 22mg Vit. E/ kg diet – NRC, Nutrient Requirements of Laboratory Animals, 1995 
 
Vitamin Mix: 
10g vit E/kg Vitamin mix 
 = 1% vit E 
 = 0.01g vit E/100g diet 
 = 100mg vit E/kg diet 
 
Corn Oil (5%): 
896ppm = 896 mg vit E/kg CO 
 since 5% of diet 
 = 44.80mg vit E/kg diet 
 
Corn Oil (4%): 
896ppm = 896 mg vit E/kg CO 
 since 4% of diet 
 = 35.84mg vit E/kg diet 
 
DHA Ethyl Ester: 
3.0mg vit E/g SAF 
 = 3000mg vit E/kg DHA 
 since 1% of diet 
 = 30mg vit E/kg diet 
 
 
Total Vitamin E in each diet: 
 
CO diet: 
= 5% CO + Vitamin Mix 
= 44.80mg  + 100mg 
= 144.80mg vit E/kg diet 
 
DHA diet: 
=1% DHA  + 4% CO + Vitamin Mix 
= 30mg + 35.84mg + 100mg 
= 165.84mg vit E/kg diet 
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APPENDIX B-22 
 
EXPT. 6 Cell Preparation 
 
DAY 0 
 
Take out T cell columns and buffer, Lympholyte M, and 10% FBS-RPMI and warm to room 
temperature. 
 
Necropsy 
Þ Fill 15ml tubes (one for each set of 3 animals) with 3ml of 10% FBS-RPMI  
Þ Assemble necessary equipment to take downstairs to basement: 
__labcoat 
__sterile scissors and forceps 
__gloves 
__EtOH 
__15ml tubes 
__keys 
Þ Asphyxiate mice (1 cage at a time) with CO2, then weigh mice in sets of three 
Þ Remove spleens aseptically and place 3 each in 15cc tubes 
 
Homogenization  
Þ Have the following equipment ready and in the hood: 
__sterile glass homogenizers (1 per 3 spleens) 
__5cc syringes 
__20 gauge needles 
__wire filters 
Þ Take out the bottom portion of the homogenizer from the sterile pouch –be careful to not touch any 
part of the homogenizer that will come in contact with the spleen 
Þ Pour the spleens and RPMI into the homogenizer 
Þ Homogenize with the top portion of the homogenizer until no spleen is visible (~5-7 strokes) 
Þ Pass homogenate through wire filter and 20 gauge needle to produce a single cell suspension 
· Screw a 20 gauge needle into the smaller opening of the filter 
· Screw a 5cc syringe into the larger opening of the filter 
· Remove the syringe plunger 
· Place assembly over 15cc tube 
· Pour homogenate into syringe and reinsert plunger to push all cells gently  through the filter 
Þ Fill tube with RPMI to wash 
Þ Centrifuge at 200xg for 5 min 
Þ Aspirate supernatant 
 
RBC Removal 
Þ Resuspend cells in 3ml RPMI 
Þ Add an equal amount of Lympholyte M 
· Using a 2ml pipet, insert the tip into the bottom of the tube 
· Layer Lympholyte M underneath the cell suspension by slowly adding it to the bottom of the 
tube 
· Should have two distinct layers 
Þ Careful not to knock the tubes, centrifuge at 500xg for 15 min with the brake turned OFF 
Þ Carefully remove from centrifuge 
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Þ Pipet off the lymphocyte layer (layer at the interface between the two layers) by using a slow swirling 
motion with the pipet  
Þ Place lymphocytes into a new 15cc tube, fill with RPMI and spin at 300xg for 5 min 
Þ Aspirate 
Þ Resuspend cells in 1ml of 1x R&D wash buffer (see below) 
 
Column Loading for T Cell Purification 
Begin preparing columns during 15 min spin from above 
Þ Dilute 10x R&D wash buffer to 1x using sterile H2O (Will need 18ml/column) 
Þ Place columns in the R&D column rack 
Þ Remove the TOP cap first – to avoid drawing air into the bottom of the column 
Þ Remove the bottom cap 
Þ Rinse tip with EtOH while column drains into a waste receptacle (a beaker) 
Þ Wash the column with 6ml of 1x wash buffer by applying the buffer to the top of the column 
Þ Replace the waste receptacle with a sterile 50cc tube 
Þ Apply the 1ml cell suspension to the top of the column.  The cells will enter the column and displace 
the wash buffer in the column.  This is collected in the 50cc tube. 
Þ Incubate the cells within the column at room temperature for 10 min 
Þ Elute the T cells from the column with 8ml of 1x wash buffer 
Þ Centrifuge the collected T cells at 200xg for 5min 
Þ Aspirate and resuspend in 1ml of RPMI for counting 
 
Cell Counting with Trypan Blue 
4. Add 198ul of Trypan Blue to a 12x75mm tube with cap 
Þ Mix the cells by pipetting 
Þ Add 2ul of cells to 198ul Trypan Blue and resuspend 
Þ Resuspend the cells without forming bubbles and add to one side of a hemocytometer 
Þ Add the next sample to the other side of the hemocytometer 
Þ Using a 10x or 20x magnification look at the entire grid to make sure the cells are evenly distributed 
Þ Count the viable cells in one of the four 16-square grids 
Þ Write down number and repeat 
Þ 1 16-square grid = ___x106 cells/ml.  Take the average of the two counts 
Þ Culture cells at 5 x 106/ml  
Calculation: 
(___x106 cells/ml)(1ml) = (5x106 cells/ml)(X) – 1ml 
 
Example: 
Count 7x106 cells/ml 
(20x106 cells/ml)(1ml) = (5x106 cells/ml)(X) 
 X = 4 – 1ml (volume cells are presently in), so add 3ml 10%FBS-RPMI to cell suspension 
 
Cell Culture 
Þ Have the following solutions prepared ahead of time (in the AM): 
· aCD3/aCD28  (1ug/ml / 5ug/ml) 
· aCD3/PMA  (1ug/ml / 0.5ng/ml) 
· PMA/Iono  (1ng/ml / 500nM) 
Þ Label 24-well plates (for large experiments label ahead of time) 
Þ Rinse plates containing incubating aCD3 from day before 
· Carefully  aspirate aCD3 solution from each well – tilt plates so as to avoid touching well 
bottoms with pastuer pipet 
· Add 300ul RPMI to each well with a repeator pipet  
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· Shake briefly and aspirate 
· Repeat 2 more times 
Þ Add 1ml stimuli solutions to the appropriate wells 
Þ Add 1ml cells at 5x106 cells/ml concentration to the wells with the solutions 
· Culture 2 wells / sample for each stimulation 
Þ Place in 37°C incubator for 48h incubation 
 
 
48 HOUR 
 
Þ Remove 24-well plates from incubator and harvest cells into 15cc tubes (2 wells/tube) 
Þ Centrifuge the collected T cells at 200xg for 5min 
Þ Aspirate  sup. and resuspend cells in1ml RPMI for counting 
Þ Count cells in 200ul Trypan Blue 
Þ Bring cells to a concentration of 3x106 cells/ml 
Þ Add 1ml cells/well, 2 wells per sample to 24-well plates containing 1ml/well RPMI 
Þ Place in 37°C incubator overnight 
Þ Coat plates with aCD3 (1ug/ml) for Day 3, store @4°C overnight 
 
 
DAY 3 
 
Þ Prepare stimulation solutions for reactivation (aCD28, PMA/Iono) 
Þ Remove 24-well plates from incubator and harvest cells into 15cc tubes (2 wells/tube) 
Þ Centrifuge the collected T cells at 200xg for 5min 
Þ Aspirate sup. and resuspend cells in 1ml RPMI 
Þ Add an equal amount of Lympholyte M 
· Using a 2ml pipet, insert the tip into the bottom of the tube 
· Layer Lympholyte M underneath the cell suspension by slowly adding it to the bottom of the tube 
· Should have two distinct layers 
Þ Careful not to knock the tubes, centrifuge at 500xg for 15 min with the brake turned OFF 
Þ Carefully remove from centrifuge 
Þ Pipet off the lymphocyte layer (layer at the interface between the two layers) by using a slow swirling 
motion with the pipet  
Þ Place lymphocytes into a new 15cc tube, fill with RPMI and spin at 300xg for 5 min 
Þ Aspirate sup. 
Þ Resuspend cells in 2ml RPMI (should be ~ 2x106 cells/ml) 
Þ Rinse plates containing incubating aCD3 from day before 
· Carefully aspirate aCD3 solution from each well – tilt plates so as to avoid touching well bottoms 
with pastuer pipet 
· Add 300ul RPMI to each well with a repeator pipet  
· Shake briefly and aspirate 
· Repeat 2 more times 
Þ Add 500ul cells/well, 1 well per sample to 24-well plates containing 500ul/well of initial (Day0) 
stimulus 
Þ Place in 37°C incubator 4-5h 
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STIMULI CALCULATIONS 
 
DAY 0 
 
aCD3  1ug/ml 
Make 25ml, 1ug/ml sol’n 
(1000ug/ml)(x) = (1ug/ml)(25000ul) 
 25ul stock into 25ml PBS  Þ   500ul/well 
 
aCD28  5ug/ml 
Make 25ml, 10ug/ml sol’n 
(1000ug/ml)(x) = (10ug/ml)(25000ul) 
 250ul stock into 24.75ml RPMI  Þ  1ml/well 
 
PMA  0.5ng/ml 
Make 25ml, 1ng/ml sol’n 
(2000ng/ml)(x) = (1ng/ml)(25000ul) 
12.5ul stock into 25ml RPMI  Þ  1ml/well 
 
PMA  1ng/ml 
Make 25ml, 2ng/ml sol’n 
(2000ng/ml)(x) = (2ng/ml)(25000ul) 
25ul stock  
 
Ionomycin  500nM 
Make 25ml, 1000uM sol’n  
(1000uM)(x) = (1uM)(25000ul) 
 25ul stock  
 
 
 
DAY 3 
 
aCD3  1ug/ml 
Make 13ml, 1ug/ml sol’n 
(1000ug/ml)(x) = (1ug/ml)(13000ul) 
 13ul stock into 13ml PBS  Þ   500ul/well 
 
aCD28  5ug/ml 
Make 13ml, 10ug/ml sol’n 
(1000ug/ml)(x) = (10ug/ml)(13000ul) 
 130ul stock into 13ml RPMI  Þ  500ul/well 
 
PMA  0.5ng/ml 
Make 13ml, 1ng/ml sol’n 
(2000ng/ml)(x) = (1ng/ml)(13000ul) 
6.5ul stock into 13ml RPMI  Þ  500ul/well 
Add both to 
25ml RPMI 
1ml/well 
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PMA  1ng/ml 
Make 13ml, 2ng/ml sol’n 
(2000ng/ml)(x) = (2ng/ml)(13000ul) 
13ul stock  
 
Ionomycin  500nM 
Make 13ml, 1000uM sol’n  
(1000uM)(x) = (1uM)(13000ul) 
 13ul stock  
 
Add both to 
13ml RPMI 
500ul/well 
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APPENDIX B-23 
 
EXPT. 7 – Th1 AICD – Experimental Description 
 
Diets: 
1. 5% Corn oil 
2. 4% Fish oil (+ 1% corn oil) 
 
4 mice/n, n = 6/diet group = 24 mice/diet group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Intracellular cytokine staining (IFNg, IL-4) 
    Apoptosis (AICD) 
 
n=6 /diet = 12 samples for  each analysis X 2 (for MS and FBS) = 48 TOTAL samples 
 
Each n will have 4 outcomes: 
1. FBS – AICD 
2. FBS – cytokines 
3. MS – AICD 
4. MS – cytokines 
 
CD4+ T cells 
Th1 cocktail + PMA/Iono 
in 5% homologous MS 
Th1 cocktail + PMA/Iono 
in 5% homologous MS 
d 0-2 
d 2-5 
IL-2 + IL-12 
in 5% MS 
IL-2 + IL-12 
in 5% FBS 
5h                        
Reactivate (PMA/Iono)   
+/- monensin 
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APPENDIX B-24 
 
EXPT. 7 Diet Composition and Preparation 
 
14g/mouse/day for 2 weeks  
24 mice per group x 14 d x 14g/m/d _____ 
  4704 g per diet   Þ  make 5000 g per diet 
 
2  Diet Groups: 
 
1. 5% Corn Oil 
2. 4% Menhaden fish oil + 1% CO 
  
Use Basal Mix (95/5) from Harlan-Teklad (see ingredients below) 
  * use 950 g/kg diet in conjunction with 50 g of fat source 
 
 for 5000 g diet = 4750 g Basal Mix + 250 g fat source 
 
CO Diet 
CO lot # 856-03 
FO Diet 
FO lot # L951088B 
Basal Mix 4750 g Basal Mix 4750 g 
CO 250 g FO (4%) 200 g 
  CO (1%) 50 g 
 
 
 
Basal Mix (95/5)  Harlan-Teklad 
 
Ingredient g/kg 
Casein 210.53 
DL-methionine 3.16 
Sucrose 441.89 
Corn Starch 231.58 
Cellulose 63.16 
Mineral Mix, AIN-76 36.84 
Vitamin Mix, AIN-76 10.53 
Choline Chloride 2.11 
TBHQ 0.21 
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APPENDIX B-25 
 
EXPT. 7  -  Th1 Polarization 
 
Reagents 
--  5% FBS-RPMI 
 per 500 ml: 
· 500 ml RPMI-1640 HEPES (Irvine Scientific #9159) 
· 25 ml Heat inactivated FBS (Irvine Scientific #3003) 
· 5.5 ml L-Glut (Gibco #3050-061) 
· 5.5ml Pen-Strep. (Gibco #15140-148) 
· 100 ml  [10 mM] 2-ME (Sigma #M-7522) 
--  5% homologous mouse serum (MS)-RPMI 
 5% (2.5% MS + 2.5% FBS) 
per 150 ml: 
· 150 ml RPMI-1640 HEPES  
· 3.75 ml heat inactivated MS-CO/MS-FO 
· 3.75 ml heat inactivated FBS 
· 1.5 ml L-Glut  
· 1.5 ml Pen-Strep. 
· 30 ml  [10 mM] 2-ME  
--  Lympholyte-M (Cedarlane #CL5031) 
--  CD4+ T cell enrichment columns 
Mini Columns (can load up to 100 x 106 cells) (R&D Systems #MCD43) 
Small Columns (can load up to 200 x 106 cells) (R&D Systems #MCD4C-1000) 
--  Phorbal Myristate Acetate (PMA) (Sigma #P8139) 
--  Ionomycin (Calbiochem #407952) 
--  recombinant mouse IL-2 (Pharmingen #554592) 
--  recombinant mouse IL-12 (R&D Systems #402-ML) 
--  rat anti-mouse IL-4 (11B.11) (gift from NCI) 
 
DAY 0 
Take out CD4+ T cell columns and buffer, Lympholyte M, and 10% FBS-RPMI and warm to room 
temperature. 
 
Necropsy 
Þ   Fill 15ml tubes (one per 4 animals) with 3ml of RPMI  
Þ Assemble necessary equipment to take down to basement: 
__scissors and forceps 
__gloves 
__EtOH 
__15ml tubes 
__keys 
Þ Asphyxiate mice (1 cage at a time) with CO2 
Þ Remove spleens aseptically, removing as much fat as possible, and place in 15ml tubes (4 
spleens/tube) 
 
Homogenization  
Þ Have the following equipment ready and in the hood: 
__sterile glass homogenizers  
__5cc syringes 
__20 gauge needles 
__wire mesh filters 
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Þ Take out the bottom portion of the homogenizer from the sterile pouch –be careful to not touch any 
part of the homogenizer that will come in contact with the spleen 
Þ Pour the spleen and RPMI into the homogenizer 
Þ Homogenize with the top portion of the homogenizer until no spleen is visible (~5-7 strokes) 
Þ Pass homogenate through wire filter and 20 gauge needle to produce a single cell suspension 
· Screw a 20 gauge needle into the smaller opening of the filter 
· Screw a 5cc syringe into the larger opening of the filter 
· Remove the syringe plunger 
· Place assembly over 15ml tube 
· Pour homogenate into syringe and reinsert plunger to push all cells gently through the filter 
Þ Fill tube with RPMI to wash 
Þ Centrifuge at 200xg for 5 min 
Þ Aspirate supernatant 
 
RBC Removal 
Þ Resuspend cells in 3ml RPMI 
Þ Add an equal amount of Lympholyte M 
· Using a 2ml pipet, insert the tip into the bottom of the tube 
· Layer Lympholyte M underneath the cell suspension by slowly adding it to the  
· bottom of the tube 
· Should have two distinct layers 
Þ Careful not to knock the tubes, centrifuge at 500xg for 15 min with the brake turned OFF 
Þ Carefully remove from centrifuge 
Þ Pipet off the lymphocyte layer (layer at the interface between the two layers) by using a slow swirling 
motion with the pipet  
Þ Place lymphocytes into a new 15ml tube, fill with RPMI and spin at 300xg for 5 min 
Þ Resuspend cells in 1ml of 1x R&D column wash buffer (see below) 
 
Column Loading for CD4+ T Cell Enrichment 
Begin preparing columns during 15 min spin from above 
Þ Dilute 10x R&D column wash buffer to 1x using sterile H2O (Will need 50ml/column) 
Þ Place columns in the R&D column rack 
Þ Remove the TOP cap first – to avoid drawing air into the bottom of the column 
Þ Remove the bottom cap 
Þ Rinse tip with EtOH while column drains into a waste receptacle  
Þ Wash the column with 10ml of column wash buffer by applying the buffer to the top of the column 
Þ Replace the waste receptacle with a sterile 50ml tube 
Þ Add contents of 1 vial of monoclonal antibody cocktail (0.5ml) to each tube of cells 
Þ Incubate at room 15 min   
Þ Wash cells 2x with 10ml column wash buffer, 300xg for 5 min 
Þ Resuspend cells in 2ml column wash buffer 
Þ Apply the 2ml cell suspension to the top of the column.  The cells will enter the column and displace 
the wash buffer in the column.  This is collected in the 50ml tube. 
Þ Incubate the cells within the column at room temperature for 10 min 
Þ Elute the T cells from the column with 10ml of buffer 
Þ Centrifuge the collected CD4+ T cells at 200xg for 5min 
Þ Resuspend in 1ml of 10% FBS-RPMI for counting 
 
Cell Counting with Trypan Blue 
Þ Add 198ml of Trypan Blue to a 12x75mm tube with cap 
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Þ Mix the cells by pipetting 
Þ Add 2? l of cells to 198ml of Trypan Blue and resuspend 
Þ Resuspend the cells without forming bubbles and add to one side of a hemocytometer 
Þ Add the next sample to the other side of the hemocytometer 
Þ Using a 10x or 20x magnification look at the entire grid to make sure the cells are evenly distributed 
Þ Count the viable cells in one of the four 16-square grids 
Þ Write down number and repeat 
Þ 1 16-square grid = ___x106 cells/ml.  Take the average of the two counts 
Þ Culture cells at 5 X 106 cells/ml 
Calculation:  
(___ x 106 cells/ml)(1ml) = (5 x 106 cells/ml)(X) – 1ml 
 
Example: 
Counted 10x106 cells/ml 
(10 x 106 cells/ml)(1ml) = (5 x 106 cells/ml)(X)-1ml 
X = 2ml –1ml (volume cells are presently in), so add 1ml 5%FBS/MS to cell suspension 
 
Cell Culture for Th1 Polarization 
 
 
 
 
 
 
 
Þ Prepare solution containing Th1 cocktail plus desired stimulus (ex. PMA/Iono) 
 
Th1 Cocktail 
10 mg/ml aIL-4 
20 ng/ml rmIL-2 
5 ng/ml rmIL-12 
 
Þ Label 24-well plates (for large experiments label ahead of time) 
Þ Add 1ml/well Th1 Cocktail/stimulus solution to the appropriate wells 
Þ Add 1ml of cells at [5 x 106 cells/ml] to the wells with the solution 
Þ Incubate at 37°C for 2 d  
 
DAY 2 and DAY 3 
 
Þ Remove 24-well plates from incubator, pooling cells as needed 
Þ Harvest cells and wash once with RPMI at 200xg 
Þ Resuspend cells in 5%FBS/MS at volume equal to number of wells that will be cultured        
(i.e. if culturing 2 wells, then resuspend in 2ml) 
Þ Prepare  rmIL-2 + rmIL-12 solution 
20ng/ml rmIL-2 
5ng/ml rmIL-12 
 
Þ Add 1ml rmIL-2 + rmIL-12 solution per well and 1ml cells per well to 24-well plates 
Þ Incubate at 37°C until D3/D5 
 
Reactivation 
Th1 
cocktail/stimulus 
CD4+ T cells 
0-2 d d 2-5  
rmIL-2 
rmIL-12 
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DAY 5 
 
Þ Remove 24-well plates from incubator, pooling cells as needed 
Þ Harvest cells and wash once with RPMI at 200xg 
Þ Resuspend cells in 3ml RPMI 
Þ Add an equal amount of Lympholyte M (see procedure from above) 
Þ Careful not to knock the tubes, centrifuge at 500xg for 15 min with the brake turned OFF 
Þ Carefully remove from centrifuge 
Þ Pipet off the lymphocyte layer 
Þ Place lymphocytes into a new 15ml tube, fill with RPMI and spin at 300xg for 5 min 
Þ Resuspend cells in 1ml of 5%FBS/MS for counting with Trypan Blue (see above) 
Þ Bring cell suspension to [2 x 106 cell/ml] 
Þ Reactivate 500ml cells/well in 500ml/well of initial D0 stimulus, i.e. PMA/Iono (w/o cytokines)*** 
Þ Incubate at 37°C for 4-5h 
 
***For cells designated for intracellular cytokine staining, add Golgistop (monensin) to PMA/Iono (see 
Intracellular Cytokine Staining protocol) to cultures at D5 reactivation 
 
 
 
STIMULI CALCULATIONS 
 
DAY 0 
 
**Make 14 ml of 3 solutions of PMA/Iono + Th1 Cocktail (1 in each medium:  
5% FBS, 5%MS-CO, 5%MS-FO) 
PMA/Iono: 
PMA (1 ng/ml) 
(2000 ng/ml)(X) = (2 ng/ml)(14000 ml) 
  14 ml stock 
 
Ionomycin (500 nM) 
(1000 mM)(X) = (1 mM)(14000 ml) 
  14 ml stock 
 
Th1 Cocktail: 
rhIL-2 (20 ng/ml) 
 (20,000 ng/ml)(X) = (40 ng/ml)(14000 ml) 
  28 ml stock 
 
rhIL-12 (5 ng/ml) 
 (50,000 ng/ml)(X) = (10 ng/ml)(14000 ml) 
  2.8 ml stock 
 
aIL-4 (10 mg/ml) 
 (17,000 mg/ml)(X) = (20 mg/ml)(14000 ml) 
  16.5 ml stock 
 
Add all to 14 ml 
 5% FBS 
 5% MS-CO 
5% MS-FO 
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DAY 2 & 3 
 
**Make 24 ml of rmIL-2 + rmIL-12 solution (in 5% FBS) 
 
rhIL-2 (20 ng/ml) 
 (20,000 ng/ml)(X) = (40 ng/ml)(24000 ml) 
  48 ml stock 
 
rhIL-12 (5 ng/ml) 
 (50,000 ng/ml)(X) = (10 ng/ml)(24000 ml) 
  4.8 ml stock 
 
**Make 14 ml of 2 solutions of rmIL-2 + rmIL-12 (1 in each medium: 5% MS-CO and 5% MS-FO) 
 
rhIL-2 (20 ng/ml) 
 (20,000 ng/ml)(X) = (40 ng/ml)(14000 ml) 
  28 ml stock 
 
rhIL-12 (5 ng/ml) 
 (50,000 ng/ml)(X) = (10 ng/ml)(14000 ml) 
  2.8 ml stock 
 
 
Add both to 24 ml 5% FBS 
Add both to 14 ml 5% MS-CO and 
5% MS-FO 
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APPENDIX B-26 
 
Intracellular Cytokine Staining 
 
Reagents and Equipment: 
 
§ FC Block  (0.5 mg/ml) Pharmingen #553142 
-  dilute to 5 mg/ml in Staining Buffer 
§ aIFN? -FITC  (0.5 mg/ml) Pharmingen #554411 
-- dilute to 2.4 mg/ml in 1x Perm/Wash solution 
§ aIL-4-PE  (0.2 mg/ml) Pharmingen #554435 
--dilute to 0.3 mg/ml in 1x Perm/Wash solution 
§ IgG1 –FITC  (0.5 mg/ml) Pharmingen #554684 
-- dilute to 2.4 mg/ml in 1x Perm/Wash solution 
§ IgG1 –PE  (0.2 mg/ml) Pharmingen #554685 
-- dilute to 0.3 mg/ml in 1x Perm/Wash solution 
§ BD Cytofix/Cytoperm Kit with Golgistop   Pharmingen #554715 
Contents: 
--Cytofix/cytoperm solution 
--Perm/Wash solution, 10x concentrate (dilute 1:10 in dH2O prior to use) 
--Golgistop (monensin) 
§ Staining Buffer (pH 7.4-7.6), filtered with 0.2mM pore membrane: 
-  PBS without Mg2+ or Ca2+ 
-  1% heat inactivated FBS 
-  0.09% NaN3  
§ 2.0ml microtubes 
§ 12x75mm Polystyrene FACS tubes (for the flow cytometer) 
§ Aluminum foil 
 
 
Protocol: 
 
Reactivation of cells with Golgistop (monensin) 
In order to induce measurable accumulation of intracellular cytokines, cells must be reactivated in the 
presence of a golgi trafficking inhibitor such as monensin or brefeldin-A 
 
See also Th1 Polarization protocol for reactivation 
DAY 5 
· Remove 24-well plates from incubator 
· Harvest cells and wash once with RPMI at 200xg 
· Resuspend cells in 3ml RPMI 
· Add an equal amount of Lympholyte M (see procedure from Th1 Polarization protocol) 
· Careful not to knock the tubes, centrifuge at 500xg for 15 min with the brake turned OFF 
· Carefully remove from centrifuge 
· Pipet off the lymphocyte layer 
· Place lymphocytes into a new 15ml tube, fill with RPMI and spin at 300xg for 5 min 
· Aspirate 
· Resuspend cells in 1ml of 10%FBS-RPMI for counting with Trypan Blue  
· Bring cell suspension to [2 x 106 cell/ml] 
· Prepare Reactivation solution containing initial D0 stimulus (without cytokines) and Golgistop.  Use 
4ml Golgistop per 6ml cell culture 
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Since we dilute Reactivation solution 1:1 with cell suspension in each well prepare  
8ml Golgistop/6ml Reactivation solution 
NOTE:  Golgistop is toxic so keep in cell culture < 12h 
· Add 500ml/well of Reactivation/Golgistop solution and 500ml/well cells 
· Incubate at 37°C for 4-5h 
 
Staining  -  4-5h post-reactivation 
NOTE:  Keep samples on ice following harvesting 
· Harvest cells from 24-well plates and add to 2.0ml microtubes (one well/tube) 
· Centrifuge cells at 200xg, 5 min @ 4°C. Aspirate supernatant leaving cell pellets behind. 
· Resuspend cells in 100ml Fc Block (5mg/ml).  Incubate on ice 15 min 
· Centrifuge cells at 200xg, 5 min @ 4°C. Aspirate supernatant leaving cell pellets behind. 
· Resuspend cells in 250ml Cytofix/Cytoperm solution.  Incubate on ice 20 min 
· Wash 2x in 1x Perm/Wash solution (1ml/tube) 
COMPLETE FOLLOWING IN DARK 
· Resuspend fixed and permeabilized cells in 100ml of appropriate fluorochrome-conjugated anti-
cytokine Ab solution or appropriate negative control. Incubate on ice 30 min 
· Wash 2x in 1x Perm/Wash solution (1ml/tube) 
· Resuspend cells in 500ml Staining Buffer 
· Store @ 4°C, covered in Al foil until analysis 
· Immediately prior to Flow cytometric analysis, transfer stained cells to 12x75mm polystyrene FACS 
tubes. 
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APPENDIX B-27 
 
EXPT. 8 – Th1 Raft – Experimental Description  
 
Diets:    
1 - 5% Corn oil  
2 - 4% FO (+ 1% corn oil) 
 
10 mice/n, n = 3/diet group = 30 mice/diet group; 60 mice total 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**Take 1/2 cells for DAY 0 (~25 x 106).  Divide remaining 1/2 between FBS and MS cultures 
 
Analyses:  For Raft and Soluble fractions 
- FA composition following TLC separation of PL 
- cholesterol 
 
DAY 0 analyses = CO & FO, n=3, 6 samples (of rafts and soluble) 
 
DAY 5 analyses =   
 
1 – FBS (for CO-fed mice)  n=3 
2 – FBS (for FO-fed mice)  n=3 
3 – MS-CO                          n=3 
4 – MS-FO                           n=3 
 
CD4+ T cells 
Th1 Polarization 
 
5 days 
**DAY 0 Isolate Raft and Soluble 
membrane fractions 
Cultured in: 
 
1- FBS 
2- MS-CO 
3- MS-FO 
DAY 5 
Isolate Raft and Soluble 
membrane fractions 
12 samples 
(of rafts and soluble) 
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APPENDIX B-28 
 
EXPT. 8 Diet Composition and Preparation 
14g/mouse/day for 2 weeks  
30 mice per group x 14 d x 14g/m/d _____ 
  5880 g per diet   Þ  make 6100 g per diet 
 
2  Diet Groups: 
1. 5% Corn Oil 
2. 4% Menhaden fish oil + 1% CO 
  
Use Basal Mix (95/5) from Harlan-Teklad (see ingredients below) 
  * use 950 g/kg diet in conjunction with 50 g of fat source 
 
 for 6100 g diet = 5795 g Basal Mix + 305 g fat source 
 
CO Diet 
CO lot # 856-AR 
FO Diet 
FO lot # L97029BB 
Basal Mix 5795 g Basal Mix 5795 g 
CO 305 g FO (4%) 244 g 
  CO (1%) 61 g 
 
 
 
Basal Mix (95/5)  Harlan-Teklad 
 
Ingredient g/kg 
Casein 210.53 
DL-methionine 3.16 
Sucrose 441.89 
Corn Starch 231.58 
Cellulose 63.16 
Mineral Mix, AIN-76 36.84 
Vitamin Mix, AIN-76 10.53 
Choline Chloride 2.11 
TBHQ 0.21 
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APPENDIX B-29 
 
EXPT. 8  -  Th1 Raft Analysis 
 
Reagents 
--  5% FBS-RPMI 
 per 500 ml: 
· 500 ml RPMI-1640 HEPES (Irvine Scientific #9159) 
· 25 ml Heat inactivated FBS (Irvine Scientific #3003) 
· 5.5 ml L-Glut (Gibco #3050-061) 
· 5.5ml Pen-Strep. (Gibco #15140-148) 
· 100 ml  [10 mM] 2-ME (Sigma #M-7522) 
--  5% homologous mouse serum (MS)-RPMI 
 5% (2.5% MS + 2.5% FBS) 
per 150 ml: 
· 150 ml RPMI-1640 HEPES  
· 3.75 ml heat inactivated MS-CO/MS-FO 
· 3.75 ml heat inactivated FBS 
· 1.5 ml L-Glut  
· 1.5 ml Pen-Strep. 
· 30 ml  [10 mM] 2-ME  
--  Lympholyte-M (Cedarlane #CL5031) 
--  CD4+ T cell enrichment columns 
Mini Columns (can load up to 100 x 106 cells) (R&D Systems #MCD43) 
Small Columns (can load up to 200 x 106 cells) (R&D Systems #MCD4C-1000) 
--  Phorbal Myristate Acetate (PMA) (Sigma #P8139) 
--  Ionomycin (Calbiochem #407952) 
--  recombinant mouse IL-2 (Pharmingen #554592) 
--  recombinant mouse IL-12 (R&D Systems #402-ML) 
--  rat anti-mouse IL-4 (11B.11) (gift from NCI) 
 
DAY 0 
 
Take out CD4+ T cell columns and buffer, Lympholyte M, and 10% FBS-RPMI and warm to room 
temperature. 
 
Necropsy 
Þ Fill 15ml tubes (one per 4 animals) with 3ml of RPMI  
Þ Assemble necessary equipment to take down to basement: 
__scissors and forceps 
__gloves 
__EtOH 
__15ml tubes 
__keys 
Þ Asphyxiate mice (1 cage at a time) with CO2 
Þ Remove spleens aseptically, removing as much fat as possible, and place in 15ml tubes (4 
spleens/tube) 
 
Homogenization  
Þ Have the following equipment ready and in the hood: 
__sterile glass homogenizers  
__5cc syringes 
__20 gauge needles 
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__wire mesh filters 
Þ Take out the bottom portion of the homogenizer from the sterile pouch –be careful to not touch any 
part of the homogenizer that will come in contact with the spleen 
Þ Pour the spleen and RPMI into the homogenizer 
Þ Homogenize with the top portion of the homogenizer until no spleen is visible (~5-7 strokes) 
Þ Pass homogenate through wire filter and 20 gauge needle to produce a single cell suspension 
q Screw a 20 gauge needle into the smaller opening of the filter 
q Screw a 5cc syringe into the larger opening of the filter 
q Remove the syringe plunger 
q Place assembly over 15ml tube 
q Pour homogenate into syringe and reinsert plunger to push all cells gently through the filter 
Þ Fill tube with RPMI to wash 
Þ Centrifuge at 200xg for 5 min 
Þ Aspirate supernatant 
 
RBC Removal 
Þ Resuspend cells in 6ml RPMI.  Pool all 3 tubes/n, then split into 2 tubes (3ml/tube) 
Þ Add an equal amount of Lympholyte M 
q Using a 2ml pipet, insert the tip into the bottom of the tube 
q Layer Lympholyte M underneath the cell suspension by slowly adding it to the  
 bottom of the tube 
q Should have two distinct layers 
Þ Careful not to knock the tubes, centrifuge at 500xg for 15 min with the brake turned OFF 
Þ Carefully remove from centrifuge 
Þ Pipet off the lymphocyte layer (layer at the interface between the two layers) by using a slow swirling 
motion with the pipet  
Þ Place lymphocytes into a new 15ml tube, fill with RPMI and spin at 300xg for 5 min 
Þ Resuspend cells in 1ml of 1x R&D column wash buffer (see below) 
 
Column Loading for CD4+ T Cell Enrichment 
Begin preparing columns during 15 min spin from above 
Þ Dilute 10x R&D column wash buffer to 1x using sterile H2O (Will need 50ml/column) 
Þ Place columns in the R&D column rack 
Þ Remove the TOP cap first – to avoid drawing air into the bottom of the column 
Þ Remove the bottom cap 
Þ Rinse tip with EtOH while column drains into a waste receptacle  
Þ Wash the column with 10ml of column wash buffer by applying the buffer to the top of the column 
Þ Replace the waste receptacle with a sterile 50ml tube 
Þ Add contents of 1 vial of monoclonal antibody cocktail (0.5ml) to each tube of cells 
Þ Incubate at room 15 min   
Þ Wash cells 2x with 10ml column wash buffer, 300xg for 5 min 
Þ Resuspend cells in 2ml column wash buffer 
Þ Apply the 2ml cell suspension to the top of the column.  The cells will enter the column and displace 
the wash buffer in the column.  This is collected in the 50ml tube. 
Þ Incubate the cells within the column at room temperature for 10 min 
Þ Elute the T cells from the column with 10ml of buffer 
Þ Centrifuge the collected CD4+ T cells at 200xg for 5min 
Þ Resuspend in 1ml of 10% FBS-RPMI for counting (combine duplicate tubes for ea. n = 6 tubes) 
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Cell Counting with Trypan Blue 
Þ Add 198ml of Trypan Blue to a 12x75mm tube with cap 
Þ Mix the cells by pipetting 
Þ Add 2ml of cells to 198ml of Trypan Blue and resuspend 
Þ Resuspend the cells without forming bubbles and add to one side of a hemocytometer 
Þ Add the next sample to the other side of the hemocytometer 
Þ Using a 10x or 20x magnification look at the entire grid to make sure the cells are evenly distributed 
Þ Count the viable cells in one of the four 16-square grids 
Þ Write down number and repeat 
Þ 1 16-square grid = ___x106 cells/ml.  Take the average of the two counts 
Þ Resuspend cells at 5 X 106 cells/ml.  **Remove 1/2 of cells from each sample for day 0 raft isolation 
(see T cell Raft Isolation protocol) 
 
Calculation:  
(___ x 106 cells/ml)(1ml) = (5 x 106 cells/ml)(X) – 1ml 
 
Example: 
Counted 10x106 cells/ml 
(10 x 106 cells/ml)(1ml) = (5 x 106 cells/ml)(X)-1ml 
X = 2ml –1ml (volume cells are presently in), so add 1ml 10%FBS-RPMI to cell suspension 
 
 
Cell Culture for Th1 Polarization 
 
 
 
 
 
 
 
Þ Prepare solution containing Th1 cocktail plus desired stimulus (ex. PMA/Iono) 
 
Th1 Cocktail 
10mg/ml aIL-4 
20ng/ml rmIL-2 
5ng/ml rmIL-12 
 
Þ Label 24-well plates (for large experiments label ahead of time) 
Þ Add 1ml/well Th1 Cocktail/stimulus solution to the appropriate wells 
Þ Add 1ml of cells at [5 x 106 cells/ml] to the wells with the solution 
Þ Incubate at 37°C for 2 d  
 
DAY 2 and DAY 3 
 
Þ Remove 24-well plates from incubator 
Þ Harvest cells, pooling cells as needed, and wash once with RPMI at 200xg 
Þ Resuspend cells in 5%FBS/MS at volume equal to number of wells that will be cultured        
(i.e. if culturing 2 wells, then resuspend in 2ml) 
Þ Prepare  rmIL-2 + rmIL-12 solution 
20ng/ml rmIL-2 
5ng/ml rmIL-12 
Reactivation 
Th1 
cocktail/stimulus 
CD4+ T cells 
0-2 d 4-5 h 
rmIL-2 
rmIL-12 
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Þ Add 1ml rmIL-2 + rmIL-12 solution per well and 1ml cells per well to 24-well plates 
Þ Incubate at 37°C until D3/D5 
 
DAY 5 
 
Þ Remove 24-well plates from incubator 
Þ Harvest cells, pooling cells as needed, and wash once with RPMI at 200xg 
Þ Proceed with raft isolation (see T cell Raft Isolation protocol) count cells before isolation 
 
 
 
STIMULI CALCULATIONS 
 
DAY 0 
 
**Make 3 solutions of PMA/Iono + Th1 Cocktail (20 ml in 5% FBS, 10 ml in 5% MS-CO and MS-FO)  
 
5% FBS solution 
PMA/Iono: 
PMA (1 ng/ml) 
(2000 ng/ml)(X) = (2 ng/ml)(20000 ml) 
  20 ml stock 
 
Ionomycin (500 nM) 
(1000 mM)(X) = (1 mM)(20000 ml) 
  20 ml stock 
 
Th1 Cocktail: 
rhIL-2 (20 ng/ml) 
 (20,000 ng/ml)(X) = (40 ng/ml)(20000 ml) 
  40 ml stock 
 
rhIL-12 (5 ng/ml) 
 (50,000 ng/ml)(X) = (10 ng/ml)(20000 ml) 
  4 ml stock 
 
aIL-4 (10 mg/ml) 
 (17,000 mg/ml)(X) = (20 mg/ml)(20000 ml) 
  23.5 ml stock 
 
 
Add all to 20 ml 5% FBS 
 
223 
5% MS solution 
PMA/Iono: 
PMA (1 ng/ml) 
(2000 ng/ml)(X) = (2 ng/ml)(10000 ml) 
  10 ml stock 
 
Ionomycin (500 nM) 
(1000 mM)(X) = (1 mM)(10000 ml) 
  10 ml stock 
 
Th1 Cocktail: 
rhIL-2 (20 ng/ml) 
 (20,000 ng/ml)(X) = (40 ng/ml)(10000 ml) 
  20 ml stock 
 
rhIL-12 (5 ng/ml) 
 (50,000 ng/ml)(X) = (10 ng/ml)(10000 ml) 
  2 ml stock 
 
aIL-4 (10 mg/ml) 
 (17,000 mg/ml)(X) = (20 mg/ml)(10000 ml) 
  11.8 ml stock 
 
DAY 2 & 3 
 
**Make 20 ml of rmIL-2 + rmIL-12 solution (in 5% FBS) 
 
rhIL-2 (20 ng/ml) 
 (20,000 ng/ml)(X) = (40 ng/ml)(20000 ml) 
  40 ml stock 
 
rhIL-12 (5 ng/ml) 
 (50,000 ng/ml)(X) = (10 ng/ml)(20000 ml) 
  4 ml stock 
 
**Make 10 ml of 2 solutions of rmIL-2 + rmIL-12 (1 in each medium: 5% MS-CO and 5% MS-FO) 
 
rhIL-2 (20 ng/ml) 
 (20,000 ng/ml)(X) = (40 ng/ml)(10000 ml) 
  20 ml stock 
 
rhIL-12 (5 ng/ml) 
 (50,000 ng/ml)(X) = (10 ng/ml)(10000 ml) 
  2 ml stock 
 
 
Add both to 20 ml 5% FBS 
Add both to 10 ml 5% MS-CO and 
5% MS-FO 
Add all to 10 ml 5% MS-CO 
and 5% MS-FO 
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APPENDIX B-30 
 
T cell Raft Isolation  adapted from YY Fan  
 
 
Reagent preparation:
Use volumetric flasks  for all solutions, make fresh
Lysis Buffer   (100ml) Final conc.
584.4 mg NaCl (MW: 58.44) 100 mM
83.2 mg EDTA (MW: 416.2) 2 mM
28.8 ml AEBSF (stock: 500mM) 144 mM
100 ml Na 3VO4 (stock: 200mM) 0.2 mM
12.5 ml NaF (stock: 200 mM) 50 mM
595.8 mg Hepes (MW: 238.3) 25 mM
        pH to 6.9
 -- bring up to volume with dd H 2O
Brij-58 Buffer   (5 ml)
Add 0.05 g Brij-58 (Fluka, cat. # 16004) to 5 ml Lysis Buffer
Put tube in beaker of slightly warm H 2 O to help dissolve Brij-58
85% Sucrose   (25 ml)
21.25 g sucrose
 -- bring up to volume (25 ml) with Lysis Buffer
Stir solution on slightly warm hot plate    ***takes a long time to dissolve!
35% Sucrose   (25 ml)
8.75 g sucrose
 -- bring up to volume (25 ml) with Lysis Buffer
Stir solution without heat
5% Sucrose   (25 ml)
1.25 g sucrose
 -- bring up to volume (25 ml) with Lysis Buffer
Stir solution without heat
Transfer the following volumes of solutions to 1.7 ml epi-tubes, then add protease inhibitor 
Put all tubes on ice
Tube vol./1 sample vol. Protease Inhibitor Cocktail
1 500 ml Brij-58 buffer 20 ml
2 500 ml 85% Sucrose 20 ml
3 1.2 ml 35% Sucrose 48 ml
4 500 ml 5% Sucrose 20 ml
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Perform everything on ice!
 *** pre-cool Beckman Bench Optima MAX-E ultracentrifuge and TLS-55 swing-bucket rotor
to 4 degrees C
 1- Obtain T cells, transfer cells to 2 ml epi-tubes
 2- Spin cells at 200 x g for 5 min., 4 degrees C
 3- Aspirate supernatant and resuspend cell pellet in 300 ml Brij-58 Buffer
 4- Pass cells through a 27-G needle once and incubate on ice 30 min.
pass cells Quickly through needle -- hold onto needle so it doesn't come off
of syringe
 5- Add 330 ml 85% Sucrose  to the lysate, mix well by pipetting up and down a few times
** final sucrose concentration at this point is 45%  ( 330 ml x 85%)/624 ml)
 6- Transfer the mixture to the bottom of a Polyallomer clear centrifuge tube 
(Beckman cat. # 347357),  put sample on ice
 7- Carefully layer 1 ml 35% Sucrose  to the top of the above mixture
should see a definitive interface band if layered properly
 8- Carefully layer 300 ml 5% Sucrose  to the top of the tube
should see a definitive interface band if layered properly
 9- Balance the tubes with less than 0.01 g difference between paired tubes 
use 5% Sucrose for balancing
 10- Put the centrifuge tubes into the rotor
 11- Spin samples in ultracentrifuge at 200,000 x g (~48,340 RPM) overnight, Accl/Decl = 9
(~16h, adjust time so that as soon as the samples stop spinning you are ready to  
collect fractions)
The following morning:
Keep everything on ice
Use low-retention (siliconized) tips for collecting fractions
 12-  RAFT fraction = collect 0.6 ml  from the top and transfer to a 25 ml glass screw-top tube
       INTERMEDIATE fraction = continually collect 0.4 ml  and transfer to a 25 ml glass screw-top tube
       SOLUBLE fraction = continually collect 1 ml  and transfer to a 25 ml glass screw-top tube
 13- Proceed to lipid extraction
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Lipid Extraction
 1- Add 400 ml  0.1 M KCl to the RAFT tubes and 600 ml  0.1 M KCl to the INTERMEDIATE tubes 
(to bring-up the aqueous solution to 1 ml)
 2- Add 5 ml Folch (MeOH:CHCl3, 1:2, v/v) to each tube
 3- Vortex for 1 min.
 4- Use glass pastuer pipet to transfer the LOWER phase to a 12 ml glass screw-top tube
 5- Double extract the 25 ml sample with 5 ml Folch
 6- Dry the lipid extract down with N2
 7- Redissolve the lipids in exactly 2 ml Folch.  Transfer to 4 ml glass dram vials with green lids, 
flush with N2 and store at -20 degrees C
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Thin Layer Chromatography (TLC) 
Quantitating fatty acid mass of total phospholipids of T cells 
 
After lipid extraction of the samples: 
 
Þ Prepare 12ml glass screw-top leak-proof vials (will need 7/sample) 
· Put 1ml Acetone into each vial 
· Mark Acetone level and tightly screw a black vinyl lid on 
· Place at 80°C for 1h 
· Use only vials that didn’t evaporate 
Þ Pre-activate TLC plate by heating at 110°C for 1h 
Þ Remove extracts from -20°C and place on ice 
Þ Dry the samples under N2  
Þ Redissolve the sample in 25ul FOLCH (MeOH/CHCl3, 1:2, v:v) and place on ice 
· Use a 25ul Wiretrol to add the FOLCH, then vortex thoroughly (make sure to vortex along sides 
of vial) 
· Flush with N2 
Þ Make-up TLC system solvents  
(CHCl3/MeOH/Acetic Acid/H2O,  90 : 8 : 1 : 0.8, v/v) 
· Make ~100ml per TLC tank 
· Use HPLC-grade H2O and Tracepur Acetic Acid, MeOH and CHCl3 
· Use glass pipets to add all solvents 
Þ Pour solvent mixture into a TLC tank  
Þ Gently place 1/3 sheet of filter paper into tank width-side up to equilibrate the solvents 
Þ Place glass lid onto the top of tank and a heavy object (e.g. the top from the N2 tank) on top of the lid 
to prevent evaporation 
Þ Allow solvents to equilibrate for at least 30 min 
Þ Spot the TLC plate after it has cooled from the pre-activation 
· Lie plate silica-side up 
· Using the extra wiretrol needle scrape a line across the plate 1/2” from the top 
· Place the TLC “plate grid” on top of the plate and mark evenly spaced lines for the number of 
lanes needed.  Scrape lines from top to bottom of the plate.  (make sure to leave ~1/2” on both 
sides of the plate) 
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· Put “plate grid” back onto plate and use the shadow of the edge of the grid to spot the sample 
(make sure the shadow falls ~1” from the bottom of the plate) 
· Vortex sample well and aspirate sample into the 25ul Wiretrol 
· Spot the sample in one lane by releasing droplets, one-after-another, onto shadow-line 
-Spot in the center of the lane, staying away from the edges 
-Be sure not to touch the plate with tip of the Wiretrol 
-If needed, respot over previous spot once dry 
· After spotting add 25ul additional FOLCH to sample, vortex and repot in same lane 
· Wipe Wiretrol needle with FOLCH between each sample 
· Include a standard (such as rat liver extract) on each plate 
Þ Place TLC plate, top side up, into tank.  Replace glass cover and heavy object. 
· Place the plate’s edge in the middle of the bottom of the tank  
Þ Run for about 2h or until solvents reach <0.5cm from the top line 
Þ While the plate is running prepare leak-proof tubes 
· Will need 7 tubes per sample spotted 
· Label the tubes for: Chol. ester, TG, DG, FFA, MG, PL, 17:0 ISD 
· Pour off the Acetone.  Dry by inverting tubes in rack 
· Rinse tubes and lids with 1ml MeOH (Tracepur grade) and pour off.  Dry by inverting in rack 
-Invert and rotate tube to thoroughly rinse   
-Make sure not to mix up lids (tubes are only guaranteed to be leak-proof w/ the corresponding 
lids) 
· Add 50ng (10ul of the 5ng/ul stock) of 17:0 free fatty acid.  This serves as an internal standard. 
· Add 3ml 6% HCl/MeOH and invert tube to mix with the ISD 
· Keep tubes in dark until ready to use 
Þ Once plate in done running remove from tank and dry for ~5 min 
Þ In dark spray plate with 0.1% ANS (8-Anilino-1-naphthalene-sulfonic acid) to view bands 
· To make: 200ml H20 + 0.2g ANS 
· 0.1% ANS is stored at 4°C and is light sensitive 
· Place plate inside 3-sided box to contain ANS 
· Spray plate by attaching flask container (containing 0.1% ANS) to N2 
· Spray evenly, but not so much as to soak the plate 
Þ View the plate with UV (if unable to see the bands clearly, spray again) 
Þ Circle the bands with pencil while viewing under UV
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Þ Bands should be located similar to illustration below: 
 
                                                                                              Top 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Þ Scrape the circled bands into the appropriate leak-proof tubes 
· Use a TLC scraper blade  (similar to an Exacto knife) 
· Scrape in an upward motion so as not to lose the band 
· Scrape over a funnel into tube 
· Tap out all remaining pieces of plate caught in funnel into tube 
Þ Flush with N2 and vortex for 1 min 
Þ Methylate at 76°C for 15h 
 
 
Þ Extract FAME: 
· Add 2ml Hexane and 1ml 0.1M KCl to the leak-proof tubes 
· Vortex for 1 min 
· Centrifuge for 5 min at 3000rpm at 4°C (Jouan centrifuge) –use rubber tube inserts to prevent 
tubes from breaking  
· Transfer upper phase, using Pasteur pipet, to a labeled 4ml glass vial- be sure to replace black 
lids with green lids for organic solvents 
· Repeat the 2ml Hexane extract 
Þ Dry down the FAME under N2 
Þ Redissolve in 25ul CH2Cl2, flush with N2 and vortex 
Þ Run GC to calculate the mass of the phospholipids 
 
                               
 
 
                                 
                                 
 
 
                                  
 
                               
 
  
 
Chol. ester 
TG 
DAG 
FFA 
MG 
PL 
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Cholesterol Assay  
Amplex Red Cholesterol Assay Kit  
(Molecular Probes #A-12216) 
 
Stock Solutions: 
 
20 mM Amplex Red reagent (Component A): 
 Add 200 ml of DMSO (supplied in kit) to one vial of Amplex Red reagent (1 mg) 
 Aliquot 40 ml/tube, store at -20°C protected from light 
 
1X Reaction Buffer: 
 Dilute 5X Reaction Buffer stock solution (Component E) to 1X using dd-H2O 
 Make fresh for each assay 
 
200 U/ml horseradish peroxidase (HRP) (Component C): 
 Add 1 ml of 1X Reaction Buffer to the vial of HRP 
 Aliquot 125 ml/tube, store at -20°C 
 
20 mM H  2O  2 working solution: 
 Mix 1.15 ml of 3% H2O2 stock (Component D) into 488.5 ml of dd-H2O 
 Make fresh for each assay 
 
200 U/ml Cholesterol Oxidase (Component F): 
 Add 250 ml of 1X Reaction Buffer to the vial of cholesterol oxidase 
 Aliquot ~32 ml/tube, store at -20°C 
 
200 U/ml Cholesterol Esterase (Component G): 
 Add 250 ml of 1X Reaction Buffer to the vial of cholesterol esterase 
 Aliquot ~32 ml/tube, store at -20°C
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Protocol: 
1.    Prepare cholesterol standards: 
 Dilute 2 mg/ml of cholesterol reference standard (Component H) with 1X Reaction Buffer 
 to produce cholesterol concentrations of 0-8 mg/ml 
  
*** Prepare Triplicates of each standard 
*** Add 248 ml of 1X Reaction Buffer to 2 ml of 2 mg/ml cholesterol reference standard to 
 make 16 mg/ml Std. Dilute (S1) 
 
 20 mg/ml Std. Dilute ml of 1X Reaction 
Buffer 
Conc. [mg/ml] 
S1 120 ml S1 0 ml 16 
S2 60 ml S1 60 ml  8 
S3 60 ml S2 60 ml  4 
S4 60 ml S3 60 ml 2 
S5 60 ml S4 60 ml 1 
S6 60 ml S5 60 ml 0.5 
S7 0 ml 120 ml 0 
 
2.    Take 25 to 50 ml of lipid extract in Folch to be analyzed and transfer to a 2 ml glass vial.  Dry  down 
under N2 and redissolve in 120 ml of 1X Reaction Buffer. 
3.    Prepare 300 mM Amplex Red reagent mix containing 2 U/ml HRP, 2 U/ml cholesterol oxidase and 2 
U/ml cholesterol esterase 
  
For 10 wells: 
7.5 ml Component A Amplex Red reagent 
5.0 ml Component C HRP 
5 ml Component F Cholesterol oxidase 
0.5 ml Component G Cholesterol esterase 
482 ml  1X Reaction Buffer 
 
4.    Add 50 ml of sample or standard to a 96-well plate.  Run standards in triplicate and samples in 
duplicate. 
5.    Add 50 ml of the 300 mM Amplex Red mix to each well. 
6.    Cover plate with foil to protect from light and incubate at 37°C for at least 30 min. 
7.    Measure the fluorescence using excitation in the range of 530-560 nm and emission detection at ~ 590 
nm 
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Using Lupton Fluorometer 
· Turn on Bio-Tek machine and start-up Bio-Tek KC4 program from desktop. 
· Select from protocol menu: YY-Fluor.prt 
· Click on Settings button, and then click on Options button 
· Check “Automatic sensitivity adjustment” and “Scale to high well” 
· Scale to wells with highest readings (usually highest set of wells on standard curve) 
· High value should be 50,000 
· Starting sensitivity should be 35 
· For Amplex Red Cholesterol settings: 
o Excitation = 530/25 
o Emission = 590/35 
o Optics position = Top 
· To export to Excel: 
· Select Data, export from menu 
· Highlight “M530/590” 
· Click on “Add” button 
· Save as txt file 
· Import into Excel as txt file as semicolon delimited 
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